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ABSTRACT 
Oysters are described as keystone species serving an important ecological role. 
As filter-feeders they help in maintaining water quality. Oyster reefs provide refuge and 
support to different organisms. The eastern oyster, Crassostrea virginica, native to the 
East Coast of United States and Gulf of Mexico is a part of the rapidly growing 
aquaculture industry. Aquaculture production depends on a healthy and constant supply 
of oyster larvae that are provided by hatcheries. Several hatcheries on the east coast that 
provide C. virginica seed to oyster farms face significant losses owing to Vibrio 
infections causing massive larval mortalities. Use of antibiotics is avoided due to 
possibility of development of antibiotic resistance. The probiotic bacteria, Phaeobacter 
inhibens S4 and Bacillus pumilus RI06-95 have been shown to successfully protect C. 
virginica larvae from V. coralliilyticus RE22 infection. Use of these probiotics in 
hatcheries can reduce mortalities due to disease thereby avoiding significant economic 
losses. In order to design best practices for probiotic use it is crucial to understand their 
mechanisms of action. There has been great progress in understanding the components 
of oyster immune system, its functioning in response to various stimuli and its 
uniqueness as compared to other organisms. This is in part due to availability of 
sophisticated tools like high throughput sequencing and various –omics analyses such 
as proteomics, genomics and transcriptomics and partly due to interest in controlling 
diseases affecting aquaculture. As such most of our knowledge is based on studies that 
focus on oyster-pathogen or oyster-environmental stimuli interaction. Little is known 
about the effect of bacteria other than pathogens on the oysters. Moreover, very little 
about larval immunity of eastern oyster, C. virginica. This is the first study to investigate 
  
the effect of both pathogen and probiotic bacteria on C. virginica larval immunity using 
transcriptomes. The aim of this study is to test the safety and efficacy of formulated 
probiotic Bacillus pumilus RI06-95 in a hatchery, understand the mechanisms of action 
of both probiotics and to characterize the effect of V. coralliilyticus RE22 infection on 
the larval immune system of eastern oysters.  
Chapter 1 reviews the current knowledge of oyster immune system and the 
mechanisms of action of probiotics especially mechanisms related to 
immunomodulation of innate immunity. Previous studies have demonstrated successful 
protection of C. virginica larvae from V. coralliilyticus RE22 infection in a laboratory 
based setting as well as in a hatchery using laboratory grown cultures of probiotics. The 
ultimate use of the probiotics is in a hatchery setting, which would require easy to use 
and stable formulation of the probiotics instead of time consuming laboratory-grown 
probiotic cultures that are viable for only a short duration of time.  
Chapter 2 discusses methods of formulation of probiotic Bacillus pumilus RI06-
95, testing the formulation in a hatchery and its effect on larval survival at the hatchery 
and post V. coralliilyticus RE22 experimental challenge in the laboratory. A spray dried 
formulation of Bacillus pumilus RI06-95 was both shelf-stable and effective in 
protecting C. virginica larvae from V. coralliilyticus RE22 challenge. The formulation 
did not show any adverse effects on the larvae during the course of the trial.  
Chapter 3 investigates the host–pathogen interaction between C. virginica larvae 
and V. coralliilyticus RE22 using transcriptomes produced after experimental challenge. 
Exposure of larvae to the pathogen for 6 hours provided information of the changes in 
the larval oysterimmune system brought about by the pathogen in the early stages of 
  
disease. Overall, despite upregulation of several pattern recognition receptors, immune 
signaling pathways leading to the production of antimicrobial effectors, such as protease 
inhibitors and the pore forming protein perforin-2, were suppressed by V. coralliilyticus 
RE22. The transcriptomic evidence suggests that lack of an adequate immune response 
to thwart the infection of RE22, combined with a high metabolic load and decreased 
feeding, leads to large-scale mortalities of C. virginica larvae. This research allows for 
a better understanding of the disease process caused by V. coralliilyticus RE22 in larval 
eastern oysters. 
Chapter 4 investigates the effect of exposure to non-pathogenic probiotic 
bacteria P. inhibens S4 and B. pumilus RI06-95 on the immune system of the host, C. 
virginica larvae. It presents evidence of immunomodulation of C. virginica larval 
immunity by both probiotic organisms. High upregulation of immune effectors such as 
serine protease inhibitors is seen in larval oysters after short exposures to the probiotic 
(6 and 24h) in the laboratory as well as after exposure for several days during a hatchery 
trial. Other important modulations that help larvae protect themselves from V. 
coralliilyticus RE22 infection include activation of pathogen receptors and signaling 
pathways, modulation of mucin genes, and upregulation of pore-forming protein 
perforin-2. 
Chapter 5 summarizes and advocates the of use of probiotics in the larviculture 
of C. virginica and suggests their potential role in limiting vibriosis.  
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1. “Use of formulated probiotic Bacillus pumilus RI06-95 for preventing vibriosis 
in larviculture of the eastern oyster Crassostrea virginica.” prepared for 
submission to Journal of Shellfish Research. 
2. “Characterizaton of Crassostrea virginica larval response to Vibrio 
coralliilyticus RE22” prepared for submission to Developmental and 
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CHAPTER 1 
 
LITERATURE REVIEW: IMMUNITY IN OYSTERS AND GENERAL 
MECHANISMS OF ACTION OF PROBIOTICS 
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Abstract 
Oysters are a unique model of immunology since they lack a classic adaptive immune 
system and only possess an innate immune system. Some research suggests presence of 
memory although a lot more remains to be elucidated. Oysters possess a wide variety 
of pattern recognition receptors. Most of the components of signaling pathways like 
TLR, NF-kB and MAPK are known while others like the complement system are not 
fully known yet. Immune effectors like antimicrobial peptides and enzymes like 
lysozyme are important in oysters especially in mucosal immunity. Exposure to 
probiotics leads to modulation of host immune genes that eventually provide protection 
from pathogens. Probiotics can modulate expression of receptors, signaling pathways 
and production of effectors in specific hosts. Immunomodulation as a mechanism of 
action of probiotics is seen in a variety of organisms including invertebrates and 
vertebrates alike and therefore may play an important role in the mechanism of 
probiotics in oysters.  
 
 
 
 
 
 
 
 
 
  
 
3 
 
Immunity in oysters 
Oysters are sessile filter feeding animals that provide important ecological and 
economical services. As such immunological studies to understand disease resistance 
and improve aquaculture practices has given a boost in our understanding of the oyster 
immunology.  Although some research suggests presence of immunological memory 
(Green et al., 2015) it is generally recognized that oysters lack adaptive immunity and 
only possess innate immunity. The circulating phagocytic hemocytes form the cellular 
branch of the innate immunity in oysters. The production of antimicrobial effectors via 
activated signaling pathways due to recognition of PAMPs (pathogen-associated 
molecular patterns) by PRRs (pattern recognition receptors) forms the humoral branch 
of innate immunity (Wang et al., 2018). Current research of the oyster immunity is 
reviewed below with emphasis on (i) Recognition (ii) Signaling pathways (iii) Effectors 
(iv) Apoptosis and autophagy and (v) Mucosal immunity. Immune-related genes in the 
eastern oyster Crassostrea virginica are illustrated in Fig 1. 
 
Recognition  
Recognition of non-self is achieved via PRRs that comprise of peptidoglycan 
recognition proteins (PGRPs), lectins, toll-like receptors (TLRs), Gram-negative 
binding proteins (GNBPs), scavenger receptors (SRs) and fibrinogen-related proteins 
(FREPs) (Gerdol et al., 2018, Wang et al., 2018). Lectins are further classified into 
major families including C-type, F-type, R-type, H-type, P-type, X-type, I-type lectins, 
pentraxins, galectins (formerly S-type lectins), ficolins, and others (Vasta et al. 2007). 
  
 
4 
Several of these PRRs are highly diversified in oysters (Zhang et al., 2014, Zhang et al., 
2015). C-type lectins require a special mention since they are not only involved in 
pathogen recognition but also in activation of complement cascade.  
 
Signaling pathways  
Signals transmitted by receptors allow activation of several signaling pathways like 
TLR signaling pathway, NF-kB signaling pathway, mitogen-activated protein kinase 
(MAPK) signaling cascade, prophenol/phenol oxidase cascade and complement 
pathway in oysters. Sophisticated tools like whole genome sequencing and –omics 
analysis have led to tremendous progress in understanding molecules involved in these 
pathways that are common with other organisms as well unique to oysters. The 
TLR/NF-kB signaling pathway is a crucial pathway that upon recognition by TLR 
receptors activate transcription factors facilitating production of effectors like 
cytokines, interleukins, antimicrobial peptides (AMPs) and others (Gerdol et al., 2018). 
MyD88 serves as a critical cytosolic adaptor modulating TLR signaling pathway and 
Pacific oyster genome encodes an expanded set of 10 MyD88 genes (Zhang et al., 2015). 
MAPK pathway comprises of many protein kinases and its active involvement in oyster 
immunity is evidenced by their activation upon bacterial exposures (Qu et al., 2016). 
Although studies support existence of a complement pathway in bivalves (Gerdol et al., 
2015, Li et al., 2015) the exact components and mechanisms of activation remain to be 
identified (Gerdol et al., 2018).  
  
Effectors 
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Broad ranged effectors are produced upon induction of signaling pathways by PRR 
recognition and function in elimination of pathogens. These include antimicrobial 
peptides (AMPs), defensins, lysozymes, cytokines, protease inhibitors, antioxidant 
enzymes and acute phase proteins. Serine protease inhibitors have been identified for 
their role as important effectors in granting resistance to pathogens (La Peyre et al. 2010, 
Xue et al. 2006, McDowell et al., 2014). Enzymes, such as superoxide dismutase, 
catalase and glutathione peroxidase defend oysters by eliminating reactive oxygen 
species (ROS).  They are important especially during increased oxidative stress caused 
by pathogen infection. Another important member of effectors are the heat shock 
proteins (HSPs) that help oysters modulate stress response and protect them from 
environmentally induced cellular damage caused by a variety of stressors (Wang et al., 
2018).  
 
Apoptosis and autophagy 
Apoptosis, programmed cell death is an extremely important process in oysters involved 
in immune system homeostasis and function, defense against parasite and pathogens 
and self/non-self recognition. The baseline apoptosis rates observed in circulating and 
resident hemocytes in oysters is high (Sokolova, 2009). Apoptosis in oysters has two 
major pathways intrinsic and extrinsic. The main players consist of caspases and 
inhibitors of apoptosis (IAPs) that regulate the process. Apoptosis limits the spread of 
pathogen while preventing inflammatory damage of surrounding tissues (Sokolova, 
2009). Although apoptosis has been studied for a long time the exact functional 
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relevance of its modulation by biotic and abiotic factors is still unknown in bivalves 
(Gerdol et al., 2018, Wang et al., 2018).  
Autophagy plays a housekeeping role in organisms and is important in innate immunity. 
It is activated in oysters in response to bacterial, viral and environmental stimuli (Gerdol 
et al., 2018, Wang et al., 2018). Its role in protecting Pacific oysters from viral and 
bacterial challenge was demonstrated recently (Moreau et al., 2015) but a lot more 
remains to be investigated.   
 
Mucosal immunity 
Mucus forms an external barrier of defense and plays a key role in host-microbe 
interactions. Mucus consisting of crosslinked glycoproteins forms a physical barrier to 
microbes and contains a myriad of effectors that defend the host from infection (Allam 
and Espinosa, 2016).  These include enzymes like lysozymes, hydrolases and proteases, 
AMPs, antioxidants and lectins to name a few (Espinosa et al., 2016). Mucus 
composition can affect pathogen adhesion and production of components is often 
regulated by them (Linden et al., 2008, Allam and Espinosa, 2016). This understudied 
topic is a crucial part of the innate immunity in oysters and needs further exploration. 
  
Most of the knowledge of oyster immunity is based on a large body of research that is 
centered on bacterial and viral pathogens and environmental stressors but we know very 
little about the impact of friendly or beneficial bacteria on the immune system of oysters. 
Addressing this dearth of knowledge might reveal important novel insights in the oyster 
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immune system. The next section of this review discusses the effect of probiotics on 
different organisms focusing especially on their impact on immune system.  
 
General mechanisms of action of probiotics  
Probiotics, as defined by Food and Agricultural Organization and World Health 
Organization, are live microorganisms that when administered in adequate amounts 
confer a health benefit on the host (FAO and WHO 2006). Although probiotic uses for 
better growth, digestion, immunity and disease resistance of the host have been known 
their mechanisms have not been fully elucidated yet. Some of the known mechanisms 
of action are summarized in Fig 2 and discussed in detail below.  
 
Nutrient availability  
Probiotics improve the utilization of feed by the host by producing or stimulating 
production of exoenzymes that digest ingredients in feed such as carbohydrates, proteins 
and fat. This aid in increased digestibility of feed, boosts host growth. Probiotics 
Bacillus subtilis, Lactococcus lactis and Saccharomyces cerevisiae showed increased 
secretion of amylase, trypsin, protease and lipase in sea bass (Labeo rohita) (Tovar-
Ramirez et al., 2002, Mohapatra et al., 2012). Application of probiotic strains of Bacillus 
in white shrimp (Litopenaeus vannamei) and Fenneropenaeus indicus feed, improved 
feed digestibility resulting in increased size of the shrimp (Heizhao et al., 2004). In fact, 
production of chitinases, proteases, cellulases, lipases and trypsin by the bacteria 
isolated from the digestive tract of various aquatic organisms have been shown 
contribute to fish nutrition (Vine et al., 2006, Ray et al. 2012). Increasing nutrient 
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availability and stimulation of growth through increased volatile fatty acids production 
by probiotics has been studied in poultry industry as well (Ajuwon., 2016). 
 
Production of inhibitory compounds 
Probiotics produce or stimulate production of several non-specific compounds that are 
effective in inhibiting pathogen growth including, antimicrobial compounds (hydrogen 
peroxide, nitric acid and bacteriocins), siderophores, proteases and lysozymes. A non-
pathogenic strain Vibrio mediterranei 1 produces bacteriocin-like inhibitory substance 
against Vibrio parahaemolyticus spp (Carraturo et al., 2006). In fact, bacteriocin 
production allows probiotics to compete within complex microbial communities and 
influence the health of the host (Dobson et al., 2012). Probiotics administered to tilapia 
(Oreochromis niloticus) increased lysozyme activity in host (Taoka et al., 2006). 
Phaeobacter inhibens S4 produces tropodiethic acid (TDA) that kill pathogenic V. 
coralliilyticus RE22, Vibrio harveyi BB120 and Alioseovarius crassostreae CV919-
312T in oysters (Karim et al., 2013, Zhao et al., 2016). Enterococcus durans strain 
LAB18s showed antimicrobial and antioxidant activity against several pathogenic 
bacteria (Pieniz et al., 2014). 
 
Competitive exclusion of pathogenic bacteria  
Probiotics often compete with pathogenic bacteria for space and nutrients that hinder 
their proliferation. Direct inhibition of pathogens by production of inhibitory 
compounds as discussed above is one way they competitively exclude pathogens. Other 
mechanisms include formation of biofilms, blocking adhesion sites and profuse 
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probiotic growth. An oyster probiotic, P. inhibens S4 produces biofilms that inhibit the 
growth of pathogens V. coralliilyticus and V. anguillarum (Zhao et al., 2016). 
Lactobacilli reduced the adhesion of rainbow trout pathogens (Balcazar et al., 2007). 
Exclusion of pathogenic bacteria by competition from probiotic bacteria was also shown 
in poultry. Native bacteria from adult chickens were used to protect chicks from 
infestation of Salmonella infantis (Rantala and Nurmi., 1973) as well as other 
enteropathogens (Schneitz, 2005). Porcine probiotics Lactobacilli and Bifidobacteria 
compete for attachment sites on epithelial cells and exclude pathogens in the intestine 
(Gross et al., 2008).  
 
Enhancement of the Epithelial Barrier 
Gut is in constant contact with a large number of bacteria and its integrity is often one 
of the most important barriers against invading pathogens. Increased expression of 
genes involved in tight junction signaling due to probiotic treatment reinforces this 
barrier (Anderson et al., 2010). Escherichia coli Nissle 1917 (EcN1917) has been shown 
to not only prevent disruption of the mucosal barrier by enteropathogenic E. coli, but 
also restore mucosal integrity (Anderson et al., 2010). Probiotics differentially modulate 
epithelial cell responses via activation or suppression of distinct signaling pathways in 
a strain-dependent manner (Llewellyn et al., 2017). 
 
Immunity 
Effects on mucosal immunity  
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Mucus is made up of polymerized mucins that protect hosts from pathogens, enzymes, 
toxins, dehydration and abrasion (Hardy et al., 2013). Lactobacillus plantarum 299v 
and Lactobacillus rhamnosus GG have been shown to up-regulate production of MUC2 
and MUC3 intestinal mucins that weakens the adherence of pathogenic Escherichia coli 
O157:H7 (Mack et al., 1999). Probiotics mediate modulation of mucin expression as a 
strategy for intestinal colonization of beneficial microbes to the host (Caballero-Franco 
et al., 2007). Mucus contains lysozymes, antimicrobial substances, antibodies and 
enzymes that have added benefits in controlling pathogenic invasion. Production of 
these substances can be modulated by presence of probiotics. Probiotic treatment led to 
increase in lysozyme production in Japanese flounder (Ye et al., 2011). Probiotic strains 
such as Lactobacillus GG, Bifidobacterium actis Bb-12 (Rautava et al., 2006) and 
Saccharomyces boulardii (Rodrigues et al., 2000) have been demonstrated to enhance 
IgA production and secretion.  
 
Immunomodulation  
Probiotic research shows mounting evidence of probiotic-host communication through 
pattern recognition receptors resulting in modulation on key signaling pathways such as  
NF-kB and MAPK to enhance or suppress activation and influence downstream 
pathways (Bermudez-Brito et al., 2012, Hardy et al., 2013, De et al., 2014). Probiotics 
and pathogens share PAMPs/MAMPs that can induce innate inflammatory pathways. 
Secondary and chronic exposure to probiotics induce suppressive /tolerogenic response 
that modulate NF-kB and MAPK pathways (Llewellyn et al., 2017). Effect in humans 
for some example probiotics is illustrated in Fig 3. L. casei CRL 431 interacts with 
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epithelial cells through TLR2 and induces an increase in the number of CD-206 and 
TLR2 receptors in the cells involved in the innate immune response in humans 
(Vinderola et al., 2005). Lactobacillus stimulates TLR9 that induces cytoplasmic 
accumulation of ubiquitinated IkB and inhibition of NF-kB activation (Lee et al., 2006). 
L. reuteri and L.  casei engage with C-type lectin, prime dendritic cells and that lead to 
increased production of IL-10 (Smits et al., 2005). In contrast, L. reuteri strains DSM 
17938 and ATCC PTA 4659 downregulates expression of TNF-a, TLR4 and NF-kB 
and upregulates IL-10 expression in rats (Bermudez-Brito et al., 2012). Along with the 
influence on innate immunity probiotics also have impacts on adaptive immunity 
(Hardy et al., 2013).  
In addition, increase in phagocytic activity in probiotic fed Nile tilapia (Oreochromis   
niloticus) (Vieira et al., 2010) and increase in total hemocyte count and serum 
agglutination activity in probiotic fed and challenged marine shrimp (Sayed et al., 2011) 
are also documented. Probiotics have also been shown to confer protection against many 
cellular stresses, which include oxidative stress-mediated apoptosis (Llewellyn et al., 
2017). 
Thus, probiotic bacterial strains can be generalized to exert immune-activation, -
deviation or -regulation/suppression responses (Hardy et al., 2013). Selection of 
probiotic strains especially in combination along with prebiotics can have beneficial 
effects on hosts. However, it is crucial to gain full knowledge of their modulatory 
capabilities and formulate their use with careful consideration.  
 
Goals of this study 
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There has been much progress in understanding immunity in mollusks especially in 
bivalves but we still lack knowledge of larval immunity in eastern oyster C. virginica. 
There is also a dearth of understanding in the effect of bacteria on larval immunity. 
Probiotics protect several organisms from Vibrio spp infection including crayfish 
(Cherax tenuimanus) (Ambas et al., 2013), brine shrimp (Artemia franciscana) (Giarma 
et al., 2017), oyster (C. virginica) (Karim et al., 2013), turbot (Scophthalmus maximus) 
(Villamil et al., 2002) as well as humans (Carraturo et al., 2006) using mechanisms like 
antibiotic production and indications of immunomodulation. However, we need a 
thorough investigation of the nature of their immunomodulatory ability.  
The overall goal of this study was to understand the mechanism of action of probiotics 
B. pumilis RI06-95 and P. inhibens S4 against pathogen V. coralliilyticus RE22 and 
formulate them for use in the field.  
Laboratory grown bacterial culture of B. pumilis RI06-95 was previously shown to 
protect C. virginica larvae from infection of V. coralliilyticus RE22 (Karim et al., 2013). 
The first aim was to formulate the probiotic such that it can be effectively used in 
hatcheries and to test their efficacy. A series of formulations were prepared and tested 
in lab as well as in hatcheries to establish their efficacy. 
The second specific aim was to understand the immunological response of C. virginica 
larvae to both probiotics B. pumilis RI06-95 and P. inhibens S4 in order to understand 
if immunomodulation is one of the mechanisms of action of these probiotics. Next 
generation RNA sequencing technology was used to obtain the transcriptomic response 
of C. virginica larvae to probiotics in a lab controlled and a hatchery environment to 
thoroughly investigate their effect on several larval genes at a time.  
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The third specific aim was to understand the immunological response of C. virginica 
larvae to pathogen V. coralliilyticus RE22 in order to understand its pathogenesis. To 
investigate this, larval transcriptomes generated post challenge with V. coralliilyticus 
RE22 were compared to control transcriptomes.  
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Figure 1: Immune-related genes present in the eastern oyster, Crassostrea virginica. 
Adapted from Zhang et al., 2014. 
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Figure 2: Major mechanisms of action of probiotics. Illustration adapted from 
Bermudez-Brito et al., 2012.   
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Figure 3: Examples of modulation of innate immune response by probiotics. Adapted 
from Bermudez-Brito et al., 2012.   
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T. Modak contributions: Design and performance of hatchery trial with spray-dried 
formulation (Envera); further compilation with previous results for final manuscript.   
 
 
Abstract 
Vibriosis is a major disease affecting larval eastern oysters, Crassostrea virginica, 
causing sudden and massive larval mortalities. A candidate probiotic strain, Bacillus 
pumilus RI06-95, was previously investigated as a disease prevention method and found 
to reduce mortality due to vibriosis in oyster larvae and juveniles. The goal of this 
research was to develop a stable formulation of probiotic RI06-95 to facilitate storage 
and delivery in a hatchery setting. Three types of formulations (granulated, lyophilized 
and spray dried) of RI06-95 were developed. Cell viability of all formulations remained 
above 105 colony forming units (CFU) per mL for up to 8 weeks of storage. The 
granulated and spray-dried formulation had no adverse impacts on larval oyster survival 
and provided protection against challenge with the bacterial pathogen Vibrio 
coralliilyticus RE22 (Relative Percent Survival, RPS, as compared to probiotic 
untreated control: 69 ± 1 % and 52 ± 35 % respectively). However, treatment of larval 
oysters with the lyophilized formulation led to a significant decrease in survival 
compared to non-treated controls and afforded no protection. Daily treatment of oyster 
larvae with the spray dried formulation in pilot-scale hatchery trials provided significant 
protection against laboratory challenge with RE22 (RPS 43 ± 4 %). These results 
demonstrate that a sprayed-dried formulation for probiotic RI06-95 can be safely and 
effectively used for disease prevention in shellfish hatcheries.  
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Introduction 
The bivalve shellfish (oysters, clams, scallops, and mussels) industry is an 
important and rapidly expanding area of aquaculture production. The total landings for 
oysters, clams and scallops in United States alone valued at $859 million (NMFS 2016). 
A primary requisite for the aquaculture of most bivalve shellfish species is an abundant, 
reliable, and inexpensive supply of seed/small juveniles (Helm et al. 2004). Shellfish 
larvae, however, are prone to infectious diseases, which can result in a rapid and high 
rate of larval mortality in commercial hatcheries (Elston 1998), leading to substantial 
economic losses. For instance, pathogenic strains from several Vibrio spp. including V. 
alginolyticus, V. anguillarum, V. coralliilyticus, V. ordalii, V. splendidus, V. tubiashii, 
and others, cause bacillary necrosis of larval bivalve shellfish. Clinical signs of vibriosis 
in bivalves include necrosis of mantle epithelium, clumping of the cilia, and rapid 
mortality (Tubiash et al. 1965; Berthe 2004; Gomez-Leon et al. 2005; Kesarcodi-
Watson et al. 2009).   
 Given the absence of an adaptive immune system in bivalves allowing for the 
use of vaccines as disease prevention tools, the use of probiotics is one of the most 
promising management strategies for shellfish disease prevention and control (Elston 
1998; Verschuere et al. 2000; Prado et al. 2010). Probiotics are defined as live, non-
pathogenic microorganisms which, when administered in adequate amounts, confer a 
health benefit to the host (Food and Agricultural Organization of the United States 
2006). The most widely used probiotics in human and animal health belong to Bacillus 
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spp., Bifidobacterium spp., and lactic-acid bacteria such as Lactobacillus spp. (Hong et 
al. 2005, Cutting S 2011). In particular, Bacillus spp. are attractive for commercial 
products because they are aerobic, spore-forming bacteria. Spores are capable of 
surviving extreme conditions such as the high temperatures and pressure conditions 
sometimes used for formulating a commercial probiotic product. Formulations of 
Bacillus spp. are stable for long periods without significant loss in viability because 
spores enable survival in harsh conditions until germination and proliferation occur in 
more favorable environments (Lalloo et al. 2010; Cutting 2011; Azevedo de & Tavares 
Brag 2012; Sorokulova 2013; Edna et al. 2014).  
We previously reported that marine Bacillus pumilus RI06-95, a producer of the 
antibiotic amicoumacin (Socha 2008), antagonized growth of the shellfish pathogen V. 
coralliilyticus RE22 in vitro and protected eastern oyster Crassostrea virginica and bay 
scallop Argopecten irradians larvae against experimental challenge with V. 
coralliilyticus RE22 (Karim et al. 2013b; Sohn et al. 2016a). It was also shown that 
daily treatment of larval rearing tanks in a hatchery with RI06-95 led to a decline in the 
levels of Vibrio spp. on tank surfaces and an increase in the survival of larval oysters 
when challenged with a pathogen (Sohn et al. 2016a).  Bacillus spp., have shown 
promise as probiotic bacteria to improve host survival, growth, and development in 
aquaculture (Queiroz & Boyd 1998; Luis-Villaseñor et al. 2011; Martínez Cruz et al. 
2012; Li et al. 2014). Additionally, some bacilli exhibit antagonistic effects against 
pathogenic Vibrio spp. (Decamp & Moriarty 2006; Vaseeharan & Ramasamy 2003). 
Whole genome analysis of RI06-95 reveals that it is most closely related to B. pumilus 
SAFR-32 (Hamblin et al. 2015), a strain isolated as a contaminant in spacecraft 
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assembly facilities (Gioia et al. 2007). B. pumilus strains have been isolated from a wide 
range of habitats, from aquatic and terrestrial hosts (Hill et al. 2009) to desert basalt 
(Benardini et al. 2003), and have been suggested as probiotics for plants, humans, 
crustaceans, and finfish (Duc et al. 2004; Hill et al. 2009; Sun et al. 2010; Murugappan 
et al. 2013). 
Although many studies have shown promising results for the use of probiotics 
in shellfish aquaculture, no commercial products are available with demonstrated safety 
and efficacy in bivalve larviculture. Probiotics typically are available in several types of 
commercial formulations, including dry materials (such as wettable powders, dusts, and 
granules) and liquid products (such as cell suspensions in water, oils, and emulsions) 
(Austin et al. 1995; Schisler et al. 2004; Salinas et al. 2006; Savini et al. 2010; Dagá et 
al. 2013). An appropriate formulation should offer several advantages in addition to 
host protection, including: the stabilization of microorganisms during distribution and 
storage; ease in handling and delivery of the product; protection of the microbes from 
adverse environmental factors; and safety to the aquaculture species. Therefore, the 
successful development of an appropriate probiotic formulation requires testing for 
efficacy, safety, and stability, especially in bivalve hatchery facilities. 
Here, we evaluate three novel formulations of the candidate shellfish probiotic 
B. pumilus RI06-95. We determine storage and usage potential, and test each 
formulation along with fresh cultures of the same probiotic bacterium for safety and 
host protection in both laboratory and in semi-commercial scale hatchery experiments. 
While all three formulations resulted in stable products with suitable shelf lives, only a 
spray-dried formula provided a high level of safety and efficacy desired for a 
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commercially viable product. Our results demonstrate a safe, stable, and easy-to-use 
formulation for C. virginica larval aquaculture production.  
 
Methods 
Oyster larvae  
 Laboratory challenge experiments: For the bacterial challenge experiments, 
eastern oysters, C. virginica, (4 - 6 day old) were obtained from the Blount Shellfish 
Hatchery at Roger Williams University (Bristol, RI, USA) or Virginia Institute of 
Marine Science (VIMS) (Wachapreague, VA, USA). Oyster larvae were transported to 
the laboratory at the University of Rhode Island (Kingston, RI, USA) and acclimated at 
room temperature (~20°C) for at least 24 h before treatment. The larvae were fed instant 
algae Shellfish Diet 1800TM (Reed Mariculture Inc., San Jose, CA. USA) during the 
experiments.  
 Hatchery trials: Adult eastern oysters were spawned at the Blount Shellfish 
Hatchery for Trials I, II, III and V and at the VIMS Shellfish Hatchery at the 
Aquaculture Genetics & Breeding Technology Center (ABC), VIMS for Trial IV. 
Larval oysters were distributed into 100-120 L conical tanks at the Blount Shellfish 
Hatchery 2 days after fertilization and fed live microalgae, a mix of Tisochrysis lutea 
(CCMP1324; formerly Isochrysis sp., Tahitian strain) and Pavlova lutheri 
(CCMP1325), daily. Larvae were distributed into 60 L tanks at the VIMS Shellfish 
hatchery, and fed Pavlova sp. days 1 - 4 and a mix of Pavlova sp. and Chaetocerus 
gracilis from day 5 on.  
Pathogen and probiotic strains 
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V. coralliilyticus RE22 was supplied by H. Hasegawa, Department of 
Biomedical Sciences, Oregon State University (USA). The freshly cultured B. pumilus 
RI06-95 for comparison with formulated versions was cultured in the laboratory. Both 
bacteria were maintained as stocks in 50% glycerol at -80 °C until use. They were 
cultured on yeast peptone with 3% NaCl (YP30) media (5 g L-1 of peptone, 1 g/L of 
yeast extract, 30 g/L of ocean salt (Red Sea Salt, Ohio, USA)) at 28 °C with shaking at 
175 rpm as described in Karim et al. 2013a.  
Formulation process  
Granulated Product Formulation (RI-G) 
Probiotic B. pumilus RI06-95 was incubated in 2.25% NaCl (YP22.5) broth 
(yeast extract 1 g/L, peptone 5 g/L, 22.5 g/L ocean salt, Instant Ocean) at 25 °C and 175 
rpm. An initial culture was incubated for 2 d, then transferred to fresh YP22.5 and 
incubated for 4 d. The culture was partitioned into 50 mL sterile centrifuge tubes and 
centrifuged for 10 min at 2,350 × g. After centrifugation, cell pellets were transferred 
into a sterile petri dish (100 × 15 mm), and dishes were swirled with 2-3 mL culture 
media to ensure that the surfaces were completely covered in cells. The dishes were then 
covered with single ply, light duty paper (Kimwipes®) and placed in a convection oven 
to dry at 30 °C with constant airflow for 24-48 h, depending on initial volume. The dry 
cell mass was extruded through three particle size (40s, 80s, and 325s) USA Standard 
Sieve stainless steel screens (Cole Palmer, Illinois, USA), yielding products with 
average particle sizes of 43, 177, and 420 µm, respectively. The resulting granulated 
products were transferred into sterile glass vials and stored at 4 °C. For hatchery trials 
the granulated formulations were scaled up following the same formulation procedure 
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as above except bacterial cultures were centrifuged at 9,300 × g for 10 min and the final 
cell pellet was dried at room temperature (22 ± 3 °C) for approximately 2 days. 
Lyophilized Product Formulation (RI-L) 
Probiotic B. pumilus RI06-95 was cultured from frozen stocks and then 
centrifuged as above. After discarding the liquid supernatant, 25 mL of Sugar Salt 
Solution (SSS) (2.5 g/L Instant Ocean, 200 mM sucrose, filtered deionized (DI) water 
(pre-filtered through a 0.2 µm filter)) was added to each tube, and the cell pellet was re-
suspended using a vortex. The re-suspended cells were frozen at -20 °C for 12 h, and 
then lyophilized for 48 h (Labconco FreeZone 4.5 lyophilizer, Kansas City, MO, USA). 
The tubes were stored at 4 °C until use. 100 mM sucrose was used as a cryoprotectant 
during the lyophilization process. For hatchery trials, individual tubes with a single dose 
of formulation for a target dose of 5 × 104 CFU/mL for 100 L were prepared. 
Spray-dried formulations (RI-SD) 
Spray-dried formulations were prepared by Envera LLC (West Chester, PA) 
using a proprietary formula. Computer controlled fermentation vessels were used to 
grow the probiotic and pasteurized to make 100% spore-based product. After 
pasteurization, the probiotic was centrifuged and spray dried into a fine powder that can 
be easily hydrated with seawater. The final concentration of the probiotic in the 
formulation was 8.6 × 1011 CFU/mg of powder. For the hatchery trial, tubes of the 
appropriate amount of formulation for a target dose of 5 × 104 CFU/mL in each 100 L 
tank were prepared. At the hatchery seawater was added to the tubes and mixed 
thoroughly. The mixed formulation was then added to the tanks daily during feeding.   
Fresh culture controls (RI) 
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In order to determine the influence of the formulation process itself on the 
effectiveness of the probiotic in vivo, we tested simultaneous treatments of freshly 
cultured B. pumilus RI06-95 (cultures prepared as described in Sohn et al. 2016b) 
alongside formulated treatments in all lab and hatchery trials.  
Viability and stability of formulated products 
Viability and stability of each formulation was measured by counting colony 
forming units (CFU) on 2.5% yeast peptone agar plates using serial dilutions. Pre-
formulation cell concentrations in CFU/mL were measured from culture aliquots 
directly before centrifugation. The RI-L product was re-suspended in 50 mL filtered 
sterile seawater (FSSW). The RI-G was suspended at 5 mg/mL in FSSW for 10 min and 
then vortexed for 1 min. The RI-SD was suspended using 0.1 g into 50 mL FSSW, 
followed by 10-fold serial dilutions. The percent cell viability in the formulations was 
calculated as follows:  % Viability = [(sample formulation CFU/mL) / (pre-formulation 
CFU/mL)] × 100% 
RI-L was stored at 4 °C, while samples of RI-G were stored at either room 
temperature or 4 °C and RI-SD stored at room temperature. The stability of the 
formulated probiotics was measured immediately after formulation (t = 0) and 1, 2, 5, 
and 8 weeks after formulation, except RI-SD. Each assay was performed in triplicate.   
Laboratory pathogen challenge experiments 
Laboratory challenge assays were conducted following protocols outlined in 
(Karim et al. 2013a). Briefly, larval oysters were placed into six-well plates with 5 mL 
of filtered sterile sea water (FSSW, 28 psu). Probiotic treatments were added to the 
larvae at a concentration of 104 CFU/mL and incubated at room temperature with gentle 
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shaking. After 24 h, the larvae were placed onto a 42 µm nylon mesh and washed gently 
using FSSW, then placed back into the original wells. Finally, V. coralliilyticus RE22 
was added to each well, with the exception of the non-challenged controls, at a final 
concentration of 105 CFU/mL. Larval survival was quantified ~ 24 h after the pathogen 
was added using the neutral red technique (Gómez-León et al. 2008). Survival was 
calculated by using the formula:  Survival (%) = 100 × (number of live larvae/total 
number of larvae).  
The relative percent survival (RPS) of probiotic pretreatment compared to the 
challenged control was calculated using the formula:  RPS (%) = [1 - (% survival 
challenged control treatment / % survival challenged treatment)] × 100 as described in 
Karim et al., 2013. 
Hatchery trials 
Hatchery experiments were conducted at Roger William University (RWU), 
Bristol, RI or the Aquaculture Breeding Center at the Virginia Institute of Marine 
Sciences (ABC), following standard operating procedures at each hatchery. For each 
trial, twelve 60 L (ABC) or 100 L (RWU) conical larval rearing tanks were used. We 
performed four independent trials at RWU between January 2014 and July 2016, and 
one trial at VIMS in June 2015 (Trial IV), testing each of the formulations at least once. 
Each trial was initiated by adding 8 -10 larvae/mL (800,000 to 1,000,000 initial larvae) 
per tank 1-2 d post-fertilization to the conical tanks. Tanks were randomly assigned to 
treatments and probiotic formulations were added daily at the time of feeding mixed 
with the algal food. Larvae were kept in static conditions and tanks were drained-down 
  
 
32 
every other day, cleaned, and re-stocked with fresh water.  Treatments, number of tanks 
per treatment, and trial duration for each trial is shown in Table 1.  
Larval survival and growth during hatchery trial 
Data was collected at the time of selected drain-down events. Oyster larvae were 
passed through different sized mesh screens (35, 55, 75, and/or 105 µm for Trials I, II, 
and III; 35, 48, or 63 µm for Trial IV; 35 or 75 µm for Trial V) depending on the age 
and size of the larvae. Oyster larvae retained in each of the screens were collected in a 
container, seawater was adjusted to a fixed volume (1 – 5 L depending on the amount 
of larvae), and aliquot samples (1 mL each) were placed in Sedgewick Rafter counting 
chambers (Graticules ® S50). Larvae were fixed with Lugol’s iodine (Trials I-III) or 
temporarily immobilized with a 2:1 mixture of freshwater: 70% isopropyl alcohol 
(Trials IV, V). Larvae were counted under a microscope and the presence of live and 
dead larvae were recorded. After counting, 50 larvae from each tank (25 from top 
screen, 25 from bottom screen) from Trial I and 25 larvae from each tank from Trials 
II, III, and V were randomly selected from the slides and photographed with an Olympus 
BX51 microscope (Olympus) and measured using an Olympus DP25 camera and 
CellSens Standard 1.6 image software (Olympus). During Trial IV, 5 larvae from each 
tank were randomly selected and measured on a Nikon E200 microscope. A random 
sample from each culture was photographed using a Nikon DS-Fi2 camera and DS-L3 
camera control unit. Interval survival rate was determined by dividing the number of 
live larvae at each time point by the number of live larvae returned to the tank on the 
previous time point.  
Laboratory pathogen challenge of probiotic-treated larvae from hatchery 
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An aliquot of larvae from each tank collected at selected drain-down events was 
transported to the laboratory at University of Rhode Island. Oysters (about 40 – 50 
larvae) were placed in six-well plates and then challenged with V. coralliilyticus RE22 
at a final concentration of 105 CFU/mL following the methods described in the 
laboratory challenge section. Oyster larvae from Trial IV could not be challenged since 
very low number of oyster larvae were left in the probiotic treated groups at the 
hatchery.  
Determination of levels of Vibrio spp in the hatchery 
Total number of Vibrio spp. was evaluated using a plate count method on 
thiosulfate-citrate-bile salts-sucrose medium (TCBS, Difco) (Sohn et al. 2016a). 
Samples were collected from water in the rearing tank (3 x 10 mL), tank surfaces (by 
swabbing), and oysters (about 1,000) when the tanks were drained. Swab samples (3 per 
tank) of tank surfaces (about 48 cm in length in total) were collected from each tank for 
all except Trial V.  Each cotton swab was placed into a sterile Falcon tube containing 1 
ml of FSSW and then mixed vigorously. Oyster larvae were rinsed with FSSW, 
homogenized using a sterile pestle, and suspended in FSSW. Ten-fold serial dilutions 
of each sample were prepared in triplicate, and then triplicate 10 µL of each dilution 
were plated on TCBS agar plates. After a ten-fold serial dilution, 10 µL samples of each 
of the dilutions were spotted evenly onto TCBS agar plates in triplicate for all except 
trial 5. The inoculated plates were incubated for 16 - 20 h at 28 ˚C and the colony 
forming units (CFU) were calculated. Results are expressed as CFU/mL, where 1 mL 
corresponds to 1 mL of water in the tank, 1 mL of swab suspension, or 1 mL of water 
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contacting about 1,000 larvae. Determination of Vibrio spp. levels could not be 
performed on larvae from trial IV due to very low numbers of surviving larvae.  
 
Statistical Analysis 
Larval oyster survival data were subjected to arcsine square root transformation prior to 
statistical analysis. The one-way analysis of variance (ANOVA) was used to determine 
significance between treatments within each time point. The two-way ANOVA was also 
used to determine significance between groups with time and treatment as factors. The 
Tukey’s or Sidak’s multiple comparison tests were used for post-hoc pairwise 
comparisons. A p-value < 0.05 was considered to be statistically significant.  
Formulation cell viability data were analyzed by two-way ANOVA followed by 
Tukey’s Test for each temperature and each time point. All statistical analyses were 
performed using Graphpad Prism, version 6.0 (Graphpad Software, Inc.). Differences 
were considered to be significant at values of p < 0.05.  
 
Results  
Viability and stability of formulated products 
The stability of the three formulated products was assessed after storage for 8 weeks 
(RI-G and RI-L) (Figure 1) or 16 weeks (RI-SD) at ambient temperature. The three 
formulated products varied in their final CFU/ml following storage. RI-L and RI-G had 
similar pre-formulation concentrations of 1 × 108 CFU/mL and 1.27 × 108 CFU/mL, 
respectively. We observed a loss in viability immediately after the RI-G formulation 
process (data for RI-SD not available), and then again one week after storage at both 4 
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and 27 °C. However, we note strong stability after this initial loss. The spray dried 
formulation had a concentration ~200-250-fold higher at 2.65 × 1010 CFU/mL 16 weeks 
post formulation.   
 
Effectiveness of B. pumilus RI06-95 formulations at promoting survival after a 
pathogen challenge  
Laboratory challenge experiments: Pretreatment with fresh or formulated probiotic 
had no adverse impact on larval survival (i.e. in the absence of pathogens) over a 48h 
period aside from a single instance (L, Fig. 2B), where the formulation reduced larval 
survival by 46% compared to the unchallenged control. In the same trial, treatment of 
sucrose alone also showed significant reduction in larval survival (L, Fig. 2B). The 
ability of formulations to protect oyster larvae from exposure to the pathogen V. 
coralliilyticus RE22 was either higher or equal to that of fresh cultures in all experiments 
conducted, except in the one instance where sucrose alone was shown to reduce larval 
survival (Table 2, L, Fig. 2B). Larval survival was significantly greater in both fresh 
and formulated treatments versus controls for one of the three L treatments (Fig.2D), 
the G treatment (Fig.2A), and both SD treatments (Fig. 2E, F) (Table 2). In only two 
instances was there a significantly higher protection by formulation against the pathogen 
challenge than the fresh culture (Table 2, L III and SD II, Fig. 2D and 2F respectively).  
 
Hatchery Trials: 
Effect of daily treatment with probiotics in the hatchery on larval growth and survival 
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Based on successful protection from pathogen challenges in laboratory trials, all three 
formulations were tested in a hatchery. Treatments included in each hatchery trial and 
the length of treatment is described in Table 1. The formulations did not have an effect 
on the larval growth as shown by larval size measurements compared to control except 
for Trial IV with RI-L (Figure 3). None of the formulations had a significant detrimental 
impact on survival in the hatchery (Figure 4) except Trial I (RI-G) that showed a 
significant negative effect of the probiotic additions. None of the trials showed a 
significantly positive effect on larval survival due to probiotic addition (Figure 4). Of 
the three formulations, the spray-dried product had the smallest impact on larval 
survival. Thus, the SD-formulation is safe for use with oyster larvae in the hatchery. 
Effect of daily treatment with probiotics in the hatchery on larval survival to bacterial 
challenge 
Larvae from the hatchery experiments were tested for improved survival following 
challenge with V. coralliilyticus RE22. Since pathogens could not be introduced into 
the hatchery, larvae were collected and subjected to laboratory challenges as described 
in methods section. Larvae exposed to the granulated or lyophilized probiotics in the 
hatchery did not show significantly higher survival to a 24 h bacterial (V. coralliilyticus 
RE22) challenge as compared to non-treated challenged larvae (One-way ANOVA; p > 
0.05) (Figure 5). A fresh culture of RI06-95 offered some protection on day 12 in Trial 
II (One-way ANOVA; p < 0.05; Figure 5 D). Relative percent survival (RPS) provided 
by the fresh culture of RI06-95 in this trial was 36 ± 6 % on day 12 (Table 3). On the 
other hand, trial V showed significantly improved survival both with RI-SD and fresh 
culture of RI06-95 as compared to controls (One-way ANOVA; p < 0.05; Figure 5 G). 
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The relative percent survival (RPS) with fresh culture was 28 ± 6% and RI-SD was 
43±4% (Table3).  
  
Effect of daily treatment with probiotics in the hatchery on levels of total Vibrio spp.  
In general, daily treatment of tanks with either formulation of B. pumilus RI06-95 did 
not lead to a significant decrease in the levels of total Vibrio spp. in water, tank surfaces, 
or oyster larvae as compared to control groups at each of the time points (Figure 6 and 
Figure 7). High levels of variability were observed between tanks and trials within 
treatments. Interestingly, levels of Vibrios in the water were lower than 103 CFU/mL in 
Trial I (Figure 6A) and none were detected on the tank surfaces during this trial (Figure 
6D). Trial I was performed in January, a month in which lower levels of Vibrios are 
present in coastal waters in the region (and therefore in water being pumped into the 
hatchery) (Duan & Su 2005, Parveen et al. 2008). Similarly, very low levels of Vibrios 
were found in Trial V in the water (Fig 6G). Levels of Vibrios on tank surfaces and 
larvae were not measured during Trial V. Overall the results show that certain days 
probiotic treated tanks (formulated or fresh) show reduced level of Vibrios spp. as 
compared to control but there is no significant trend to specifically ascertain that effect. 
  
 
Discussion 
We outline three formulation protocols, a granulation process (G), a lyophilization 
process (L), and a commercial spray-dried process (SD). Variation in terms of success 
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was achieved for each of the formulations, with the spray-dried formulation showing 
overall the best performance. 
Granulation process: A traditional approach for formulating microorganisms is air-
convective drying, which is a cost-effective process for the dehydration of 
microorganisms (Fu & Chen 2011, Guergoletto et al. 2012). Granulation after an air-
convective drying is necessary to prevent segregation of the constituents of the powder 
and to provide consistent particulate sizes. The loss of viability of probiotic bacteria 
during granulation is associated with granulation operating conditions such as 
temperature, mechanical and moisture stress, and the characteristics of the selected 
microorganisms (Hiolle et al. 2010). This process did cause an immediate loss in 
viability from fresh cultures over the short term, as dehydration of bacterial cells poses 
serious physiological challenges to the survival of cells, such as conformational and 
chemical changes in structural proteins and membrane lipids (Ananta 2005, 
Santivarangkna et al. 2008, Ohtake & Wang 2011). However, after these initial short-
term losses the cell count stabilized and remained consistent over 8 weeks. Storage 
conditions such as temperature and humidity have also been shown to affect the stability 
of granulated probiotic product (Ananta 2005). Mortality of probiotic bacteria during 
storage is associated with various stress factors such as temperature, oxygen/air, light, 
moisture/humidity, and package material, a combination of which tends to damage or 
destroy cells (Wang et al. 2004, Ananta 2005, Chávez & Ledeboer 2007). Our results, 
however, suggest that beyond an initial decrease in viability, the granulated product of 
RI06-95 could be stored at either 4 °C or room temperature and maintain viability for 
up to for 8 weeks. The stability of the granulated product during storage may be due to 
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the adaptation of Bacillus spp. to extreme environmental stress by spore-formation 
characteristics (Desmond et al. 2002, Driks 2002, Hong et al. 2005, Cutting 2011).  
RI-G showed protection in laboratory experiments and did not show any 
detrimental effect on the larvae in any of the laboratory assays. However, in the hatchery 
trial formulation treated larvae showed reduced survival as compared to control and 
freshly grown probiotic. It demonstrated protection from pathogen challenge in 
laboratory trials but was unsuccessful in doing so in the hatchery trial. Despite the 
favorable results from viability and storage of the granulation protocol, research on the 
granulated product was discontinued in this study due to a negative influence on survival 
of larval oysters in hatchery settings.  
 
Lyophilization: The lyophilized formulation (L) did not significantly impact cell 
viability after the formulation process. Lyophilization has previously been investigated 
as a way of preserving and formulating Bacillus spp. as probiotic products (Henn et al. 
2015). To ensure sufficient viability after freeze-drying, a disaccharide cryoprotectant 
such as sucrose or trehalose is typically added to provide structural support to cell 
membranes and proteins (Leslie et al. 1995). We successfully used sucrose at a 
concentration of 100 mM that provided stability and viability over time.  
RI-L led to variable results in larval survival in hatchery trials. It failed to 
provide protection from pathogen challenge in the 2 out of 3 laboratory experiments and 
the hatchery trial. It produced no observable negative effect on water quality. Our results 
suggest that the addition of sucrose may be responsible for the negative impact on larval 
survival, as sucrose alone (without B. pumilus RI06-96) lowered larval survival in 2 of 
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4 trials where it was investigated. Because a wide range of bacterial taxa can readily use 
sucrose, we suggest that its addition to the formulated product may encourage 
antagonistic bacterial growth, and presents greater risks than advantages.  
 
Spray drying: Of the three formulations tested, the commercially prepared spray dried 
formulation was found to maintain the highest concentration at room temperature over 
time while also showing no negative impact on larval oysters in the laboratory or in the 
hatchery trials. After 16 weeks at room temperature, the SD-product still contained 
>2.65 × 1010 CFU/g. Previous research has shown that probiotic concentrations of 
Bacillus products at around 1 × 104 CFU/ml provide optimal performance (Karim et al. 
2013a; Sohn et al. 2016a), meaning to reach a final target concentration of 1×104 
CFU/ml in a 1,000 L commercial tank, only ~0.4 g of RI-695 would need to be added. 
This would be extremely cost effective for use at a larger scale. Another added benefit 
of the formulation is its ease of use. The powder quickly suspends in seawater and is 
added to the tank very easily. 
The spray-dried formulation was also shown to perform as well or better than 
freshly prepared B. pumilus RI06-95 in both laboratory experiments and hatchery trials. 
In hatchery experiments, RI-SD showed no significant reduction in larval survival, 
water quality or larval growth. In fact, it increased survival compared to freshly prepared 
culture in the hatchery trial by day 12. RI-SD also performed well in pathogen challenge 
experiments, increasing survival of larvae after the challenge at the same rate or greater 
as compared to freshly prepared culture. 
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As seen in previous hatchery experiments (Sohn et al. 2016), high levels of 
variability were seen between tanks and trials within a treatment. The variation in results 
within and/or between experiments in this study could be due to several factors: (1) a 
different quality and health status of larvae from each trial; (2) the impact of various 
environmental and biological factors such as salinity, pH, temperature/season at the 
hatchery; (3) variability in the characteristics of different rearing systems, such as tank, 
source or treatment of water, and location of hatchery (Balcazar et al., 2006; Gatesoupe, 
1999; Martínez Cruz et al., 2012; Utting and Millican, 1997); and 4) the effect of 
variability in the composition of microbial communities and how these communities 
may interact with the probiotic. Due to above factors the variability is more pronounced 
in hatchery trials than controlled laboratory experiments. Although variability is seen 
within and/or between experiments in this study for RI-G and RI-L, it is highly 
minimized in the trials using RI-SD. More importantly there is consistency in the goal 
of achieving protection from pathogen challenge with use of RI-SD.   
 The use of probiotics as a disease control mechanism has particular and critical 
relevance to shellfish hatcheries, where disease losses are high, vaccination is not 
possible and use of antibiotics is not recommended. Our results demonstrate successful 
formulation of the candidate probiotic B. pumilus RI06-95 for its use in shellfish 
hatcheries using the spray drying method. It also demonstrates the challenge in 
formulating the probiotic and the need of thorough testing in both laboratory and 
hatchery setting to confirm the effect of formulation. The laboratory and hatchery trials 
confirm that the RI-SD formulation is stable over a long term, remains viable and shows 
comparable performance to freshly grown cultures of the probiotic. It is suitable for 
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storage, transportation and can be easily applied in a hatchery by mixing with sea water. 
Although the addition of RI-SD did not show reduction in Vibrio spp. in general, this 
might not be a strategy used by the probiotic as its mechanism of action. Probiotics are 
known to modulate the immune system of the host (Hardy et al., 2013, Mortha et al., 
2014, Sanchez et al., 2015). This could be one the strategies used by B. pumilus RI06-
95 to provide protection in the event of vibriosis.  
Future research in mechanism of action of the probiotic would help in optimization of 
the use formulation in terms of dosage timing and frequency.   
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Figure 1. Impact of formulation processing (granulation or lyophilization) and 
temperature storage on the stability of Bacillus pumilus RI06-95.  Cell count in the 
reconstituted formulation after storage for up to 8 weeks was determined using a plating 
method. Data expressed as mean ± SEM of CFU/mg of formulation. 
 
 
Hatchery 
Trial Treatments 
Tanks per 
treatment 
Treatment 
period 
(days) 
Dates 
performed 
I Control, RI-G 6 14 01/03/14 – 01/24/14 
II 
Control, 
ConwS, RI, RI-
L 
3 12 
01/29/15 – 
02/10/15 
III 
Control, 
ConwS, RI, RI-
L 
3 12 
02/22/15 – 
03/06/15 
IV Control, RI-L 4 (control), 3(RI-L) 10 06/24/15 – 07/08/15 
V Control, RI, RI-SD 3 12 
06/06/16-
06/17/16 
 
Table 1: Treatments included in each hatchery trial and the total length of treatment in 
days. Abbreviations: controls (no probiotic provided); ConwS = 100 mM sucrose (no 
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probiotic, control for lyophilized formulation); RI-G = granulated formulation; RI-L = 
lyophilized formulations (in 100 mM sucrose); RI-SD = spray-dried formulation; RI = 
RI06-95 freshly cultured in lab.  
 
 Treatment 
Relative Percent 
Survival 
(RPS, % ± SEM) 
Plots 
Granulated  RI-G 69 ± 1 (Figure 2 A) 
Lyophilized I 
RI 26 ± 5 
(Figure 2 B) 
RI-L -93 ± 86 
Lyophilized II 
RI 22 ± 11 
(Figure 2 C) 
RI-L 25 ± 6 
Lyophilized III 
RI 56 ± 4 
(Figure 2 D) 
RI-L 74 ± 1 
Spray-dried I RI 
RI–SD 
23 ± 6 
21 ± 13 
(Figure 2 E) 
Spray- dried II RI 
RI–SD 
75 ± 5 
83 ± 2  
(Figure 2 F) 
 
Table 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster 
larvae for 24 h with RI06-95 formulated products on survival (RPS, % ± SEM) after 
challenge with V. coralliilyticus RE22.  Survival was measured 24 h after challenge 
and 48 h after addition of the probiotic. Data is expressed as Relative Percent Survival 
(RPS, % ± SEM) of challenged oysters exposed to probiotics compared to V. 
coralliilyticus RE22 challenged control. Abbreviations: RI-G = granulated 
formulation; RI-L = lyophilized formulation (in 100 mM sucrose); RI-SD = spray 
dried formulation, RI = fresh; RE22 = V. coralliilyticus RE22. 
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Figure 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster 
larvae with Bacillus pumilus RI06-95 formulated products for 24 h on survival (% ± 
SEM) after challenge with V. coralliilyticus RE22. Survival was measured 24 h after 
challenge and 48 h after addition of the probiotic. (A) Exposure to a granulated product 
of Bacillus pumilus RI06-95; (B), (C), and (D) Exposure to lyophilized formulations 
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(representative experiments) (E) and (F) Exposure to spray dried formulations. 
Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated 
formulation; RI-L = lyophilized (in 100 mM sucrose) formulation 5; RI = fresh RI06-
95; RE22 = V. coralliilyticus RE22. Different letters indicate statistically significant 
differences between the treatments. 
 
 
  
E
 
 
Figure 3. Effect of daily treatment with different formulations of Bacillus pumilus 
RI06-95 of larval eastern oysters (Crassostrea virginica) in the hatchery on mean larval 
size (µm ± SEM) at selected time points. (A) Trial I; (B) Trial II; (C) Trial III; (D) Trial 
IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G 
= granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD 
C ConwS RI-L RI
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= formulation RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*) 
indicates statistical significances compared to controls. 
 
 
  
  
E 
 
Figure 4. Effect of daily treatment with probiotics in the hatchery on interval survival 
(% ± SEM) of oyster larvae between selected time points. (A) Trial I; (B) Trial II; (C) 
Trial III; (D) Trial IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100 
mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) 
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formulation; RI-SD = spray dried formulation; RI = fresh RI06-95. An asterisk (*) 
indicates statistical significances between treatments. 
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Figure 5. Effect of daily probiotic treatment in the hatchery on larval survival to a 
laboratory challenge with the pathogen Vibrio coralliilyticus RE22. Larvae were 
brought to the laboratory and survival was measured 24 h after challenge with RE22. 
(A) Larvae collected on Day 3 after fertilization in Trial I; (B) Day 7 in Trial I; (C) Day 
5 in Trial II; D) Day 12 in Trial II; E) Day 5 in Trial III; F) Day 12 in Trial III. (G) Day 
8 in Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = 
granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = 
spray-dried formulation; RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. A 
different letter indicates a significant difference between treatments (One-way 
ANOVA; p < 0.05). 
 
 
 
 
 
Trial Treatments Relative Percent Survival (RPS, % ± SEM) 
  Day 3 Day 7 
I RI-G+RE22 -10 ± 2 -78 ± 88 
  Day 5 Day 12 
II 
RI+RE22 
RI-L+RE22 
36 ± 9 
46 ± 3 
36 ± 6 
2 ± 5 
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III 
RI+RE22 
RI-L+RE22 
2 ± 13 
- 36 ± 28 
16 ± 3 
26 ± 1 
IV No challenge data due to low survival of larvae  
  Day 8  
V 
RI + RE22 
RI-SD + RE22 
28 ± 6 
43 ± 4 
 
 
Table 3. Effect of daily exposure to formulations of B. pumilus RI06-95 in the hatchery 
on larval oyster survival (%) 24 h after challenge with Vibrio coralliilyticus RE22.   Data 
is expressed as Relative Percent Survival (RPS, % ± SEM) of challenged oysters 
exposed to probiotics compared to V. coralliilyticus RE22 challenged control. 
Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated 
formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = spray dried 
formulation, RI = fresh RI06-95; RE22 = V. coralliilyticus RE22 
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Figure 6. Effect of daily treatment with probiotics on total vibrio levels 
(Log10(CFU/mL) ± SEM) in water (A, B, C, G) and tank surfaces (D, E, F) in a hatchery. 
(A and D) Trial I (no bacteria were detected in tank surfaces in Trail I); (B and E) Trial 
II; and (C and F) Trial III. (G) Trial V. Abbreviations: C = no probiotic; ConwS = 100 
mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose) 
formulation;RI-SD = spray-dried formulation; RI = fresh RI06-95; RE22 = V. 
coralliilyticus RE22. An asterisk (*) indicates significant differences between 
treatments (mean ± SEM, p < 0.05; Two-way ANOVA). 
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Figure 7. Effect of daily treatment with probiotics on total vibrio levels 
(Log10(CFU/mL) ± SEM) on oyster larvae in the hatchery. (A) Trial I; (B) Trial II; and 
(C) Trial III. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = 
granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI = fresh 
RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*) indicates significant 
differences between treatments (mean ± SEM, p < 0.05; Two-way ANOVA). 
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Abstract 
 
Vibrio spp. are ubiquitous in marine environments and, in the case of pathogenic 
species, responsible for causing disease in several marine organisms. Vibrio 
coralliilyticus has emerged as a pathogen affecting a variety of invertebrate species. In 
corals, certain strains cause bleaching, while V. coralliilyticus RE22 causes massive and 
rapid mortality of eastern oysters (Crassostrea virginica) larvae. Such mortality events 
in hatcheries where oyster larvae are reared, lead to heavy losses and subsequent 
shortage of oyster seed for the grow-out industry. A better knowledge of oyster-
pathogen interactions and the mechanisms involved in RE22 pathogenicity may aid the 
development of effective management strategies.  This study aims to characterize the 
larval immune response to experimental challenge by V. coralliilyticus RE22. Six to 
ten-day old C. virginica larvae were exposed to V. coralliilyticus RE22 for 6 hours to 
understand the host response in the early stages of the disease. Transcriptomes were 
obtained by high throughput sequencing of cDNA from three replicate experiments. 
Comparison of RE22 treated larval transcriptomes to untreated control larvae yielded 
1,534 differentially expressed transcripts (p £ 0.05).  Overall, transcriptomic data 
showed evidence of suppression of key immune signaling pathways but possibly 
activated antiviral pathways. The larval response to RE22 lacked production of protease 
inhibitors, hypothesized to be involved in providing protection against the proteases that 
are a key virulence factor of RE22. In addition, transcriptomic data suggests modulation 
of mucus and cytoskeletal components. The transcriptomic response was also 
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characterized by differential expression of metabolic genes, suggesting high metabolic 
demand and oxidative stress contributing to larval mortality. This study fills a major gap 
in our knowledge on the immune responses in larval stages of this economically and 
ecologically important species. This information could aid in developing solutions to 
control disease and design better management practices for hatcheries. 
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1. Introduction 
 
Vibrio spp. are common pathogens causing disease in a wide variety of aquatic species, 
including several species of mollusks. Strains of V. coralliilyticus also cause disease in 
corals, leading to bleaching (Ben-Haim et al., 2003, Wilson et al., 2013). V. 
coralliilyticus RE22, previously known as V. tubiashii RE22, causes vibriosis in bivalve 
larvae (Richards et al., 2015).  The disease resulted in heavy mortalities that severely 
affected oyster seed production of shellfish hatcheries (Elston et al., 2008).  
 
Infection by vibrios in bivalve larvae is dramatically rapid in progression and 
characterized with signs of bacillary necrosis, reduced feeding, and swarming of 
bacteria around the moribund larvae (Tubiash et al., 1965). An investigation of the 
colonization and infection process in Manila clam (Ruditapes philippinarum) larvae 
using a GFP-tagged Vibrio sp. showed pathogen entry through ingestion, with infection 
quickly spreading to other organs and followed by colonization and proliferation in the 
entire body (Dubert et al., 2016). The genome of V. coralliilyticus RE22 shows that it 
encodes several extracellular metalloproteases, serine proteases, hemolysins and type 
secretion systems as virulence factors (Hasegawa et al., 2008, Hasegawa et al., 2009, 
Spinard et al., 2015). Experimental infection of C. virginica larvae and juveniles with 
V. coralliilyticus RE22 showed differences in susceptibility based on the age and genetic 
background of the oysters (Gómez-León et al., 2008). 
 
V. coralliilyticus YB1 specifically infects coral Pocillopora damicornis causing coral 
tissue lysis at higher seawater temperatures (26-29°C) and its virulence factors include 
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a potent extracellular protease (Ben-Haim and Rosenberg, 2002, Ben-Haim et al., 
2003a) whose production is also temperature regulated (Ben-Haim et al., 2003b). V. 
coralliilyticus P1 genome and mutant studies demonstrated presence of 17 
metalloproteases, serine protease, hemolysin-related protein RbmC, chitinase and 
effector genes including vgrG, hlyA and hcp (Santos et al., 2011).  Transcriptomic 
studies investigating the responses of coral Pocillopora damicornis to V. coralliilyticus 
YB1 reported immunosuppression of the host as a pathogenesis strategy of YB1 (Vidal-
Dupiol., et al., 2014) including repression of the antimicrobial damicornin (Vidal-
Dupiol et al., 2011a). Innate immunity related genes involved in P. damicornis 
responses to V. coralliilyticus YB1 include lectins, cystatin B, ferretin, and selenium-
binding protein (Vidal-Dupiol et al., 2011b).  
Several studies have characterized changes in gene expression patterns in larval stages 
of bivalves during development including Pinctada fucata (Li et al., 2016), C. angulata 
(Qin et al., 2012) and in response to vibrio infection in Crassostrea gigas (Hasegawa et 
al., 2008) and C. virginica (Genard et al., 2012). This study aims to enhance knowledge 
on bivalve-vibrio interactions by analyzing the transcriptomic response of larval eastern 
oysters, an economically and ecologically important species, to infection with V. 
coralliilyticus RE22, a bacterial pathogen capable of causing rapid and high levels of 
mortality in bivalve hatcheries.  The goals of this study are to (1) characterize the 
response of C. virginica larvae to experimental challenge with V. coralliilyticus RE22; 
and (2) provide hypotheses on possible strategies used by V. coralliilyticus RE22 to 
overcome larval immune defenses. This information will aid in developing solutions to 
control disease and design better management practices for hatcheries.  
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2. Materials and methods 
 
2.1 Vibrio coralliilyticus RE22 culture:  
The pathogen (supplied by H. Hasegawa, Department of Biomedical Sciences, Oregon 
State University) was maintained and stored in 50 % glycerol stocks at -80°C until use. 
Inocula from freezer stocks were plated on yeast peptone with 3%NaCl (YP30; 5 g L-1 
of peptone, 1 g L-1 of yeast extract, 30 g L-1 of ocean salt, Instant Ocean) agar plates 
for 2 d, then transferred to 5 mL of YP3 broth incubated at 25°C on a shaker (134 rpm) 
for 1 d. Cultures were washed using Artificial Filtered Sterile Seawater (AFSW, 28-30 
psu salinity) twice by centrifugation at 23,000 rpm for 10 min. The OD at 550 nm was 
measured and the stock was diluted such as to obtain a sub lethal concentration of 5 × 
104 CFU mL-1 for transcriptome analysis and a lethal concentration (Karim et al., 2013) 
of 5 × 105 CFU mL-1 for disease progression analysis.  
 
2.2 Oyster larvae:  
C. virginica larvae were obtained from shellfish hatcheries on the east coast of United 
States. Larvae 6-10 days old were collected at the hatchery and shipped overnight to the 
lab at the University of Rhode Island on a wet filter. Upon arrival to the laboratory, 
larvae were washed with AFSW on top of a 40 µm nylon mesh and placed in stock 
containers containing AFSW. Larvae were acclimatized to the laboratory environment 
(room temperature) for 24 h prior to the experiments.   
 
2.3 Effect of V. coralliilyticus RE22 on mortality of C. virginica larvae 
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In order to understand the rate of progression of disease, C. virginica larvae were 
experimentally challenged with 5 x 105 CFU mL-1 V. coralliilyticus RE22 (Karim et al., 
2013).  Larval density (larvae/mL) of the stock was determined using a Nikon E200 
microscope. Larvae (~100) were distributed in wells of a 6-well plate with 5 mL AFSW 
and maintained at 22 - 23 °C with gentle rocking. Two treatments (control and 
challenge) were each conducted in triplicate. Larval mortality was recorded at 6, 9, 14, 
18 and 20h post addition of V. coralliilyticus RE22 by evaluation of active swimming 
and/or gut and cilia movement using a Nikon E200 microscope. 
 
2.4 Effect of pathogen exposure on larval gene expression 
 
2.4.1 Experimental set up  
For biological replicates, the complete set up as explained below was performed using 
larvae from three different hatcheries (n = 3 experiments, operationally designated as 
K, M, and V). Larvae from the stocks were distributed into tissue culture flasks (~10,000 
per flask) in 500 mL AFSW and kept on a shaker with gentle shaking at ~50 rpm at 
room temperature. Larvae were acclimatized to the experimental set up for an additional 
24h prior to challenge. Each treatment (control and challenge) was conducted in 
duplicate to serve as technical replicates. Larvae were fed with 1 mL of instant algae 
Shellfish Diet 1800TM (20,000 cells/mL; Reed Mariculture Inc., San Jose, CA. USA) 
immediately prior to treatment in order to promote pathogen ingestion. Challenge with 
V. coralliilyticus RE22 was performed with a sub lethal concentration of 5 × 104 CFU 
mL-1 for 6h. 
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2.4.2 Larval Collection post treatments  
Control larvae were collected at 0h and RE22 treatments were collected 6h post 
challenge. Larvae were aspirated gently from the flasks using a 100mL serological 
pipette, and filtered through a 40 µm sterile filter for collection. Since dead larvae settle 
to the bottom, the last 25 mL of each flask was not collected to avoid bias in 
transcriptomic response. Larvae were washed with 2mL of AFSW on a 40µm filter, 
followed by a wash using 2mL of RNAlater™, aspirated from the filter using a pipette, 
placed in labeled 2 ml RNase free microfuge tubes, and held at 4°C for 24h in 
RNAlater™ followed by storage at -20°C.  
 
2.4.3 RNA extraction, cDNA prep and sequencing  
Tri-reagentä (Sigma-Aldrich) was used for extracting total RNA from all the samples 
following manufacturer’s instructions (TRI Reagentä Protocol, Sigma-Aldrich). RNA 
extracts were DNase treated using the DNA-freeä DNA removal kit from Ambion and 
purity and concentration of RNA was assessed using a Nanodrop 8000 
spectrophotometer (Thermo Scientific). RNA from technical replicates was pooled at 
equimolar concentration. The quality and quantity of the pools were assessed using 
Agilent 2100 Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples 
were selectively enriched for poly-A containing mRNA and cDNA libraries were 
prepared using the PrepX RNAseq library Prep Kit (Takara Bio USA, inc). Samples 
were sequenced on Illumina HiSeq platform with 2x125 reads at a targeted sequencing 
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coverage of 20-30M per sample at the Harvard University, FAS Center for Systems 
Biology, MA. 
 
2.4.4 Assembly, annotation and analysis 
Raw reads obtained from sequencing were filtered, trimmed and adapters were removed 
using bbduk program in BBTools suite from Joint Genome Institute and viewed in 
FASTQC (Andrews, 2010). Processed reads were aligned to C. virginica reference 
genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed 
using Stringtie (Pertea et al., 2016) using default parameters. To compare the depth of 
sequencing across all samples preseq package was used (Daley and Smith., 2013). 
Differential gene expression analysis was performed by comparing transcript counts 
between RE22 6 h treatment (replicates K, M, V) vs control 0 h (replicates K, M, V) 
using DESeq2 (Love et al., 2014). Transcripts with Benjamini-Hochberg adjusted p 
value £ 0.05 and log fold change of ≥ 2 or ≤ -2 were considered significantly 
differentially expressed. This analysis design only allowed for the most conservative 
estimates and only showed differentially expressed genes representing all the biological 
replicates. Annotation for differentially expressed genes (DEGs) was performed by 
mapping to NCBI protein non-redundant (NR) database using BLASTx (Altschul et al., 
1997) with an e-value cutoff of 1e-3 and hit number threshold of 20. Mapping DEGs to 
GO terms was conducted using BLAST2GO v4.1.9 (Conesa et al., 2005) and functional 
enrichment was done using topGO (Alexa et al., 2006) with default parameters. ReviGO 
(Supek et al., 2011) was used to plot and visualize results obtained from topGO with 
default parameters (allowed similarity was set to medium). Significantly enriched GO 
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terms were obtained by using Fishers exact test (p £ 0.01). Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway annotations were also obtained using the KEGG 
Automatic Annotation Server (KAAS).   
 
3. Results  
3.1 Effect of V. coralliilyticus RE22 on mortality of C. virginica larvae 
Mortality in larval oysters exposed to 5´105 CFUmL of V. coralliilyticus RE22 was 
initially seen at 14h after challenge, increasing exponentially after that (Figure 1a).  The 
larvae appeared normal at 6h, but 9h after challenge many showed reduced motility and 
feeding (Figure1b).  
 
3.2 Transcriptome alignment 
Depth of sequencing for all the transcriptomes ranged from 16,617,375 – 39,681,499 
paired end reads. Sequencing saturation curves for all transcriptomes were close to full 
saturation, indicating that all but the rarest transcripts would be represented in the 
transcriptome (Figure 2). The alignment rate to the Crassostrea virginica reference 
genome using HISAT2 ranged from 85 – 89 % (Table 1).  
 
3.3 Differential expression Analysis  
Comparison of transcriptomes obtained from RE22 treated (6h) larvae to control (0h) 
larvae using DESeq yielded 1,534 differentially expressed transcripts (p ≤ 0.05, 
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Refer to 
supplementary data tables in appendix for descriptions and log fold change values.  
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3.4 GO and KEGG annotation  
A Gene Ontology (GO) term enrichment analysis was performed on all the differentially 
expressed transcripts in response to RE22 challenge. There were 22 biological processes 
significantly enriched (p<0.05) that mainly belonged to metabolism and signaling, but 
none related to immunity (Table 2, Figure 3); 17 metabolic functions significantly 
enriched (p<0.05) including “receptor activity” (Figure 4) and membrane related terms 
significantly enriched in the cellular component (CC). The highest number of DEGs 
mapped to KEGG annotations belonged to signal transduction (Table 3).  
 
3.6 Differentially expressed immune genes in response to RE22 
3.6.1 Immune related genes 
Described below are some of the important immune-related genes showing differential 
expression in RE22 exposed larvae (6h) as compared to control (0h) (Table 4).  
Transcripts corresponding to immune receptors upregulated in response to RE22 
included TLR receptors (TLR4, TLR13 and TLR Tollo isoform X2), lectin and 
fucolectin, and leucine-rich repeats (LRRs). Transcripts identified as scavenger 
receptor, complement C1q-like protein 2 and 4, LRR9, and fibronectin type III domain-
containing protein 2 were downregulated.  
Transcripts related to the TLR signaling pathway, including myeloid differentiation 
primary response protein MyD88-like (MyD88), TNF receptor-associated factor 4-like 
(TRAF4), mitogen-activated protein kinase kinase kinase 7-like (TAK1) and toll-
interacting protein-like (TOLLIP), showed downregulation in response to RE22 
exposure. Important members of the NF-kB pathway that were downregulated included 
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NF-kappa-B-activating protein-like (NKAP) and IkB-alpha. An essential component of 
the MAP kinase signal transduction pathway, dual specificity mitogen-activated protein 
kinase kinase 7-like (MKK7), was upregulated. Surprisingly, transcripts related to 
antiviral pathways including stimulator of interferon genes protein-like (STING) and 
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 (USP25) and some members 
of the JAK-STAT pathway were upregulated in response to RE22.  
In terms of immune effectors, some mucin transcripts were differentially expressed in 
response to RE22, showing a mixed response (both up and downregulation).  
In addition, cytoskeleton related transcripts including cytoplasmic actin and septin-11-
like were downregulated, but dynamin-1-like transcripts showed high levels of 
upregulation. 
 
3.6.2 Cell death 
Transcripts corresponding to autophagy related gene ATG9A were highly upregulated 
in response to RE22. Several transcripts that belong to the apoptosis pathway were 
differentially expressed in response to RE22 including transcripts identified as death 
domain-containing protein CRADD-like, caspases (1, 2, 6, 7-like) and IAP3 were 
upregulated while caspase 3 and IAP2 were downregulated (Table 4).  
 
3.6.3 Metabolism and oxidative stress  
Transcripts involved in metabolism that were differentially expressed included Cyt 
p450 and Cyt c subunits I and III. Heat shock proteins HSP12A and HSP12B were 
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highly upregulated, while a few limited antioxidant enzymes were upregulated in 
response to RE22 (Table 4).   
 
4. Discussion 
 
Both differential expression and functional enrichment analyses of oyster larvae 6h after 
challenge with the bacterial pathogen V. coralliilyticus RE22 suggest increased 
metabolic demand and activated pattern recognition receptors but repression of immune 
signaling pathways, preventing production of immune effectors against RE22. This 
pattern of gene expression is in line with the rapid disease progression observed, with 
clinical signs evident 14h after challenge, and heavy mortality by 24h. This acute pattern 
of infection allows for a very short window to activate immune responses. Therefore, 
the host likely relies on a strong constitutive response and a rapid induction of immune 
effectors to combat infection. Such rapid progression of disease in larvae is 
characteristic of Vibrio spp. (Tubiash et al., 1965, Dubert et al., 2016). These results are 
in accordance with immunosuppressive response to V. coralliilyticus YB1 as seen in 
coral Pocillopora damicornis (Vidal-Dupiol et al., 2011a, Vidal-Dupiol et al., 2014) as 
well as those seen in C. gigas in response to virulent Vibrio spp (Decker and Saulnier, 
2011).  
4.1 Differentially expressed immune genes in response to RE22 
Highlights of the immunological response of C. virginica larvae to V.  coralliilyticus 
RE22 at 6h of exposure include pathogen detection via activated pathogen recognition 
receptors. However, along with an increased expression of immune receptors, an overall 
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suppression of key immune signaling pathways and lack of specific immune effectors 
against RE22 was seen, suggesting that the pathogen is able to neutralize the immune 
response of the larval host.  
Pattern recognition receptors (PRRs) are extremely important to innate immune system 
that recognize conserved pathogen-associated molecular patterns (PAMPs) and trigger 
signaling pathways that produce a variety of antimicrobials (Akira et al., 2006). 
Activation of TLR receptors indicate larvae can detect presence of bacteria especially 
via TLR4, which detects LPS (Chow et al., 1999) and hence Gram-negative pathogens 
like RE22. Activation of TLRs (Lorgeril et al., 2011, Zhang et al., 2011, Wang et al., 
2016b), lectin (Chen et al., 2011, Genard et al., 2013) and C1q domain containing 
proteins (Lv et al., 2018) by several Vibrio spp. and parasitic exposures (Tanguy et al. 
2004) have been demonstrated in bivalves. Lectins can activate the complement system 
and promote phagocytosis and killing of potential pathogens (Fujita et al., 2004). 
However, downregulation of complement C1q-like protein 2 and 4 in response to RE22 
suggest suppression of recognition via C1q proteins by RE22.  
Consistent with the observed response to V. coralliilyticus YB1 in coral Pocillopora 
damicornis (Vidal-Dupiol et al., 2014), key immune signaling pathways in larval 
oysters such as TLR, NF-kB, and IL-17 were also downregulated by RE22. Myeloid 
differentiation primary response protein 88 (MyD88) is currently the only known 
adaptor protein in bivalves (Gerdol et al., 2017) that modulates functioning of TLR 
pathway to promote activation of NF-kB pathway (Janssens and Beyaert, 2002). 
Downregulation of this fundamental signaling mediator suggests suppression of TLR 
pathway. However, MyD88 was upregulated at 24h and TRAF at 48h post challenge 
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with V. coralliilyticus LPI  06/210 (104 bacteria/mL in final concentration) in C. gigas 
larvae with 13 and 17% mortality rate in challenged larvae as compared to 5 and 7% in 
control at 24 and 48h respectively (Genard et al., 2013). It is possible that a later 
upregulation of these transcripts upon V. coralliilyticus RE22 exposure may also occur 
in eastern oysters, but our analysis was limited to the early time points. Disturbance of 
host immune responses leading to downregulation of immune genes was reported in 2yr 
old C. gigas post challenge with virulent Vibrio sp, V. splendidus LGP32-GFP and V. 
aesturianus 02/041 during first 6h of challenge (Decker and Saulnier, 2011). 
 
4.2 Unexpected differentially expressed immune genes in response to RE22 
4.2.1 Conflicting immune gene responses:  
Along with the general agreement of suppressed immune recognition and signaling 
pathways based on the differentially expressed transcripts, there are some results that 
deviate from this observation.  Interestingly, toll-interacting protein (TOLLIP), an 
important regulator of TLR pathway that represses the TLR pathway (Zhang and 
Ghosh., 2002) was downregulated. Zhang et al., (2015) also found downregulation of 
TOLLIP at 6h of V. anguillarum infection in Yesso scallop (Patinopecten yessoensis) 
but upregulated in the acute phase at 3h. It is possible that our experiment missed the 
acute stage of the disease and the very early responses to infection.  
TRAFIP2 plays a role similar to MyD88 leading to NF-kB activation through IRAK in 
the TLR signaling pathway and it can mediate MAPK pathway via MAPK9 or cJun N-
terminal kinase (Rosani et al., 2015).  Its upregulation in response to RE22 may suggest 
activation of NF-kB pathway and production of pro-inflammatory cytokines (Gu et al., 
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2013). This contradicts the earlier notion of suppressed NF-kB pathway. Upregulation 
of MKK7 as seen here can lead to activation of MAPK pathway via stimulation of JNK 
followed by c-Jun transcriptional activity (Lu et al.,1997). This is in contrast to abalone 
challenge with virulent V. harveyi ORM4 and response of coral P.  damicornis to V. 
coralliilyticus YB1 where induction of the MAPK pathway was delayed (Travers et al., 
2009, Vidal-Dupiol et al., 2014). Both MAPK and NF-kB activation was seen in 
surviving C. gigas post challenge with virulent Vibrio spp., suggesting their importance 
in host defense (Lorgeril et al., 2011). Since this transcriptome is obtained from a pool 
of larvae perhaps these conflicting signals are derived from the presence of both 
susceptible and resistant larvae to RE22 exposure in the pools of oysters used in our 
experiments.  
4.2.2 Antiviral immune gene responses: 
Although, differentially expressed transcripts in response to RE22 indicate majority of 
the key immune signaling pathways to be suppressed, antiviral pathways seem to remain 
active. STING is a key regulator for sensing intracellular single- or double-stranded 
nucleic acids. STING via the cGAS-STING pathway complex with TAK1 and trigger 
expression of interferon genes. cGAS is activated whenever foreign DNA (both 
bacterial and viral nucleic acids) is detected in the cytoplasm (He et al., 2015, Gerdol, 
2017). These results suggest the possibility of an intracellular invasion by RE22 that 
could lead to activation of STING or effectors of type secretion systems of RE22 (T6SS 
or T1SS) inadvertently leading to activation of these pathways. A special STING 
homolog LvSTING was activated in shrimp in response to V. parahaemolyticus 
infections that participates in antimicrobial peptide production (Li et al., 2017). 
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Similarly, activation of JAK-STAT pathway has been reviewed in bivalves as an 
antiviral response (Green et al., 2015) but microbial activation of this pathway has been 
shown in Chinese mitten crab Eriocheir sinensis (Li et al., 2013).  
4.2.3 Effectors 
Extracellular metalloproteases in V. coralliilyticus RE22 are shown to be important in 
its pathogenicity to C. gigas larvae (Hasegawa et al., 2008). Therefore, the observation 
of lack of serine protease inhibitors in challenged larvae, as well as the lack of 
upregulation of other types of protease inhibitors, was unexpected.  It is possible that 
protease inhibitors are not differentially expressed at the time point tested (6 h) but 
might be at a later time point.  Expression of metalloprotease of V. tubiashii 07/118 T2 
was shown to be downregulated during early infection stage in C. gigas larvae (3 - 6 h) 
but significantly upregulated (20 fold) at 16 -18 h post infection with ~60% mortality at 
24h post-infection (Mersni-Achour et al., 2015).  
Mucus is the first line of defense in oysters besides the closed oyster shell. Mucus was 
one of the few immune effectors shown to be upregulated in larval oysters exposed to 
V. coralliilyticus RE22.  Some pathogenic Vibrio spp.  require binding to mucin in the 
gut epithelium as a part of their pathogenesis (Bhowmick et al., 2008, Jang et al., 2016), 
so it is possible that modulation of host mucus production or composition may allow 
RE22 to bind better and breach host defenses in larval oysters.  
 
4.3 Cytoskeletal reorganization 
Downregulation of septin-11 associated with the cytoskeleton in response to RE22 
suggests possible disruption of cytoskeleton by RE22, but the functional implications 
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of this downregulation is not clear. Both actin and septin 8B were shown to be 
upregulated by challenge with V. splendidus LGP32 in C. gigas (Duperthuy et al., 2011) 
and soft-shell clams, Mya arenaria (Araya et al., 2010) for hemocyte invasion. 
Cytoskeletal disruption using upregulation of ß-actin due to V. tapetis challenge in 
Ruditapes philippinarum has also been demonstrated (Brulle et al., 2012). We need to 
know more about nature of RE22 pathogenesis in cytoskeletal modulation to fully 
understand this.  
 
4.4 Cell death  
It is difficult to interpret whether apoptosis is inhibited or enhanced in response to RE22 
treatment due to modulation of both pro (caspases) and anti-apoptotic (apoptosis 
inhibitor) genes. This was also the case in surviving C. gigas on exposure of different 
strains of virulent Vibrio spp. (Lorgeril et al., 2011). IAPs were modulated in both 
susceptible and resistant C. virginica families in response to A. crassostreae (McDowell 
et al., 2014). The mechanisms underlying pathogen-induced modulation of apoptosis in 
mollusks are not well understood.  
 
4.5 Metabolism and oxidative stress 
Differential expression of heat shock proteins and cytochrome oxidases during RE22 
challenge suggests that larvae are experiencing stress and high metabolic demand due 
to the inability to rapidly clear RE22 infection. Higher stress levels and lower metabolic 
rates have been seen in late responses (24-48h) of V. coralliilyticus LPI  06/210 in C. 
gigas (Gernard et al., 2013).  Moreover, no increase in expression of antioxidant 
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enzymes, necessary to deal with oxidative stress from activated metabolism, was seen 
in our study. These results suggest that oyster larvae, which already possess a high 
metabolic demand to sustain the processes of rapid growth and development, may not 
be able to cope with the additional metabolic demand associated with infection. 
Moreover, reduced feeding in infected moribund larvae may not allow replenishment of 
energy to mount an expensive immune response (Gernard et al., 2011). It has been 
shown for several V. tubiashii strains affecting bivalves that the pathogen enters the host 
through ingestion, proliferates in the gut, then spreads to other organs, including the 
cilia that are involved in swimming and capturing particles (Tubiash et al., 1965).  
 
5. Conclusion:  
The observed absence of induced expression of protease inhibitors, antimicrobial 
peptides or other immune effectors able to block RE22 virulence factors, along with 
other indications of a suppressed immune system, suggest that larvae are left highly 
susceptible to disease and then succumb to infection. Additionally, differential gene 
expression analysis indicative of a high metabolic demand and oxidative stress are 
consistent with the rapid mortality observed during RE22 infection in oyster larvae. 
Further in-depth studies are required to tease out details of the mechanisms used by 
RE22 to manipulate the immune system of oyster larvae. 
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Figure 1a: Effect of challenge with V. coralliilyticus RE22 on mortality of C. virginica 
larvae. Cumulative percent mortality +/- standard error in oyster larvae after 6 – 20 h of 
challenge with 5x105 CFU/mL of RE22. Data was averaged over six replicates. 
Mortality was first observed at 14 h after challenge, and rapidly increasing thereafter.  
 
          
 
 
Figure 1b: Effect of Vibrio coralliilyticus RE22 on mortality of C. virginica larvae. (A) 
Actively swimming healthy control larvae (B) Active larva with cilia showing signs of 
some clumping at 6h (C) Moribund larva with retracted cilia showing reduced 
movement at 9h (D) Dead larva with empty shell at 14h 
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Figure 2: Sequencing saturation curves for control and challenged larval transcriptomes 
showing comparable depth of sequencing for all transcriptomes. Three independent 
experiments (K, M, V) with two treatments (Control, C; RE22 treatment, RE22) were 
performed. 
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Table 1. Oyster larval transcriptomes in response to a 6h challenge with Vibrio 
coralliilyticus RE22 challenge.  Number of paired end reads per sample and % 
alignment rate to Crassostrea virginica reference genome using HISAT2. Three 
independent experiments (K, M, V) with two treatments (Control, C; RE22 treatment, 
RE22) were performed in duplicate. 
 
Sample # paired 
reads 
% Alignment to Crassostrea virginica genome 
C_K_0 22,963,376 89 
C_M_0 16,617,375 87 
C_V_0 20,674,506 86 
RE_K_6 19,379,823 86 
RE_M_6 21,118,821 89 
RE_V_6 39,681,499 85 
 
 
Table 2: Gene Ontology (GO) terms of biological functions significantly (p<0.05) 
enriched in oyster larvae in response to pathogen challenge (RE22). 
 
GO Term Significant 
number of 
transcripts 
mapped 
classicFisher p 
value 
macromolecule modification 83 0.0074 
cellular protein modification process 81 0.0098 
protein modification process 81 0.0098 
cellular protein metabolic process 104 0.0125 
biological regulation 201 0.0144 
cellular macromolecule catabolic process 17 0.0202 
regulation of biological process 189 0.0204 
protein metabolic process 127 0.0221 
regulation of cellular process 169 0.0271 
regulation of cell communication 29 0.0319 
regulation of signaling 29 0.0319 
phosphorus metabolic process 86 0.0339 
phosphate-containing compound metabolic 
process 
86 0.0339 
  
 
86 
protein catabolic process 14 0.0406 
cellular protein catabolic process 14 0.0406 
proteolysis involved in cellular protein... 14 0.0406 
cell communication 112 0.0409 
protein phosphorylation 39 0.0416 
signaling 111 0.0451 
single organism signaling 111 0.0451 
regulation of signal transduction 27 0.0453 
positive regulation of cellular process 27 0.0453 
 
 
 
 
Figure 3: Functional enrichment of differentially expressed transcripts using Gene 
Ontology terms in Biological Process. The color scale in the legend shows level of 
significance, with colder colors indicating higher significance and the size of the bubble 
corresponds to the number of significant transcripts mapped to the term.  
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Figure 4: Functional enrichment of differentially expressed transcripts using Gene 
Ontology terms in Metabolic Function. The color scale in the legend shows level of 
significance, with colder colors indicating higher significance and the size of the bubble 
corresponds to the number of significant transcripts mapped to the term.  
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Table 3: Mapping of differentially expressed transcripts to biological pathways in the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Numbers indicate 
number of transcripts mapped to each category. 
 
 RE22(6h) 
Metabolism  
Carbohydrate metabolism 29 
Energy metabolism 5 
Lipid metabolism 36 
Nucleotide metabolism 21 
Amino acid metabolism 25 
Metabolism of other amino acids 8 
Glycan biosynthesis and metabolism 12 
Metabolism of cofactors and vitamins 7 
Metabolism of terpenoids and polyketids 4 
Biosynthesis of other secondary metabolites 4 
Xenobiotics and biodegradation metabolism 7 
Genetic information processing  
Transcription 10 
Translation 16 
Folding sorting and degradation 13 
Replication and repair 3 
Environmental processing  
Membrane transport 2 
Signal transduction 199 
Signaling molecules and interaction 10 
Cellular processes  
Transport and catabolism 41 
Cell growth and death 39 
Cellular community-eukaryotes 42 
Cellular community-prokaryotes 2 
Cell motility 6 
Organismal systems  
Immune system 93 
Endocrine system 112 
Circulatory system 20 
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Digestive system 37 
Excretory system 11 
Nervous system 44 
Sensory system 23 
Development 19 
Aging 8 
Environmental adaptation 17 
 
 
Table 4: Comparison of expression of selective differentially expressed genes (DEGs) 
as compared to control categorized by immune processes (p ≤ 0.05, upregulation: log 
fold change ≥ 2, downregulation: log fold change ≤ -2). Colors denote level of 
expression as compared to control. Red: all transcripts upregulated, orange: some 
transcripts upregulated while some downregulated and yellow: all transcripts 
downregulated. DEGs with * denote highly differentially expressed gene. 
 
DEGs Expressio
n as 
compared 
to control 
Recognition  
TLRs   
TLR4  
TLR4 isoform X1  
TLR13  
TLR Tollo isoform X2  
TOLLIP (toll-interacting protein-like isoform X3)  
protein toll-like  
myeloid differentiation primary response protein MyD88-like  
Lectins  
lectin-like *  
fucolectin-like  
Scavenger receptors  
scavenger receptor class B member 1 isoform B  
LRR  
leucine-rich repeat transmembrane neuronal protein 3-like isoform 
X1  
 
leucine-rich repeat-containing protein 74B-like isoform X2   
leucine-rich repeat-containing protein 9-like isoform X2   
Fibronectin type III domain  
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fibronectin type III domain-containing protein 2-like isoform X3   
Complement  
complement C1q-like protein 2  
complement C1q-like protein 4  
Metabolic Enzymes with New Role of Carbohydrate Binding  
hexokinase-2-like isoform X2   
B cell receptor  
dapp1 dual adaptor for phosphotirosine*  
Signaling pathways in Immune response   
TLR pathway  
myeloid differentiation primary response protein MyD88-like  
TNF receptor-associated factor 4-like isoform X5 (TRAF4)  
mitogen-activated protein kinase kinase kinase 7-like isoform X3 
(TAK1) 
 
JAK-STAT  
tyrosine-protein kinase JAK2-like (JAK)  
son of sevenless homolog 2-like * (SOS2)  
tyrosine-protein phosphatase non-receptor type 4-like isoform X4 
(PTPN4) 
 
tyrosine-protein phosphatase non-receptor type 23-like (PTPN23)  
NF-kB signaling pathway  
NF-kappa-B-activating protein-like (NKAP)  
NF-kappa-B inhibitor alpha-like isoform X1 (IkB)   
TNFAIP3-interacting protein 1-like * (TNIP1)  
adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS)  
Mitogen-Activated Protein Kinases (MAPK) pathway  
dual specificity mitogen-activated protein kinase kinase 7-like 
isoform X1 (MKK7) 
 
mitogen-activated protein kinase kinase kinase 7-like isoform X3 
(TAK1) 
 
cGAS-STING pathway  
stimulator of interferon genes protein-like (STING)  
Signal transduction  
death domain-containing protein 1-like  
death domain-containing protein CRADD-like *  
ubiquitin carboxyl-terminal hydrolase 14-like   
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 * 
(USP25) 
 
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 
gamma-1-like isoform X4 (PLCG1) 
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Effectors  
Signaling mucin HKR1   
mucin-12-like *  
mucin-2-like  
mucin-5B-like  
mucin-19-like, partial  
septin-11-like isoform X2  
Apoptosis   
Caspase 1  
Caspase 2  
Caspase 3  
Caspase 6  
Caspase 7  
Caspase 7 Isoform X1  
Caspase 7 Isoform X3  
baculoviral IAP repeat-containing protein 2-like  
baculoviral IAP repeat-containing protein 3-like isoform X1 *  
putative inhibitor of apoptosis*  
death domain-containing protein CRADD-like *  
XK-related protein 8-like isoform X2 *  
XK-related protein 6, partial *  
cAMP-dependent protein kinase catalytic subunit  
TPA_inf: DeltaNp63gamma  
epidermal growth factor receptor-like isoform X2  
Autophagy  
autophagy-related protein 9A-like isoform X1 *  
DNA damage-regulated autophagy modulator protein 1-like*  
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit 
delta isoform-like isoform X1* 
 
toll-interacting protein-like isoform X3 (TOLLIP)  
next to BRCA1 gene 1 protein-like isoform X1   
Phagosome  
cation-dependent mannose-6-phosphate receptor-like *  
cytoplasmic dynein 2 light intermediate chain 1-like *  
Lysosome  
cation-dependent mannose-6-phosphate receptor-like *  
AP-1 complex subunit gamma-1-like isoform X2   
Endocytosis  
phosphatidylinositol-binding clathrin assembly protein LAP-like *  
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Peroxisome  
D-aspartate oxidase-like isoform X1   
peroxisome proliferator-activated receptor delta-like isoform X1*  
peroxisome proliferator-activated receptor gamma coactivator 1-
alpha-like 
 
prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica]  
Antioxidant enzymes  
maleylacetoacetate isomerase-like*  
gamma-glutamyltranspeptidase 1-like  
thioredoxin domain-containing protein 15-like   
thioredoxin domain-containing protein 3 homolog isoform X15   
thioredoxin-related transmembrane protein 2 homolog   
Acute phase proteins  
Heat shock 70 kDa protein 12A*  
heat shock 70 kDa protein 12A-like   
heat shock 70 kDa protein 12A-like isoform X1   
heat shock 70 kDa protein 12B-like   
heat shock 70 kDa protein 12B-like isoform X4 *  
 Cholinergic immunomodulation  
Glutamate receptor *  
glutamate receptor ionotropic  
muscarinic acetylcholine receptor M3-like  
neuronal acetylcholine receptor subunit alpha-2-like  
neuronal acetylcholine receptor subunit alpha-5-like  
neuropeptide Y receptor type 2-like*  
RYamide receptor-like  
acetylcholinesterase-like isoform X1*  
Cytosletal reorganization  
septin-11-like isoform X2  
dynamin-1-like isoform X6   
PI3K-Akt signaling pathway   
PH domain leucine-rich repeat-containing protein phosphatase 2-
like isoform X2 * 
 
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit 
delta isoform-like isoform X1* 
 
phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2A-like 
isoform X4  
 
RAC-gamma serine/threonine-protein kinase-like isoform X1   
Others  
multidrug resistance protein 1-like isoform X6  
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glycine receptor subunit alpha-3-like isoform X5  
gamma-glutamyltranspeptidase 1-like  
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase 
gamma-1-like isoform X4  
 
Hemicentin-1  
Hemicentin-1 like  
Hemicentin-1 like isoform X2  
Hemicentin-1 like isoform X21*  
Hemicentin-1 like isoform X34*  
hemicentin-2-like isoform X2  
histamine H2 receptor-like  
oxidative stress-induced growth inhibitor 2-like  
cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]  
cytochrome c oxidase subunit I *  
cytochrome c oxidase subunit III (mitochondrion) *  
cytochrome P450 27C1-like  
cytochrome P450 2C28-like isoform X2 *  
cytochrome P450 2F5-like *  
dual specificity protein phosphatase 18-like [Crassostrea virginica]  
dual specificity protein phosphatase 7-like [Crassostrea virginica]  
protein phosphatase 1 regulatory subunit 16A-like isoform X3   
protein phosphatase 1 regulatory subunit 37-like  
Tripartite motif-containing protein 2   
tripartite motif-containing protein 2-like  
tripartite motif-containing protein 2-like isoform X4  
tripartite motif-containing protein 3-like  
tripartite motif-containing protein 45-like  
cAMP-dependent protein kinase catalytic subunit  
PREDICTED: stress protein DDR48-like [Salmo salar]  
Biomineralization    
perlucin-like isoform X1 *  
perlucin-like protein isoform X1*  
Chitin synthase 3*  
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Abstract 
 
The eastern oyster Crassostrea virginica is an ecologically and economically important 
species. Bacterial pathogens like vibrios cause heavy mortalities in oyster larvae in 
hatcheries. Probiotics are an inexpensive, practical, and natural method of disease 
control. Pretreatment of larval oysters with probiotics Bacillus pumilus RI06-95 and 
Phaeobacter inhibens S4 significantly decreases mortality caused by experimental 
challenge with the pathogen Vibrio coralliilyticus RE22. The aim of this study was to 
understand the oyster larval immune response to probiotics RI06-95 and S4 and the role 
it may play in protecting larvae from pathogen challenge. C. virginica larvae were 
exposed to each probiotic in two settings: controlled 6 and 24 hours laboratory 
exposures and 5 to 16 days exposure in a hatchery. Transcriptomes were sequenced 
using high throughput RNA sequencing and aligned to the C. virginica reference 
genome. Differential expression analysis compared probiotic treated transcriptomes to 
unexposed controls. Key features of the host immune response were shared despite the 
length of probiotic exposure, type of probiotic exposure and the type of environment in 
which exposures were conducted. Transcriptome analysis showed increased expression 
of genes for receptors involved in environmental sensing and detection of pathogens, 
immune signaling pathways, and immune effectors including serine protease inhibitor, 
mucins and perforin-2. In addition, patterns of differential gene expression suggest that 
inhibition of apoptosis, enhanced autophagy, and cytoskeletal reorganization may play 
a supplemental role in bacterial clearance. Thus, results from this study suggest that 
larval oysters show a robust and effective immune response to probiotic exposure, 
contributing to clearance of the probiotic within 24 hours after exposure. Activation of 
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antibacterial immune effectors by probiotics, when provided 6 – 24 hours prior to 
bacterial challenge, may play an important role in protecting larvae from mortality by 
V. coralliilyticus RE22. However, for continued effective protection, probiotics should 
be applied repeatedly and for at least 6 hours prior to RE22 challenge. This is the first 
time that immune responses of larval stages of C. virginica to bacteria are studied using 
a larval transcriptome. This research provides important new insights into host-microbe 
interactions in larval oysters that could be applied in the design of improved strategies 
for use of probiotic organisms for disease control in hatcheries. 
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1. Introduction 
The eastern oyster Crassostrea virginica is an economically and ecologically 
important species (Newell 2004, NMFS 2014). Rearing of oyster larvae is a critical step 
to ensure a healthy and sufficient supply of seed for aquaculture industry. Bacterial 
diseases commonly described in larval stages are associated with high mortalities in 
hatcheries (Lauckner et al. 1983, Sinderman et al. 1990). Vibriosis is one such disease 
that leads to mortality in oyster larvae and juveniles (Tubiash et al, 1965). Bacteria of 
the genus Vibrio are ubiquitous within marine environments and detected in tissues of 
many marine organisms including abalones, bivalves, corals, fish, shrimp, sponges, 
squid, and zooplankton (Thompson et al. 2004). Vibrio can cause larval mass mortalities 
in hatcheries in a short period of time leaving few options for treatment (Helm and 
Lovatelli 2006). In order to eliminate Vibrios and sanitize the facility, hatcheries need 
to shut down for several days after a disease outbreak before production is resumed 
(Helm and Lovatelli 2006).  In particular, V. coralliilyticus RE22 (previously V. 
tubiashii RE22) has caused high larval and juvenile mortality in hatcheries (Elston et al. 
2008). Vibrios are known to produce potent exotoxins that affects larval motility in 
oysters. Incapacitated ciliary movement affects feeding, leading to death due to 
starvation (DiSalvo et al., 1978, Brown and Roland, 1984, Kennedy, 1996). The 
extracellular metalloprotease secreted by V. coralliilyticus is toxic and induces mortality 
in oyster larvae (Hasegawa et al., 2008).    
Practices to reduce mortality due to bacterial disease include treatment with antibiotics 
and disinfection of seawater.  Water treatment, however, is expensive and could be toxic 
to the larvae if not properly done, while antibiotic treatment can lead to bacterial 
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resistance. Treatment with antibiotics raises environmental and human health concerns 
as well (Prado et al. 2009, Akinbowale et al., 2016, Ho et al., 2000). Therefore, 
alternative methods need to be developed to manage good larval rearing environment 
and to control bacterial diseases in bivalve shellfish hatcheries. 
Probiotics are defined as a live microbial food supplement that, when administered in a 
sufficient amount, confers a health benefit on the host (Food and Agricultural 
Organization of the United States 2006). Probiotics are known to benefit the host by a 
variety of means, including production of antimicrobials, improving water quality, 
enhancing the immune responses of host, and competing for space with pathogenic 
bacteria (Verschuere et al. 2000). There is growing evidence that probiotics show 
immunomodulatory effects in fish and shellfish (De et al., 2014, Newaj-Fyzul et al., 
2015).  
The benefits of probiotics have already been shown in Pacific oysters, Crassostrea gigas 
(Douillet and Langdon 1994) and the eastern oyster C. virginica (Karim et al. 2013). 
Pretreatment of larval and juvenile C. virginica with probiotic organisms Phaeobacter 
inhibens S4 (isolated from the inner shell of oysters) (referred to as S4) and Bacillus 
pumilus RI06-95 (isolated from a marine sponge from the Narrow River in Rhode 
Island) (referred to as RI) before exposure to the bacterial pathogens Alliroseovarius 
crassostreae and Vibrio coralliilyticus RE22 (referred to as RE22) improves oyster 
survival rate (Karim et al., 2013). Additionally, probiotics are not harmful to oysters in 
absence of pathogens (Karim et al., 2013).  
S4 is a Gram-negative organism and production of the antibiotic tropodithietic acid 
(TDA) and biofilm formation are two mechanisms utilized by S4 for protecting oysters 
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from infection.  Mutants of S4 unable to produce TDA and with decreased ability to 
produce biofilms, however, still provide some level of protection (Zhao et al. 2016), 
suggesting that other mechanisms are also potentially involved. RI is a Gram-positive 
organism and produces the antibiotic amicoumacin, but this antibiotic does not inhibit 
the growth of RE22 in an in vitro assay, indicating that other mechanisms of action are 
also likely involved in RI’s protection of larvae against bacterial challenge (Karim et 
al., 2013). Probiotics are known to act as immunomodulators (Hardy et al., 2013, 
Mortha et al., 2014, Sanchez et al., 2015). For example, a strain of B. pumilus has been 
shown to improve immune responses of Orange-spotted grouper Epinephelus coioides 
(Sun et al., 2010), so immunomodulation may be one of the mechanisms involved in the 
probiotic activity of RI.  
Transcriptomic analysis of C. virginica larval immune responses to pathogen V. 
coralliilyticus RE22 showed evidence of suppression of important immune signaling 
pathways and decreased expression of genes for immune effectors such as protease 
inhibitors, increased metabolic demand, and modulation of mucins in the early stages 
of infection (Modak et al, in prep; Chapter 3 of this dissertation). Immunosuppression 
as a pathogenesis strategy was also demonstrated in responses of coral Pocillopora 
damicornis to V. coralliilyticus YB1 (Vidal-Dupiol., et al., 2014). Similarly, immune 
response of soft-shell clams, Mya arenaria, to V. splendidus strain LGP32 showed an 
overall downregulation of immune genes such as ficolin, killer cell lectin-like receptor, 
natural resistance-associated macrophage protein 1 (Nramp-1), and mitogen-activated 
protein kinases (MAPK) (Araya et al., 2010).  Our hypothesis is that pre-treatment of 
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oyster larvae with probiotics may cause an activated immune state in larvae that would 
serve to counteract the immunosuppressive effects of RE22. 
Not much is known about the impact of friendly or beneficial bacteria on the immune 
system of oysters. The goal of this study is to determine the immunological response of 
C. virginica larvae to exposure to two probiotic bacterial species that differ in Gram 
character, in order to understand the potential role of immunomodulation as a potential 
mechanism of action of the probiotics in providing protection against V. coralliilyticus 
RE22. 
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2. Materials and methods 
 
2.1 Probiotic Bacterial strains:  
Probiotic isolates S4 and RI were maintained and stored in 50 % glycerol stocks at -
80°C until use. Bacteria were cultured by plating out freezer stocks on yeast peptone 
with 3% NaCl (YP30) agar plates for 1 d then transferred to 5 mL of YP30 broth (5 g 
L-1 of peptone, 1 g L-1 of yeast extract, 30 g L-1 of ocean salt, Instant Ocean) incubated 
at 28°C on a shaker (134 rpm) for 2 d. Cultures were washed using Artificial Filtered 
Sterile Seawater (AFSW, 28 - 30 psu salinity) twice by centrifugation at 23,000 g for 
10 min. The OD at 550 nm was measured and the stock was diluted to obtain a 
concentration of 5 × 104 colony forming units (CFU) mL-1 as previously described 
(Karim et al., 2013).  
 
2.2 Oyster larvae:  
C. virginica larvae were obtained from three shellfish hatcheries on the east coast of 
United States including Oyster Seed Holdings, VA, Virginia Institute of Marine 
Science, VA and Aeros Cultured Oyster Company, NY that served as three biological 
replicates. Larvae 6-10 days old were collected at the hatchery and shipped to the 
laboratory at the University of Rhode Island on a wet filter overnight. Upon arrival to 
the laboratory, larvae were washed with AFSW on top of a 40 µm pore size nylon filter 
to prepare a stock. The stock of larvae from each hatchery was used for probiotic 
exposures as described below. The same stock was also used for characterizing immune 
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response to pathogen V. coralliilyticus RE22 (Modak et al., in prep, Chapter 3 of this 
dissertation).  
 
2.3 Effect of length of probiotic pretreatment on protection against bacterial challenge 
Previous research on the effect of probiotics on protection against challenge with the 
bacterial pathogen V. coralliilyticus RE22 was performed using a 24 h pre-incubation 
period with the probiotics prior to bacterial challenge (Karim et al. 2013). In order to 
determine if a shorter pre-incubation period with probiotics would confer protection 
against bacterial challenge, ~100 larvae were placed in each well of a 6 well plate in 5 
mL of AFSW and incubated with 104 CFU mL-1 of probiotics S4 or RI06-95 for 6 or 
24h prior to bacterial challenge with 105 CFU mL-1 of RE22. Larval survival was 
determined 24 h after challenge using previously described methods (Karim et al. 2013). 
Survival rate was calculated as follows: Survival rate (%) = 100 x (number of live 
larvae/total number of larvae). One-way analysis of variance (ANOVA) was used to 
determine significance between treatments and Tukey’s multiple comparison tests were 
used for post-hoc pairwise comparisons (p < 0.05) (Sohn et al., 2016).  
 
2.4. Effect of short-term exposure to probiotics on larval gene expression  
 
2.4.1 Experimental set up for laboratory-scale experiments: For biological replicates, 
three independent experiments were performed using larvae from three different 
hatcheries. Larval density (larvae mL-1) of the stock was determined using the Nikon 
E200 microscope.  Two parallel exposures were performed with each set of larvae: (i) 
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a large-scale incubation for collection of larvae for transcriptome analysis, and (ii) a 
small-scale experiment in 6 well plates for evaluation of the effect of probiotic exposure 
on protection against bacterial challenge. 
(i) Set up for transcriptome analysis: Larvae were distributed into tissue culture flasks 
(~10,000 per flask) in 500 mL AFSW based on the larval density (larvae/mL) and kept 
on a shaker with gentle shaking at ~50 rpm at room temperature. Larvae were 
acclimatized to the laboratory environment for 24 h. Each treatment was set up in 
duplicate as separate flasks to serve as technical replicates. There were five treatment 
groups in total viz. Control(0h), RI09-95(6 h), RI09-95(24 h), S4(6 h) and S4(24 h).  
Probiotics were applied at a concentration of 104 CFU mL-1. Larvae were fed with 
instant algae Shellfish Diet 1800TM (20,000 cells/mL; Reed Mariculture Inc., San Jose, 
CA. USA) just prior to treatment in order to promote probiotic ingestion.  
(ii) Set up for verification of protection by probiotics: Oyster larvae (~100) were placed 
in each well of a 6 well plate in 5 mL of AFSW and incubated with 104 CFU mL-1 of 
probiotics S4 or RI for 6 or 24 h prior to bacterial challenge with 105 CFU mL-1 of RE22, 
as described in section 2.3 above. 
 
2.4.2 Larval Collection post treatments:  
After incubation with probiotics, larvae from the flask set up for the transcriptome 
experiment were aspirated gently using a 100 mL serological pipette and filtered 
through a 40 µm sterile filter for collection. Since the dead larvae settle to the bottom, 
the last 25 mL of each flask was not collected to avoid bias in transcriptomic response. 
Larvae were washed with 2 mL of AFSW followed by 2 mL of RNAlater™. Larvae 
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retained on the filter were aspirated with a pipette using 1.5 mL of RNAlater, placed in 
labeled 2 mL RNase free microfuge tubes, and held at 4°C for 24 h in RNAlater 
followed by storage at -20°C.  
 
2.4.3 RNA extraction, cDNA prep and sequencing:  
Tri-reagent™ (Sigma-Aldrich) was used for extracting total RNA from all the samples 
following manufacturer’s instructions (TRI Reagent™ Protocol, Sigma-Aldrich). RNA 
extracts were DNase treated using the DNA-free™ DNA removal kit from Ambion and 
purity and concentration of RNA was checked using a Nanodrop 8000 
spectrophotometer (Thermo Scientific). Technical replicates were pooled at equimolar 
concentration. The quality and quantity of the pools were assessed using Agilent 2100 
Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples were selectively 
enriched for poly-A containing mRNA and cDNA libraries were prepared using the 
PrepX RNAseq library Prep Kit (Takara Bio USA, inc). Samples were sequenced on 
Illumina HiSeq platform with 2×125 reads and sequencing coverage of 20-30M per 
sample at the Harvard University, FAS Center for Systems Biology, MA. 
 
2.5 Effect of exposure to probiotics in the hatchery on larval gene expression 
 
2.5.1 Experimental set up of hatchery experiments: 
Transcriptomes obtained from treatment of larvae with B. pumilus RI06-95 will be 
referred to as HT_RI. Adult eastern oysters were spawned at the Blount Shellfish 
Hatchery, Roger Williams University, RI. Each trial was initiated by adding 8-10 larvae 
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mL-1 (800,000 to 1,000,000 initial larvae) per tank 1 day post-fertilization. Larval 
oysters were distributed into 100 L conical tanks filled with filtered and UV treated 
seawater (20 – 24 C and 28 – 30 psu salinity) 1 day after fertilization and fed live 
microalgae daily from a microalgae production greenhouse. Water from Narragansett 
Bay, RI was filtered and UV treated and used for the larval tanks. Treatments included 
control and probiotic RI treated at a concentration of 104  CFU mL-1. Each treatment 
was conducted in triplicate. Probiotics were added daily at the time of feeding.  
 
2.5.2 Larval Collection post treatments:  
Larvae for transcriptomes were collected at three time points: 5, 12 and 16 days post 
fertilization from probiotic-treated and control tanks. Larvae had been treated with 
probiotics daily starting 1 day after fertilization, as described in Sohn et al. (2016). 
Tanks were drained on a filter with suitable pore size (75 – 150 µm depending on the 
age of the larvae) at the time of collection. Using a serological pipette, larvae were 
aspirated gently and collected in RNase free microfuge tubes with RNAlater™ and 
stored at -80°C.  
 
2.5.3 Verification of protection by probiotics: A subsample of larvae was collected from 
each treatment and control tanks on day 8 post-fertilization to determine the effect of 
exposure to the probiotics in the hatchery on protection against bacterial challenge. 
Levels of protection were determined using the methods described in 2.3. above, with 
the following modifications: larvae from each tank were placed in triplicate wells in 6-
well plates with ~100 larvae per well V. coralliilyticus RE22 at 105 CFU mL-1 dose.    
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2.5.4 RNA extraction, cDNA prep and sequencing: 
Larvae were processed for RNA extraction as described in 2.4.4 above. cDNA libraries 
were generated using random hexamer priming that were sequenced on Illumina HiSeq 
platform with 2×150 reads and sequencing coverage of 50-70M per sample at the 
McDonnell Genomics Institute, Washington University School of Medicine, MO. 
 
2.6 Assembly, annotation and analysis 
Raw reads obtained from sequencing were filtered, trimmed and adapters were removed 
using bbduk program in BBTools suite from Joint Genome Institute and viewed in 
FASTQC (Andrews, 2010). Processed reads were aligned to C. virginica reference 
genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed 
using Stringtie (Pertea et al., 2016) with default parameters. To compare the depth of 
sequencing across all samples preseq package was used (Daley and Smith., 2013). 
Differential gene expression analysis between probiotic (RI or S4) treatment at each 
time point (6 or 24 h) and control (time 0, common to all treatments) was performed 
using DESeq2 (Love et al., 2014) and transcripts with Benjamini-Hochberg adjusted 
pvalue £ 0.05 and log fold change ≥ 2 or ≤ -2 were considered significantly differentially 
expressed. For hatchery transcriptomes, each of the days (5, 12 and 16) were considered 
as biological replicates and an overall comparison of treatment vs control was 
conducted. Transcript counts for each replicate were used to determine which DEGs are 
present in each replicate individually. This analysis design only allowed for the 
most conservative estimates and only showed differentially expressed genes 
  
 
113 
representing all the biological replicates. Annotation for differentially expressed genes 
(DEGs) was performed by mapping to NCBI protein non-redundant (NR) database 
using BLASTx (Altschul et al., 1997) with an e-value cutoff of 1e-3 and hit number 
threshold of 20. Mapping DEGs to GO terms was conducted using BLAST2GO v4.1.9 
(Conesa et al., 2005) and functional enrichment was done using topGO (Alexa et al., 
2006) with default parameters. ReviGO (Supek et al., 2011) was used to plot and 
visualize results obtained from topGO with default parameters (allowed similarity 
adjusted to medium). Significantly enriched GO terms were obtained by using Fishers 
exact test (p £ 0.01). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway 
annotations were also obtained using the KEGG Automatic Annotation Server (KAAS).   
 
3. Results  
3.1 Effect of length of probiotic pretreatment on protection against bacterial 
challenge 
A short duration of S4 or RI pretreatment (6 h) showed variable levels of protection 
against bacterial challenge between technical replicates within experiments and between 
experiments, as reflected in the large standard deviations in the relative percent survival 
(RPS; Table 1).  One out of three experiments showed no protection from probiotic 
treatment. The 24h probiotic pretreatment showed a more consistent level of protection 
against RE22 challenge (Table 1). In the hatchery trial, larvae treated daily with 
probiotics for 8 days in the hatchery showed an increase of 28 ± 6 % in relative percent 
survival as compared to untreated larvae after a laboratory challenge with V. 
coralliilyticus RE22. 
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3.2 Transcriptome completeness  
Depth of sequencing for all the lab transcriptomes was comparable between samples 
ranging from 16– 25M paired end reads whereas HT_RI transcriptomes ranged from 50 
- 70M reads (Table 2).  Sequencing saturation curves for all transcriptomes were close 
to full saturation, indicating that all but the rarest (least abundant) transcripts would be 
represented (Figures 1a and b). The alignment rate to the Crassostrea virginica 
reference genome using HISAT2 ranged from 86 – 89% (Table 2).  
3.3 Differential Expression Analysis  
Probiotic treated larval transcriptomes (RI or S4) at each time point (6 or 24 h) were 
compared to control (0 h) transcriptome for normalization. S4 treated transcriptomes 
(both 6 h and 24 h) yielded more differentially expressed transcripts when compared to 
control (0 h) larvae than RI treated larval transcriptomes (p ≤ 0.05) (Table 3). Larvae 
treated with probiotics for 24 h yielded more differentially expressed transcripts than 
larvae treated with probiotics for 6h (Table 3).  
Comparison of the number of shared and unique differentially expressed genes across 
all treatments (Figure 2a) showed a dynamic response to each of the two probiotics. 
Overall, larvae treated with S4 for 6 or 24 h have a higher number of differentially 
expressed transcripts than larvae treated with RI at 6h or 24h.  The percentage of DEGs 
shared between S4 and RI is the same (26%) at 6h or 24h suggesting pronounced effect 
of treatment as compared to time. Out of the total number of differentially expressed 
transcripts in response to S4 and RI at 6 and 24h, 50% transcripts were unique to S4 
treatment and 21% were unique to RI treatment. Comparison of differentially expressed 
transcripts in hatchery transcriptomes (HT_RI) (Figure 2b) showed 43% transcripts 
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shared between RI treatments with only 8%, 3% and 8% unique transcripts in RI_5d, 
RI_12d and RI_16d respectively suggesting more of a treatment effect than time. Refer 
to supplementary data tables in appendix for descriptions and log fold change values for 
differentially expressed genes for all comparisons. 
3.4 GO annotation  
A Gene Ontology (GO) term enrichment analysis was performed on all the differentially 
expressed transcripts in response to probiotic treatment. S4 treatments at both time 
points shared terms related to recognition and signaling (Figure 3a, 3b). S4 treatment at 
6h showed enrichment in “cellular response to stimulus” whereas at 24h it showed 
enrichment in processes related to activation of receptors and signaling pathways 
suggesting a progression of immune response to S4.  Very few GO terms were 
significantly enriched among DEGs detected from comparison between the control and 
larvae exposed to RI in the laboratory and they were mostly related to larval 
development (not shown). The HT_RI transcriptomes shared enrichment of the term 
“cytoskeletal organization” (Figures 3c) with the S4 (24h) transcriptomes, but none with 
the RI laboratory transcriptomes.  
3.5 KEGG annotation 
Consistent with the results of the enrichment analysis, most of the KEGG pathways that 
were represented by differentially expressed C. virginica larval genes related to signal 
transduction, immune systems, and endocrine system (Table 4). 
3.6 Differentially expressed immune genes shared between probiotics 
An overview of the immune genes differentially expressed upon exposure to the 
probiotics is depicted in Figure 4.  Transcripts corresponding to the genes for several 
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types of PRRs were modulated by probiotic treatment, out of which Toll-like receptors 
(TLRs), lectins, recognition protein, peptidoglycan receptor protein (PGRP) and 
leucine-rich repeat receptors (LRRs) were upregulated, with TLRs and lectins being 
most upregulated, while scavenger receptors, leucine rich repeat and fibronectin type III 
domain-containing proteins (LRFN), fibronectin domain containing proteins and C1-q 
proteins were downregulated. TLR 4, 6 and 13 were consistently upregulated in 
response to both probiotics with the exception of HT_RI transcriptome where TLR 13 
is downregulated (Table 5). 
Consistent with the observation that probiotic treatment led to differential expression of 
several TLR receptors, several transcripts involved in the TLR signaling pathway, 
including TNF receptor-associated factor 3-like (TRAF3) and mitogen-activated protein 
kinase kinase kinase 7-like (TAK1), were differentially expressed upon probiotic 
treatment (Table 6).  
Moreover, DEG patterns suggested activation of the NF-kB and MAPK pathways by 
probiotic exposure. Activation of the NF-kB pathway was indicated by upregulation of 
activator B-cell lymphoma/leukemia 10-like (BCL10) and downregulation of inhibitor 
NF-kappa-B inhibitor alpha-like isoform X1 (IkB). Some of the key players of the 
MAPK pathway including dual specificity mitogen-activated protein kinase kinase 7-
like (MAP2K7), TAK1, extracellular signal-regulated kinase 2-like (ERK2) were also 
upregulated in probiotic-treated larvae. Transcripts corresponding to a key molecule of 
the MAPK pathway, MAP2K7, were uniformly upregulated in almost all probiotic 
treatments (Table 6). 
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Probiotic treatment unanimously leads to modulation of three types of major effectors: 
serine protease inhibitor (SPI), mucin and macrophage-expressed gene 1 protein-like 
(Mpeg1/Perforin-2) (Table 7). Serine protease inhibitor Cvspi2 was highly upregulated 
in all probiotic treatments including HT_RI samples. Digestive cysteine proteinase 2 
was highly upregulated in all treatments except HT_RI. Several different types of mucin 
genes were modulated in larvae due to probiotic treatment. Both secreted gel-forming 
mucins (MUC2, MUC5A, MUC5B and MUC19) and cell surface mucins (MUC3B, 
MUC4 and MUC12) were differentially expressed. MUC12 was highly upregulated in 
almost all probiotic treatments. MUC5AC was highly upregulated in probiotic 
treatments of 24h and MUC2 was upregulated at 6h. Perforin2 was highly upregulated 
in all probiotic treated larvae except in HT_RI samples.  
Various molecules associated with cytoskeleton reorganization including actin, tubulin, 
integrin, myosin and septins (Table 8) as well as those related to phagosome, 
endocytosis, peroxisome and lysosome (Table 10) were differentially expressed in 
response to probiotics. Prostaglandin G/H synthase 2-like (PTGS2), important in 
inflammation reaction, was highly upregulated in all but S4(24h) treatment.  
3.7 Differentially expressed immune genes unique to each probiotic 
Transcripts of alpha-1–macroglobulin-like, integrins and antioxidant enzymes were 
downregulated in larvae exposed to S4 (Table 9). Transcripts corresponding to Tollo 
(TLR8) and E3 ubiquitin-protein ligase LRSAM1 were highly upregulated in RI(6h) 
alone. HT_RI transcriptomes showed upregulation of histone H2B-like and GTPase 
IMAP family member 7-like (GIMAP7) transcripts that were not seen in any other 
probiotic treatments. 
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3.8 Transcripts involved in antiviral responses 
Surprisingly, several genes that are involved in antiviral pathways were also 
differentially expressed due to probiotic treatment. These included upregulation of 
recognition receptors (TLR3) for detecting intracellular nucleic acids and transcripts 
involved in the JAK-STAT and cGAS-STING pathways (Table 6). Stimulator of 
interferon genes protein-like (STING), an important part of the cGAS pathway, was 
upregulated in all probiotic treatments except HT_RI. Interferon induced protein 44 
gene was upregulated in the HT_RI sample. E3 ubiquitin-protein ligase TRIM56 was 
heavily modulated in larvae from both probiotic treatments after a 24h exposure.  
3.9 Cell death: 
Autophagy related ATG9a was highly upregulated in all probiotic treatments except 
HT_RI (Table 9). Both initiator and executioner caspases in the apoptosis pathway were 
differentially expressed in probiotic treatments (Table 9). Transcripts for the initiator 
caspase 2 were upregulated in 6 h treatments while at least one of the executioner 
caspases 1,3,6 were upregulated in all treatments. Interestingly, caspases 1, 2, 7 and 8 
were downregulated and only caspase-14 was upregulated in HT_RI. Several types of 
baculoviral IAP repeat-containing proteins were differentially expressed in response to 
probiotic treatments but the type of modulation and type of IAP differed between 
treatments. Inhibitor of apoptosis was highly up in all probiotic treatments except 
HT_RI, where GIMAP7 was highly upregulated.  
 
4. Discussion 
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Exposure of larvae to probiotics S4 and RI induced the expression of a large variety of 
immune genes, suggesting a strong immune response comprising of heightened 
pathogen recognition, activation of immune signaling pathways and production of an 
arsenal of effectors. This probiotic mechanism of larval immunostimulation is 
consistent with previous observations that probiotics are cleared from the larvae within 
12 - 24 h after treatment (Karim et al., 2013). These immune effectors activated in larvae 
upon probiotic exposure may also serve to provide protection against RE22 infection 
especially in light of the opposite effect of suppression of signaling pathways and lack 
of crucial effectors seen in response to RE22 challenge (Modak et al., in prep; Ch3 of 
this dissertation).  
4.1 Mechanisms shared between probiotics 
Overall, the immune response of larvae to each of the probiotics shared many features, 
including: (a) upregulation of a large variety of pathogen recognition receptors involved 
in environmental sensing and pathogen detection, followed by (b) activation of multiple 
signaling pathways; which ultimately led to the production of (c) an arsenal of effectors 
known to have a role in immune defenses against bacterial pathogens (Figures 4 & 5). 
Several probiotics are known to modulate (either activate or suppress) signaling 
pathways that benefit the host and protect them from pathogens (reviewed in Llewellyn 
et al., 2017). Usually, probiotics show a very strain specific response (Baarlen et al., 
2011, Llewellyn et al., 2017). In this case however, despite the difference in Gram 
character between S4 and RI, many immune transcripts, especially effectors, were 
expressed in response to both probiotics. 
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Overall, differential expression analysis suggests activation of various immune 
signaling pathways like TLR, NF-kB and MAPK by both probiotics. The TLR pathway 
is crucial for bivalve innate immune systems. It recognizes a variety of damage-
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs) to activate NF-kB and MAPK pathway that protect the host from infection by 
producing cytokines, chemokines and other effectors (Gerdol et al., 2018). Our findings 
showing that TLR3, 4, 6, 8 and 13 were upregulated in response to probiotics are 
consistent with the important role of this pathway in bivalve immune responses, and 
indicate the potential of probiotics to provide protection against a broad spectrum of 
pathogens. Such PRR activation by probiotics due to shared cell envelope components 
like lipopolysaccharides, peptidoglycan, and ß-glucans with pathogens is well known 
(Pérez- Sánchez et al., 2014). Activation of TLR6 broadens the recognition spectrum 
to bacteria, fungi, LPS and peptidoglycan (PGN) (Wang et al., 2018). Subsequent 
activation of the MAPK pathway regulates several important cellular processes like cell 
proliferation, apoptosis, inflammatory response to pathogens and involved in the innate 
immunity of oysters (Wang et al., 2018). Activation of host MAPK and NF-kB and 
other signaling pathways by probiotics is seen in human gut associated probiotics 
(Thomas & Versalovic et al., 2010, Bermudez-Brito et al., 2012). 
This transcriptome analysis also suggests that activation of these pathways leads to 
increased transcription of a variety of immune effectors. Larvae already equipped with 
effectors as a result of probiotic treatment can carry out expedited clearing of pathogen 
upon challenge. Some of these effectors have been shown in previous research to have 
the potential to be involved in protection against RE22.   
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Protease inhibitors: All probiotic treatments showed highly upregulated serine protease 
inhibitor Cvspi2. One of the important virulence factors of RE22 is production of 
proteases, most notably metalloproteases (Hasegawa et al., 2008), but also potentially 
serine proteases, which are encoded in the genome (Spinard et al., 2015, Richards et al., 
2018).  Presence of serine protease inhibitors might neutralize serine protease attack by 
RE22 in probiotic pretreated larvae thus playing a significant role in their survival from 
RE22 infection. cvSI-1 has been shown to play an important role in host defense against 
Perkinsus marinus by inhibiting proliferation of the parasite (LaPeyre et al., 2009, Yu 
et al., 2011, Nikapitiya et al., 2014) and is also upregulated in resistant oysters in 
response to challenge with the pathogen Aliiroseovarious crassostreae (McDowell et 
al., 2014) in C. virginica. 
Mucins: Mucus is an important line of defense and plays multiple roles in the host-
microbe interaction (Allam and Espinosa., 2016). Both secreted gel forming mucins and 
cell surface mucins modulated by both probiotics work in concert to clear infection 
(Linden et al., 2008). Both Gram negative and Gram-positive bacteria have been shown 
to upregulate mucins in humans (Dohrman et al., 1998) which explains how both 
probiotics could influence their production. Increased production of mucus could buffer 
action of proteases (Yan et al., 2017) used by pathogenic Vibrio spp. to penetrate mucus 
and spread infection (Silva et al., 2003). Probiotics modulate the mucus barrier to aid 
their adhesion thereby preventing invasion of pathogens (Tuomola et al., 1999, Allam 
and Espinosa, 2016). In addition, oysters can also benefit from presence of vast array of 
immune recognition and effector proteins in the mucus (Espinosa et al., 2016). Hence, 
modulation of mucins can have multiple advantages for probiotic pretreated larvae. 
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Perforin-2: Perforin-2/Mpeg1 was highly upregulated in all lab probiotic treated larvae. 
Perforin-2 is an important ancient innate immune system effector present in vertebrates 
as well as invertebrates that functions by forming pores in intracellular and extracellular 
pathogenic bacteria (McCormack and Podack, 2015). In invertebrates, LPS exposure 
significantly upregulated a homologue of perforin-2 in a sponge Suberites domuncula 
(Wiens et al., 2005) and in disk abalone Haliotis discus discus post V. parahemolyticus 
challenge (Bathige et al., 2014). In C. gigas, Cg-Mpeg1 showed significant antibacterial 
activity to both Gram-negative and positive bacteria and its transcription level was 
significantly up-regulated following infection with V. alginolyticus (He et al., 2011). 
Thus, elevated activation of perforin-2 in probiotic pretreated C. virginica larvae might 
act as an efficient effector against RE22 upon challenge.  
Cytoskeletal organization: In addition, differential expression of actin, septin and 
dynamin 1 were shared by both probiotics suggesting a likelihood of their role in 
cytoskeletal reorganization (Pagliuso et al., 2016, Sirianni et al., 2016), possibly altering 
intracellular pathogenic invasion (Torraca and Mostowy, 2016, Mazon et al., 2017). 
Cytoskeletal rearrangements can help in bacterial sensing, compartmentalization of 
pathogens (Mostowy & Cossart, 2011), autophagy and apoptosis for host protection 
(Mostowy and Shenoy, 2015) as well as phagocytosis (Vicente-Manzanares and 
Sánchez-Madrid., 2004). PTGS2, which was upregulated in almost all probiotic 
treatments, is a key enzyme producing inflammatory prostaglandins and generation of 
inflammatory response activating the immune system in advance. 
4.2 Mechanisms unique for each probiotic 
Some unique aspects of the probiotic specific response are discussed below: 
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Specific response to S4: 
In addition to protease inhibition, alpha-1–macroglobulin (which was downregulated 
only in S4) is also involved in complement and coagulation cascades (Xiao et al., 2000) 
suggesting possible modulation of complement cascades by S4. Integrins (also 
downregulated in S4(24h)) have been shown to be used by V. splendidus to enter 
hemocytes and evade immunity (Duperthuy, M, et al., 2011). Antioxidant enzymes were 
mostly downregulated with S4 treatment, suggesting that S4 treatment does not lead to 
oxidative damage, unlike pathogenic exposure (Lorgeril et al., 2008, McDowell et al., 
2014). 
Specific response to RI: 
Tollo (TLR8, upregulated in response to RI) is related to larval innate immune response 
to Gram negative and positive bacteria and shown to regulate antimicrobial production 
in Drosophila melanogaster (Akhouayri et al., 2011). E3 ubiquitin-protein ligase 
LRSAM1 (highly upregulated in RI (6 h)) is a bacterial recognition protein and ubiquitin 
ligase that defends the cytoplasm from invasive pathogens. It is important for ubiquitin-
dependent autophagy against invading intracellular bacterial pathogens (Huett et al., 
2012). 
Two unique aspects about HT_RI transcriptome were upregulated transcripts identified 
as histone H2B-like and GIMAP7. Histones show antimicrobial action against Gram 
negative bacteria like Escherichia coli (Kawasaki et al., 2008) and in C. gigas has been 
demonstrated to surround and engulf vibrios (Nikapitiya et al., 2013, Poirier et al., 
2014). GIMAP7 is member of GTPase of the immune-associated proteins family that 
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acts an apoptosis regulator (Nitta and Takahama, 2007) and its upregulation suggests 
inhibition of apoptosis.  
4.3 Unexpected responses to probiotics  
Interestingly, multiple members of antiviral pathways were also modulated in response 
to probiotics. STING, an important part of the cGAS pathway, was highly upregulated 
in all lab probiotic treatments. A special STING homolog LvSTING was activated in 
shrimp in response to V. parahaemolyticus infections that participates in antimicrobial 
peptide production (Li et al., 2017). Thus, this pathway plays an essential role in host 
response to pathogen invasion including bacteria, owing to detection of cytosolic DNA 
recognition and type I IFN production (Tao et al., 2016). Activation of these pathway 
suggests that probiotic exposure may provide protection against viruses (Thomas et al. 
2010, Bermudez-Brito et al., 2012). 
4.4 Cell death 
ATG9a was highly upregulated by all probiotic treatments suggesting activation of 
autophagy (He and Klionsky, 2009) consistently by both probiotics. Autophagy and 
septins together restrict cytosolic bacterial replication (Torraca and Mostowy, 2016) and 
maybe an additional mechanism of action against RE22 invasion. 
 Various apoptosis inhibitors were highly upregulated in response to both probiotic 
treatments suggesting overall inhibition of apoptosis in response to probiotics. 
However, patterns of expression of apoptotic genes vary across different environmental 
stressors in bivalves suggesting it is a very complex pathway that is still not completely 
understood (Gerdol et al., 2018). Surviving C. gigas also showed apoptosis inhibition 
in response to virulent Vibrio sp. (Lorgeril et al., 2011). One of the virulence factors of 
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RE22 is production of hemolysins (Spinard et al., 2015) showing toxic effects on 
hemocytes (Gómez-León et al., 2008). Inhibition of apoptosis by probiotic pretreatment 
might result in a higher number of hemocytes (Lee et al., 1993) that can potentially 
counter the effect of hemolysins secreted by RE22 upon challenge.  
4.5 Length of probiotic pretreatment for effective protection from challenge 
As seen in the results (Table 1), shorter probiotic pretreatment provides variable 
protection whereas longer pretreatment provides consistent protection from challenge. 
Comparison of 6h and 24h transcriptomes showed same key effector mechanisms 
activated at both time points viz upregulation of serine protease inhibitors, mucins and 
perforin-2. There are however subtle differences for example in types of PRRs, mucins 
and septins that are upregulated at 6 h compared to those at 24 h. Certain genes involved 
in biomineralization and larval development and growth were also upregulated at 24 h. 
This supports the observation that longer exposure provides better protection perhaps 
due to increased pathogen sensing, additional growth effects and longer time for all 
larvae to respond to probiotic pretreatment. Previous studies have also shown chronic 
exposure of probiotics work better (Llewellyn et al., 2017). 
 
5. Conclusion 
This study indicates that probiotics use immunomodulation as a mechanism of action 
that may play a role in the protection conferred against RE22 infection. Although 6 h of 
pretreatment with probiotics might suffice for some larvae to protect themselves from 
RE22 challenge, a 24 h pretreatment consistently allows majority of them to elicit the 
immune responses effective in providing protection. This knowledge might help in 
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designing better management strategies to control larval mortality in hatcheries by use 
of probiotics as a natural and environmental friendly solution. In the future, it would be 
beneficial to use this information to target the functional identification of effectors that 
serve in protecting larvae against RE22 infection.   
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Table 1: Effect of varying lengths of probiotic pretreatment on larval survival after 
experimental challenge with the pathogen V. coralliilyticus RE22.  Results are 
expressed as the relative increase in percent survival +/- standard deviation (SD) of 
larvae pretreated with probiotics as compared to non-treated and challenged larvae. S4 
+ RE22: Larvae pretreated with Phaeobacter inhibens S4 and then challenged with 
RE22. RI + RE22: Larvae pretreated with Bacillus pumilus RI0-695 and then challenged 
with RE22.  - Not Tested. 
 
Treatment RPS (average +/- SD) 6h 24h 8d 
S4 + RE22 37 ± 26 41 ± 2 - 
RI + RE22 30 ± 39 45 ± 5 28 ± 6 
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Figure 1a: Sequencing saturation curves for RNA-seq samples obtained in laboratory 
for control, RI treated 6h, RI treated 24h, S4 treated 6h, S4 treated 24h larval 
transcriptomes.  Curves are provided for each experiment (biological replicates; K, M, 
V).  
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Figure 1b: Sequencing saturation curves for RNA-seq samples obtained in hatchery for 
control and B. pumilis RI06-95 treated oyster larval transcriptomes. Larvae were 
collected on day 5, 12 and 16 after fertilization, after being treated daily starting 1 day 
after fertilization.  
 
Table 2: Oyster larval transcriptomes in response to probiotic treatment.  Laboratory 
transcriptomes:  Oyster larvae were treated with B. pumilus RI0-695 and Phaeobacter 
inhibens S4 for 6 or 24 h.  Larvae for control (C) transcriptomes were collected at time 
0h.  Hatchery transcriptomes:  Larvae were treated daily in the hatchery with RI06-95 
(RI) or not-treated (Con), and collected 5, 12 or 16 d after fertilization.  Three 
independent laboratory experiments (K, M, V) with two treatments (Control: C; RI 
treatment: RI, S4 treatment: S4) were performed in duplicate.  Number of paired end 
reads per sample and % alignment rates to Crassostrea virginica reference genome 
using HISAT2 are shown.  
 
Sample # paired reads 
% Alignment to Crassostrea virginica 
genome 
Laboratory transcriptomes 
C_K_0 22,963,376 89 
C_M_0 16,617,375 88 
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C_V_0 20,674,506 86 
RI_K_24 27,507,148 86 
RI_K_6 25,325,997 87 
RI_M_24 22,339,707 86 
RI_M_6 20,649,356 86 
RI_V_24 18,412,447 83 
RI_V_6 18,720,304 86 
S4_K_24 25,285,770 87 
S4_K_6 17,536,097 88 
S4_M_24 21,950,812 87 
S4_M_6 14,570,962 86 
S4_V_24 17,840,669 89 
S4_V_6 21,556,827 88 
Hatchery transcriptomes 
Con_5d 73,690,654 53 
Con_12d 60,768,394 93 
Con_16d 70,771,125 64 
RI_5d 61,710,678 94 
RI_12d 59,865,884 94 
RI_16d 50,226,597 61 
 
 
Table 3: Number of differentially expressed genes per comparison (p ≤ 0.05, 
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2).  
 
Comparison # DEGs 
Lab transcriptomes 
6h probiotic treatment 
RI vs Con 1,550 
S4 vs Con 2,269 
24h probiotic treatment 
RI vs Con 2,139 
S4 vs Con 3,459 
Hatchery transcriptome  
5, 12, 16d post fertilization 
RI vs Con 2,993 
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Figure 2a: Venn Diagram of shared and unique differentially expressed genes for 
each probiotic treatment (B. pumilus RI0-695 and Phaeobacter inhibens S4) at 6 h and 
24 h in laboratory samples.  
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Figure 2b: Plot comparing number of differentially expressed genes in probiotic 
treatments at 5, 12 and 16 days in a hatchery. Numbers above the highlighted bar (boxed 
in red) show the number of differentially expressed genes shared in all probiotic 
treatments.  
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Figure 3a: Functional enrichment of differentially expressed transcripts in S4 (6h) using 
Gene Ontology terms in Biological Process. The color scale in the legend shows level 
of significance (warmer colors are less significant than cooler colors) and the size of the 
bubble corresponds to the number of significant transcripts mapped to the term. 
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Figure 3b: Functional enrichment of differentially expressed transcripts in S4 (24h) 
using Gene Ontology terms in Biological Process. The color scale in the legend shows 
level of significance (warmer colors are less significant than cooler colors) and the size 
of the bubble corresponds to the number of significant transcripts mapped to the term. 
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Figure 3c: Functional enrichment of differentially expressed transcripts in hatchery RI 
transcriptomes using Gene Ontology terms in Biological Process. The color scale in the 
legend shows level of significance (warmer colors are less significant than cooler colors) 
and the size of the bubble corresponds to the number of significant transcripts mapped 
to the term. 
 
Table 4:  KEGG annotation of differentially expressed genes 
 
 RI(6h) S4(6h) RI(24h) S4(24h) 
Metabolism     
Carbohydrate metabolism 27 36 37 68 
Energy metabolism 4 10 13 17 
Lipid metabolism 25 29 40 48 
Nucleotide metabolism 10 20 16 29 
Amino acid metabolism 13 37 26 51 
Metabolism of other amino acids 6 9 19 19 
Glycan biosynthesis and 
metabolism 7 19 20 31 
Metabolism of cofactors and 
vitamins 6 17 14 16 
Metabolism of terpenoids and 
polyketids 3 3 4 5 
  
 
137 
Biosynthesis of other secondary 
metabolites 2 8 5 4 
Xenobiotics and biodegradation 
metabolism 9 8 11 13 
Genetic information processing     
Transcription 11 20 13 17 
Translation 16 25 23 44 
Folding sorting and degradation 16 23 25 43 
Replication and repair 1 5 8 15 
Environmental processing     
Membrane transport 1 3 2 5 
Signal transduction 200 261 294 387 
Signaling molecules and 
interaction 8 10 17 23 
Cellular processes     
Transport and catabolism 45 58 64 87 
Cell growth and death 38 51 64 106 
Cellular community-eukaryotes 48 59 52 70 
Cellular community-prokaryotes 1 2 0 1 
Cell motility 8 9 12 17 
Organismal systems     
Immune system 124 112 113 137 
Endocrine system 133 114 171 210 
Circulatory system 18 16 29 36 
Digestive system 33 34 41 63 
Excretory system 11 12 14 23 
Nervous system 61 50 75 101 
Sensory system 20 16 24 31 
Development 22 22 23 31 
Aging 20 20 19 22 
Environmental adaptation 30 30 31 34 
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Figure 4: Overview of the immune responses induced in oyster larvae in response to 
treatment with probiotics S4 and RI, as measured through high-throughput analysis of 
differential gene expression. Overall, PRRs including TLRs, lectins, PGRPs and LRRs 
were upregulated while others were downregulated. Signaling pathways including TLR, 
NF-kB, MAPK and antiviral pathways including JAK-STAT, cGAS-STING were 
activated. Immune effectors were activated including mucins, protease inhibitor and 
perforin-2. Autophagy was activated and apoptosis was inhibited. Antioxidant enzymes 
were downregulated. Cytoskeleton related molecules including septins were modulated 
by both probiotics.  
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Figure 5: Hypothesized role of selected effectors of immunity whose expression was 
found to be upregulated in larval oysters in response to probiotic treatment on 
providing protection against challenge to V. coralliilyticus RE22. Mucin and protease 
inhibitors provide protection outside the oyster body and perforin-2 providing 
protection once the pathogen is within oyster tissues. 
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Table 5: Patterns of differential gene expression of immune receptors in oyster larvae in response to probiotic treatment (p ≤ 0.05, 
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and 
downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus 
pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae 
exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h. 
 
 Probiotics 
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Receptors      
TLRs       
toll-like receptor 1      
TLR3 isoform X1      
TLR4      
TLR4 isoform X1      
toll-like receptor 6       
TLR6 isoform X1      
TLR13      
TLR13 isoform X1      
TLR Tollo isoform X2      
protein toll-like      
Lectins      
C-type lectin domain family 4 member E-like       
C-type lectin domain family 3 member A-like       
lectin-like *      
lectin BRA-3-like      
plectin-like isoform X4      
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hepatic lectin like      
galactose-specific lectin nattectin-like      
fucolectin-like      
Scavenger receptors      
scavenger receptor class F member 2-like       
scavenger receptor class B member 1 isoform B      
scavenger receptor class B member 1-like isoform X1      
Scavenger receptor cysteine-rich type 1 protein M130       
scavenger receptor cysteine-rich type 1 protein M130-like isoform X1      
somatomedin-B and thrombospondin type-1 domain-containing protein-like     
proteoglycan 4-like isoform X4       
PGRP      
peptidoglycan-recognition protein SC2-like *      
LRFN      
leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein      
leucine-rich repeat and fibronectin type-III domain-containing protein 5-like      
LRR      
leucine-rich repeat transmembrane neuronal protein 3-like isoform X1      
leucine-rich repeat transmembrane protein FLRT1-like      
leucine-rich repeat transmembrane protein FLRT3-like      
leucine-rich repeat-containing protein 24-like      
leucine-rich repeat-containing protein 27-like       
leucine-rich repeat-containing protein 28-like isoform X3       
leucine-rich repeat-containing protein 34-like isoform X2       
leucine-rich repeat-containing protein 40      
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leucine-rich repeat-containing protein 45-like       
Leucine-rich repeat-containing protein 49       
leucine-rich repeat-containing protein 4C-like isoform X1       
leucine-rich repeat-containing protein 70-like       
leucine-rich repeat-containing protein 71-like isoform X21      
leucine-rich repeat-containing protein 71-like isoform X22       
leucine-rich repeat-containing protein 74A-like       
leucine-rich repeat-containing protein 74A-like isoform X2       
leucine-rich repeat-containing protein 74B-like       
leucine-rich repeat-containing protein 74B-like isoform X2       
leucine-rich repeat-containing protein 74B-like isoform X3      
leucine-rich repeat-containing protein 74B-like isoform X6      
leucine-rich repeat-containing protein 9-like isoform X2       
leucine-rich repeat and IQ domain-containing protein 1      
leucine zipper putative tumor suppressor 2 homolog       
Fibronectin type III domain      
fibronectin type III domain-containing protein 1-like       
fibronectin type III domain-containing protein 2-like isoform X3       
fibronectin type-III domain-containing protein 3A-like isoform X4      
ankyrin repeat and fibronectin type-III domain-containing protein 1-like      
C1q proteins      
C1q-related factor-like *      
complement C1q-like protein 2      
complement C1q tumor necrosis factor-related protein 2-like      
complement C1q tumor necrosis factor-related protein 4-like       
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complement C1q tumor necrosis factor-related protein 4-like isoform X3      
alpha-1-macroglobulin-like      
alpha-1-macroglobulin-like isoform X2      
Macrophage mannose receptor 1       
Macrophage mannose receptor 1-like isoform X1*      
Metabolic Enzymes with New Role of Carbohydrate Binding      
Phosphoenolpyruvate carboxykinase       
hexokinase-2-like isoform X2       
B cell receptor      
dapp1 dual adaptor for phosphotirosine*      
 Cholinergic immunomodulation      
Glutamate receptor *      
glutamate receptor 2-like       
glutamate receptor ionotropic      
dopamine receptor 2-like      
muscarinic acetylcholine receptor M1-like      
neuronal acetylcholine receptor subunit alpha-6-like       
neuronal acetylcholine receptor subunit alpha-9-like      
choline transporter-like protein 2       
apoptogenic protein 1      
anti-apoptotic protein NR13-like       
neuropeptide FF receptor 2-like      
neuropeptide SIFamide receptor-like      
neuropeptide Y receptor type 1-like       
neuropeptide Y receptor type 2-like*      
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pro-neuropeptide Y-like isoform X1*      
metabotropic glutamate receptor 8-like isoform X1       
acetylcholinesterase-like isoform X1*      
acetylcholinesterase-like      
 
 
Table 6: Patterns of differential gene expression of immune signaling pathways in oyster larvae in response to probiotic treatment (p ≤ 
0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up 
and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic 
Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: 
Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h. 
 
 Probiotics    
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Signaling pathways in Immune response       
TLR pathway      
TNF receptor-associated factor 3-like isoform X3 (TRAF3)      
tumor necrosis factor receptor superfamily member 1B-like isoform X1      
tumor necrosis factor receptor superfamily member      
mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1)      
JAK-STAT      
tyrosine-protein kinase JAK2-like (JAK)      
signal transducer and activator of transcription 3-like isoform X6 (STAT3)      
Suppressor of cytokine signaling 7 (SOCS)      
son of sevenless homolog 2-like * (SOS2)      
epidermal growth factor receptor-like (EGFR)      
  
 
145 
 
epidermal growth factor receptor-like isoform X2       
epidermal growth factor receptor-like isoform X4       
tyrosine-protein phosphatase non-receptor type 11 isoform X3 (SHP2)      
tyrosine-protein phosphatase non-receptor type 4-like isoform X4 (PTPN4)      
tyrosine-protein phosphatase non-receptor type 9-like isoform X2 (PTPN9)      
tyrosine-protein phosphatase non-receptor type 23-like (PTPN23)      
NF-kB signaling pathway      
NF-kappa-B-activating protein-like (NKAP)      
NF-kappa-B inhibitor alpha-like isoform X1 (IkB)      
smad nuclear interacting protein 1-like (SNIP1)      
TNFAIP3-interacting protein 1-like * (TNIP1)      
B-cell lymphoma/leukemia 10-like (BCL10)      
ELKS/Rab6-interacting/CAST family member 1-like      
ELKS/Rab6-interacting/CAST family member 1-like isoform X3      
ELKS/Rab6-interacting/CAST family member 1-like isoform X5*      
TRAF-type zinc finger domain-containing protein 1-like *     
adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS)      
NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8       
nuclear factor NF-kappa-B p105 subunit-like isoform X2      
lipopolysaccharide-induced tumor necrosis factor-alpha factor homolog       
Mitogen-Activated Protein Kinases (MAPK) pathway     
dual specificity mitogen-activated protein kinase kinase 1-like isoform X1       
mitogen-activated protein kinase-binding protein 1-like isoform X4 (MEKK1)    
mitogen-activated protein kinase kinase kinase kinase 3-like (MKK3)     
Mitogen-activated protein kinase kinase kinase 7 (MKK7)      
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dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 (MKK7)      
mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1)     
mitogen-activated protein kinase 11-like (MAPK11)      
mitogen-activated protein kinase kinase kinase 13-like isoform X2 (MAPK13)      
mitogen-activated protein kinase 14A-like (P38)     
transforming growth factor-beta, partial      
 C-Jun-amino-terminal kinase-interacting protein 4-like *       
extracellular signal-regulated kinase 2-like isoform X4      
stress-activated protein kinase JNK-like isoform X1 (JNK)      
Regulator of G-protein signaling 3       
cGAS-STING pathway      
stimulator of interferon genes protein-like (STING)      
RIG-1 pathway related      
interferon regulatory factor 2-binding protein-like      
Signal transduction      
death domain-containing protein 1-like      
death domain-containing protein CRADD-like *      
integrin alpha-2-like isoform X5 *      
integrin alpha-4-like isoform X1 *      
integrin beta-3-like [Crassostrea virginica]      
ubiquitin carboxyl-terminal hydrolase 14-like       
ubiquitin carboxyl-terminal hydrolase 20-like isoform X2      
ubiquitin carboxyl-terminal hydrolase 22-like *      
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 * (USP25)      
cellular retinoic acid-binding protein 2-like       
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1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like isoform X4 
(PLCG1) 
     
epidermal growth factor receptor-like     
epidermal growth factor receptor-like isoform X2       
epidermal growth factor receptor-like isoform X4       
tyrosine-protein phosphatase non-receptor type 11 isoform X3       
basic leucine zipper transcriptional factor ATF-like 3      
nuclear factor of activated T-cells 5-like isoform X2      
      
 
Table 7: Patterns of differential gene expression of immune effectors in response to probiotic treatment (p ≤ 0.05, upregulation: log fold 
change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts 
mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 
or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: 
Larvae exposed to S4 for 24h. 
 
   Probiotics 
 
HT_R
I RI_6h RI_24h S4_6h  S4_24h 
Effectors      
serine protease inhibitor Cvsi-2-like *      
serine protease inhibitor dipetalogastin-like *     
kunitz-type serine protease inhibitor conotoxin Cal9.1b-like      
digestive cysteine proteinase 2-like*      
serine protease 44-like       
interferon-induced protein 44-like isoform X2       
interleukin-17 receptor D-like      
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Signaling mucin HKR1       
integumentary mucin C.1-like       
integumentary mucin C.1-like isoform X1      
integumentary mucin C.1-like isoform X3      
mucin-12-like *      
mucin-17-like isoform X2      
mucin-2-like      
mucin-2-like isoform X2       
mucin-3B-like isoform X4       
mucin-4 isoform X3      
mucin-4-like isoform X7       
mucin-4-like isoform X8      
mucin-5AC-like *      
mucin-5AC-like isoform X5      
mucin-5B-like      
mucin-19-like, partial      
mucin-19 isoform X2      
PREDICTED: mucin-19 isoform X7      
IgGFc-binding protein*      
septin-2-like      
septin-2-like isoform X1       
septin-2-like isoform X8      
septin-7 isoform X3      
septin-11-like isoform X2      
macrophage-expressed gene 1 protein-like * (Perforin-2/Mpeg1)      
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antistasin-like       
SH3-domain binding protein 2      
alpha-1-macroglobulin-like      
alpha-1-macroglobulin-like isoform X2      
cystatin-A-like      
 
 
Table 8: Patterns of differential gene expression that are part of cytoskeletal reorganization in oyster larvae in response to probiotic 
treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange 
denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with 
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; 
S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h. 
 
 Probiotics    
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Cytosletal reorganization      
Actin, cytoplasmic       
actin-like       
actin-3-like isoform X1      
septin-2-like      
septin-2-like isoform X1       
septin-2-like isoform X8      
septin-7 isoform X3      
septin-11-like isoform X2      
dynamin-1-like isoform X6       
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Table 9: Patterns of differential gene expression that are part of apoptosis and autophagy in oyster larvae in response to probiotic 
treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange 
denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with 
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 
24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h. 
 
 Probiotics    
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Apoptosis       
Caspase 1      
Caspase 2      
Caspase 3      
caspase-3-like isoform X2      
Caspase 6      
Caspase 6 Isoform X2      
Caspase 7      
Caspase 7 Isoform X1      
Caspase 7 Isoform X3      
Caspase-8      
caspase-14-like isoform X2       
caspase recruitment domain-containing protein 14-like isoform X5      
baculoviral IAP repeat-containing protein 2-like      
baculoviral IAP repeat-containing protein 2-like isoform X2       
baculoviral IAP repeat-containing protein 2-like isoform X1      
baculoviral IAP repeat-containing protein 3-like      
baculoviral IAP repeat-containing protein 3-like isoform X1 *      
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baculoviral IAP repeat-containing protein 6-like isoform X5      
baculoviral IAP repeat-containing protein 7A-like isoform X2      
baculoviral IAP repeat-containing protein 7-like isoform X3      
putative inhibitor of apoptosis*      
Apoptosis inhibitor IAP      
bifunctional apoptosis regulator-like isoform X1       
apoptogenic protein 1      
apoptosis-inducing factor 3-like       
protein kinase C iota type-like isoform X4       
multiple epidermal growth factor-like domains protein 10 isoform X2      
multiple epidermal growth factor-like domains protein 10 isoform X4     
multiple epidermal growth factor-like domains protein 6      
multiple epidermal growth factor-like domains protein 6 isoform X1       
death domain-containing protein CRADD-like *      
apoptotic chromatin condensation inducer in the nucleus-like      
cathepsin L-like isoform X2       
cathepsin L1-like      
cathepsin O-like       
programmed cell death protein 2-like isoform X1      
programmed cell death protein 6-like isoform X2       
programmed cell death 6-interacting protein-like isoform X3      
XK-related protein 8-like isoform X2 *      
XK-related protein 6, partial *      
XK-related protein 4       
cell death protein 3-like      
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cell death abnormality protein 1-like       
cell death-inducing p53-target protein 1-like isoform X5       
cell death specification protein 2      
FAS-associated factor 1-like      
serine/threonine-protein kinase/endoribonuclease IRE1-like      
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*      
cAMP-dependent protein kinase catalytic subunit      
Actin, cytoplasmic       
actin-like       
actin-3-like isoform X1      
poly [ADP-ribose] polymerase 2-like isoform X2      
poly [ADP-ribose] polymerase 3-like       
epidermal growth factor receptor-like isoform X2      
epidermal growth factor receptor-like isoform X4      
basic immunoglobulin-like variable motif-containing protein isoform X5      
Oxidoreductase HTATIP2       
ATP-dependent zinc metalloprotease YME1L1-like      
GIMAP      
tax1-binding protein 1 homolog isoform X3*      
Autophagy      
autophagy-related protein 9A-like isoform X1 *      
transcription factor SPT20 homolog isoform X1      
vacuole membrane protein 1-like       
protein kinase C delta type      
DNA damage-regulated autophagy modulator protein 2-like      
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DNA damage-regulated autophagy modulator protein 1-like*      
run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like isoform X3   
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1*     
TOLLIP (toll-interacting protein-like isoform X3)      
serine/threonine-protein kinase/endoribonuclease IRE1-like      
ubiquitin-like protein ATG12 isoform X1      
ubiquitin-like-conjugating enzyme ATG10 isoform X3       
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*      
 protein kinase C delta type*      
insulin receptor substrate 1-B-like isoform X2 *      
Homeobox protein HD1*      
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*      
alpha-soluble NSF attachment protein-like       
endophilin-B1-like       
ras-related protein rab7       
hamartin-like isoform X2*      
ras-related protein M-Ras-like       
RAC-gamma serine/threonine-protein kinase-like isoform X1       
UV radiation resistance-associated gene protein-like       
next to BRCA1 gene 1 protein-like isoform X1       
 
Table 10: Patterns of differential gene expression that are part of phagosome, endosome, peroxisome, lysosome, antioxidant enzymes 
and acute phase proteins in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, 
downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped 
to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 
  
 
154 
 
days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: 
Larvae exposed to S4 for 24h. 
 
 Probiotics 
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Phagosome      
Actin, cytoplasmic       
actin-like       
cathepsin L-like isoform X2       
cathepsin O-like       
cation-dependent mannose-6-phosphate receptor-like *      
Coagulation factor V *      
cytoplasmic dynein 1 heavy chain 1-like isoform X1 *      
cytoplasmic dynein 2 heavy chain 1-like isoform X4       
cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 *      
cytoplasmic dynein 2 light intermediate chain 1-like *      
ras-related protein Rab-5B-like isoform X1      
macrophage mannose receptor 1-like isoform X1      
nitric oxide synthase brain-like isoform X2       
 digestive cysteine proteinase 2-like*      
Lysosome      
lysosomal acid lipase/cholesteryl ester hydrolase-like       
lysosomal acid lipase/cholesteryl ester hydrolase-like isoform X2      
cation-dependent mannose-6-phosphate receptor-like *      
sulfatase-modifying factor 1-like       
  
 
155 
 
lysosomal-associated transmembrane protein 4A-like      
ADP-ribosylation factor-binding protein GGA1-like  *      
ADP-ribosylation factor-binding protein GGA1-like  *      
AP-1 complex subunit gamma-1-like isoform X2       
AP-1 complex subunit sigma-2 isoform X4 *      
 clathrin heavy chain 2 isoform X2      
lysosomal-trafficking regulator-like isoform X4       
lysosomal alpha-glucosidase-like isoform X1      
Endocytosis      
AP-2 complex subunit mu-1       
 clathrin heavy chain 2 isoform X2      
tumor susceptibility gene 101 protein-like      
hepatocyte growth factor-regulated tyrosine kinase substrate-like      
syntaxin-7-like isoform X3      
phosphatidylinositol-binding clathrin assembly protein LAP-like *      
Peroxisome      
probable peroxisomal membrane protein PEX13      
D-aspartate oxidase-like *      
D-aspartate oxidase-like isoform X1       
phytanoyl-CoA dioxygenase, peroxisomal-like      
enoyl-CoA delta isomerase 2, mitochondrial-like isoform X2      
peroxisomal acyl-coenzyme A oxidase 1-like      
peroxisomal acyl-coenzyme A oxidase 1-like isoform X2       
peroxisome proliferator-activated receptor delta-like isoform X1*      
peroxisome proliferator-activated receptor gamma coactivator 1-alpha-like      
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prostaglandin E synthase 2-like [Crassostrea virginica]      
prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica]      
prostaglandin G/H synthase 2-like isoform X2 [Crassostrea virginica] *      
prostaglandin reductase 1-like isoform X2 *      
peroxisomal carnitine O-octanoyltransferase-like      
Antioxidant enzymes      
glutathione peroxidase 7-like [Crassostrea virginica]      
glutathione S-transferase C-terminal domain-containing protein-like isoform X1 [Crassostrea 
virginica]      
glutathione S-transferase kappa 1-like [Crassostrea virginica]      
glutathione S-transferase omega-1-like       
glutathione S-transferase P 2-like      
glutathione S-transferase 3-like       
glutathione-independent glyoxalase HSP31-like      
 glutathione S-transferase P 2-like      
maleylacetoacetate isomerase-like*      
gamma-glutamyltranspeptidase 1-like      
Superoxide dismutase [Cu-Zn]      
thioredoxin domain-containing protein 15-like       
thioredoxin domain-containing protein 3 homolog isoform X15       
thioredoxin domain-containing protein 5-like       
thioredoxin-like       
thioredoxin-like protein 1       
thioredoxin-related transmembrane protein 1-like isoform X1       
thioredoxin-related transmembrane protein 2 homolog       
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Acute phase proteins      
heat shock 70 kDa protein 4*      
Heat shock 70 kDa protein 12A*      
heat shock 70 kDa protein 12A-like       
heat shock 70 kDa protein 12A-like isoform X1       
heat shock 70 kDa protein 12A-like isoform X3      
heat shock 70 kDa protein 12B-like       
heat shock 70 kDa protein 12B-like isoform X4 *      
heat shock factor protein-like       
heat shock protein 30C-like       
heat shock protein HSP 90-beta-like      
Stress response protein NhaX       
 
Table 11: Patterns of differential gene expression that are part of metabolism, biomineralization and other processes in oyster larvae in 
response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes 
downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: 
larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: 
Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h. 
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 Probiotics    
 HT_RI RI_6h RI_24h S4_6h  S4_24h 
Others      
furin-like protease kpc-1 isoform X1       
multidrug resistance protein 1-like isoform X1      
multidrug resistance-associated protein 1-like isoform X3*      
multidrug resistance protein 1-like isoform X6      
multidrug resistance-associated protein 4-like      
multidrug resistance-associated protein 5-like      
multidrug resistance-associated protein 5-like isoform X2      
multidrug resistance-associated protein 7-like      
laccase-3-like       
laccase-like      
laccase-5-like       
peptidoglycan-recognition protein SC2-like      
glycine receptor subunit alpha-3-like isoform X5      
gamma-glutamyltranspeptidase 1-like      
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like isoform X4      
cysteine proteinase inhibitor 8-like      
Hemicentin-1      
Hemicentin-1 like      
Hemicentin-1 like isoform X2      
Hemicentin-1 like isoform X3      
Hemicentin-1 like isoform X5      
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Hemicentin-1 like isoform X6      
Hemicentin-1 like isoform X9      
Hemicentin-1 like isoform X21*      
Hemicentin-1 like isoform X34*      
Hemicentin-1 like isoform X40      
hemicentin-2-like isoform X2      
histamine H2 receptor-like      
oxidative stress-induced growth inhibitor 2-like      
cytochrome b [Crassostrea virginica]      
cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]      
cytochrome c oxidase subunit I *      
cytochrome c oxidase subunit III (mitochondrion) *      
cytochrome P450 2C8       
cytochrome P450 2C42-like      
cytochrome P450 27C1-like      
cytochrome P450 2C28-like isoform X2 *      
cytochrome P450 2C42-like      
Cytochrome P450 2D14      
cytochrome P450 2F5-like *      
cytochrome P450 4F22-like      
cytochrome P450 2J5-like isoform X2*      
cytochrome P450 3A6-like      
Cytochrome P450 3A11       
cytochrome P450 3A24-like isoform X1      
cytochrome P450 3A29-like      
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cytochrome P450 4A25-like       
cytochrome P450 4V2-like isoform X1      
cytochrome P450 4F22-like *      
dual specificity protein phosphatase 1-A-like [Crassostrea virginica]     
dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica]    
dual specificity protein phosphatase 18-like [Crassostrea virginica]     
dual specificity protein phosphatase 19-like [Crassostrea virginica]     
dual specificity protein phosphatase 7-like [Crassostrea virginica]      
dual specificity tyrosine-phosphorylation-regulated kinase 4-like isoform X14 [Crassostrea virginica]   
protein phosphatase 1 regulatory subunit 12A-like isoform X2      
protein phosphatase 1 regulatory subunit 12A-like isoform X4      
protein phosphatase 1 regulatory subunit 16A-like isoform X3       
protein phosphatase 1 regulatory subunit 36-like isoform X1      
protein phosphatase 1 regulatory subunit 37-like      
protein phosphatase 1 regulatory subunit 42-like isoform X1      
Tripartite motif-containing protein 2       
tripartite motif-containing protein 2-like      
tripartite motif-containing protein 5-like      
tripartite motif-containing protein 5-like isoform X2      
tripartite motif-containing protein 2-like isoform X2       
tripartite motif-containing protein 2-like isoform X4      
tripartite motif-containing protein 2-like isoform X1      
tripartite motif-containing protein 3-like      
tripartite motif-containing protein 3-like isoform X1      
tripartite motif-containing protein 45-like      
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tripartite motif-containing protein 55-like      
universal stress protein A-like protein isoform X5      
epididymal secretory protein E1-like *      
perilipin-2-like isoform X3*      
nitric oxide synthase brain-like isoform X2      
Ig-like and fibronectin type-III domain-containing protein 2 *      
macrophage migration inhibitory factor-like      
 retinoic acid receptor RXR-gamma isoform X1       
NAD-dependent protein deacetylase sirtuin-1-like *      
cAMP-dependent protein kinase catalytic subunit      
PREDICTED: stress protein DDR48-like [Salmo salar]      
B-cell lymphoma 6 protein homolog isoform X3       
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1-like isoform X12    
cell wall integrity and stress response component 3-like isoform X3 [      
histone H2B-like       
Biomineralization        
perlucin-like       
perlucin-like isoform X1 *      
perlucin-like isoform X2      
perlucin-like protein       
perlucin-like protein isoform X1*      
Chitin synthase 3*      
Chitin synthase C      
putative carbonic anhydrase-like protein 1       
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CHAPTER 5 
 
DISSERTATION SUMMARY: USE OF PROBIOTICS BACILLUS PUMILUS 
RI06-95 AND PHAEOBACTER INHIBENS S4 IN LARVICULTURE OF 
CRASSOSTREA VIRGINICA TO STIMULATE HOST IMMUNITY AND LIMIT 
IMPACT OF VIBRIO CORALLIILYTICUS RE22 
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  This dissertation research confirms the benefits of use of probiotics B. pumilus 
RI06-95 and P. inhibens S4 as a natural and environmentally safe solution in disease 
management of C. virginica larviculture (Karim et al., 2013, Zhao et al., 2016, Sohn et 
al., 2016). 
 Use of suitably formulated probiotics can aid vibriosis management in hatchery 
larviculture of Crassostrea virginica preventing sudden and massive larval mortalities. 
This research demonstrates the successful formulation of a candidate probiotic strain, 
Bacillus pumilus RI06-95, that facilitates stable long-term storage and easy delivery in 
a hatchery setting. Daily treatment of oyster larvae with the spray dried formulation in 
pilot-scale hatchery trials provided significant protection against laboratory challenge 
with Vibrio coralliilyticus RE22 (RPS 43 ± 4 %). The results demonstrated that a 
sprayed-dried formulation for probiotic RI06-95 is a commercially viable product that 
can be safely and effectively used to limit negative impacts of vibriosis in shellfish 
hatcheries. Understanding host-microbe interactions between C. virginica larvae and 
pathogen or between larvae and probiotics would immensely help in designing protocols 
of probiotic use commercially.  
 This research showed the swift progression of disease both in terms of rapidly 
increasing mortality post 14h of exposure as well as impact on host immune system. 
Immunological responses of C. virginica larvae to pathogen V. coralliilyticus RE22, as 
measured through transcriptome analysis, suggest the ability of vibrio exposure to 
suppress immune-related pathway activation and immune effector production. The 
research also highlights the need and suitability of preventative measures like probiotics 
rather than treatment options to protect larvae from effects of V. coralliilyticus RE22.  
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 This dissertation research on the immunological responses of C. virginica larvae 
to both probiotics B. pumilus RI06-95 and P. inhibens S4 shows that the 
immunosuppression by RE22 may be counteracted by probiotics ‘priming’ of the larval 
immune response. This research demonstrates the ability of both probiotics to activate 
pathogen recognition receptors (PRRs) that could aid in pathogen detection, activation 
of immune signaling pathways and production of immune effectors that could 
potentially aid in inactivation of RE22 and its virulence factors. 
 A hypothesized model based on the findings of this dissertation research and 
previously published work is proposed here (Fig 1). When C. virginica larvae are 
pretreated with probiotics, RI and S4 for 6 to 24 h, most larvae are protected from RE22 
challenge (Fig1-1).  A more prolonged 24 h pretreatment (versus 6 h) allows for more 
consistent elicitation of immune responses, and therefore more consistent levels of 
protection against RE22. Immune responses include activation of PRRs, immune 
signaling pathways and production of immune effectors like mucins, serine protease 
inhibitors and perforn-2 (Fig1-2). Oysters have a high basal rate of apoptosis that 
regulate hemocyte number (Sokolova 2009). Transcriptomic data suggests treatment 
with probiotics may inhibit hemocyte apoptosis, leading to increase in the number of 
hemocytes (Fig1-3). This immunostimulation likely contributes to clearing probiotics 
from the system (Karim et al., 2013), but also may contribute to counteracting RE22 
virulence. When probiotic pretreated (and hence immunostimulated larvae) are 
challenged with RE22, a series of changes brought about by the probiotics in the host 
may assist the larvae in blocking RE22 (Fig1-4). Increased mucin production may 
enhance the epithelial barrier blocking penetration and prevent adhesion of pathogen. 
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Increased production of serine protease inhibitors may help to counter the effect of 
serine proteases potentially produced by RE22. This immunomodulation would 
complement other mechanisms of action of probiotics.  Probiotic biofilm established 
during the pretreatment period may reduce colonization sites for RE22 competitively 
excluding them from colonizing the gut. Biofilm formation and competition assays 
between S4 and RE22 showed pretreatment with S4 excludes RE22 (Zhao et al., 2016). 
The draft genome of RI suggested its ability to form biofilms (Hamblin et al., 2015) but 
there is no experimental data to support it yet.  Antibiotic tropodithietic acid (TDA) 
produced by S4 also aids in eliminating RE22 (Karim et al., 2013). S4 also secretes N-
acyl homoserine lactones (AHLs) that quorum quench RE22 metalloprotease gene 
expression that are a crucial part of its virulence (Zhao et al., 2018).  Increased 
production of perforin-2 due to probiotic pretreatment may also aid in neutralizing 
pathogens both intracellularly and extracellularly within oyster tissues. Increased 
number of hemocytes owing to apoptosis inhibition post probiotic treatment may 
increase phagocytic pressure on RE22 as well as buffer cytotoxic effects of hemolysins 
secreted by RE22 (Fig1-5) that diminish hemocyte survival (Gomez-Leon et al., 2008). 
All these effects probably work in concert to allow more probiotic pretreated C. 
virginica larvae to survive post RE22 challenge than those without probiotic 
pretreatment, by effectively reducing the infective dose of RE22 (Fig1-4) and providing 
larvae with mechanisms to further neutralize and kill RE22 within the oyster tissues 
(Fig1-5), leading to increased survival (Fig1-6). Due to effective clearing of probiotics 
within oysters due to the larval immune response, however, their protective effect 
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diminishes over time as also seen in experimental evidence (Karim et al., 2013) unless 
probiotics are applied repeatedly.   
 Immune effectors produced in response to probiotics, specifically highlighted in 
this study are highly suitable in blocking virulence factors and pathogenesis of RE22. 
However, application of probiotics and their overall immunostimulatory effect may 
likely help in protecting larvae from other bacterial and viral infections. Thus, this 
research advocates use of probiotic formulations in commercial shellfish aquaculture 
for their beneficial effects. In addition, it provides new insights in oyster immunity in 
response to non-pathogenic bacteria and the crosstalk between host and probiotics.  
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Figure 1: Hypothesized model showing in a series of steps (1-6) how effects of 
probiotic pretreatment on host immunity may complement other mechanisms of action 
of probiotics in providing protection from V. coralliilyticus RE22 challenge. QQ: 
quorum quenching, SPI: serine protease inhibitor, TDA: tropodithietic acid.   
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APPENDIX 
 
Table 1. Two-way ANOVA for the levels of Vibrios in water, tank surface, and oyster 
on each trial with RI formulations.  
ANOVA table SS DF MS F (DFn, DFd) P value 
Trial I: oyster      
   Interaction 9.009 2 4.505 F (2, 10) = 2.278 P = 0.1530 
   Time 1.689 2 0.8446 F (2, 10) = 0.4271 P = 0.6638 
   Treatment 0.03975 1 0.03975 F (1, 5) = 0.07956 P = 0.7892 
   Subjects (matching) 2.498 5 0.4996 F (5, 10) = 0.2526 P = 0.9289 
   Residual 19.78 10 1.978   
Trial I: water      
   Interaction 2.834 2 1.417 F (2, 10) = 2.879 P = 0.1029 
   Time 4.138 2 2.069 F (2, 10) = 4.204 P = 0.0473 
   Treatment 0.05357 1 0.05357 F (1, 5) = 0.03503 P = 0.8589 
   Subjects (matching) 7.647 5 1.529 F (5, 10) = 3.107 P = 0.0599 
   Residual 4.922 10 0.4922   
Trial II: oyster      
   Interaction 4.051 6 0.6752 F (6, 16) = 1.467 P = 0.2512 
   Time 46.39 2 23.19 F (2, 16) = 50.39 P < 0.0001 
   Treatment 8.178 3 2.726 F (3, 8) = 4.766 P = 0.0344 
   Subjects (matching) 4.576 8 0.572 F (8, 16) = 1.243 P = 0.3372 
   Residual 7.364 16 0.4603   
Trial II: tank surface      
   Interaction 5.513 6 0.9188 F (6, 16) = 0.4252 P = 0.8515 
   Time 58.79 2 29.39 F (2, 16) = 13.60 P = 0.0004 
   Treatment 20.56 3 6.854 F (3, 8) = 4.529 P = 0.0389 
   Subjects (matching) 12.11 8 1.513 F (8, 16) = 0.7004 P = 0.6872 
   Residual 34.57 16 2.161   
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Table 2: Differentially expressed genes with log fold change for probiotic or pathogen treatments when compared to control (Con 0 h) 
in laboratory transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). RI_6h: Larvae 
exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 
24h; RE22_6h: Larvae exposed to RE22 for 6h. 
 
Log2FoldChange Hit_def Treatment 
Recognition 
TLRs   
23.05478838 toll-like receptor 13 [Crassostrea virginica] S4_6h 
-22.74173118 toll-like receptor 13 [Crassostrea virginica] S4_24h 
20.83600237 toll-like receptor 13 [Crassostrea virginica] S4_24h 
21.32340853 toll-like receptor 13 [Crassostrea virginica] RI_24h 
22.15592205 toll-like receptor 13 [Crassostrea virginica] RE22_6h 
21.51071325 toll-like receptor 13 isoform X1 [Crassostrea virginica] S4_24h 
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22.42155892 toll-like receptor 13 isoform X1 [Crassostrea virginica] S4_24h 
17.30506755 toll-like receptor 13 isoform X1 [Crassostrea virginica] RI_24h 
21.06459929 toll-like receptor 3 isoform X1 [Crassostrea virginica] S4_24h 
22.49716465 toll-like receptor 3 isoform X1 [Crassostrea virginica] RI_24h 
-22.48957053 toll-like receptor 4 [Crassostrea virginica] S4_6h 
-23.60095447 toll-like receptor 4 [Crassostrea virginica] RI_24h 
21.86007267 toll-like receptor 4 [Crassostrea virginica] S4_6h 
20.06293431 toll-like receptor 4 [Crassostrea virginica] S4_24h 
18.52915288 toll-like receptor 4 [Crassostrea virginica] RI_6h 
20.85337828 toll-like receptor 4 [Crassostrea virginica] RE22_6h 
-27.08359576 toll-like receptor 4 isoform X1 [Crassostrea virginica] S4_6h 
-23.23844181 toll-like receptor 4 isoform X1 [Crassostrea virginica] S4_24h 
-22.60452533 toll-like receptor 4 isoform X1 [Crassostrea virginica] S4_24h 
-21.22164677 toll-like receptor 4 isoform X1 [Crassostrea virginica] S4_24h 
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-3.670100715 toll-like receptor 4 isoform X1 [Crassostrea virginica] S4_24h 
-21.77985815 toll-like receptor 4 isoform X1 [Crassostrea virginica] RI_6h 
-25.3837144 toll-like receptor 4 isoform X1 [Crassostrea virginica] RE22_6h 
-20.33473167 toll-like receptor 4 isoform X1 [Crassostrea virginica] RE22_6h 
-23.85245048 toll-like receptor 6 isoform X1 [Crassostrea virginica] S4_6h 
-24.52152638 toll-like receptor 6 isoform X1 [Crassostrea virginica] RI_6h 
6.948335986 toll-like receptor Tollo isoform X2 [Crassostrea virginica] RI_24h 
6.751339206 toll-like receptor Tollo isoform X2 [Crassostrea virginica] RE22_6h 
-18.59470318 toll-interacting protein-like isoform X3 [Crassostrea virginica] RE22_6h 
Lectins   
20.59470698 lectin BRA-3-like [Crassostrea virginica] S4_24h 
-21.67159 lectin BRA-3-like [Crassostrea virginica] RI_6h 
15.5998376 lectin BRA-3-like [Crassostrea virginica] RI_24h 
-21.98669883 hepatic lectin-like [Crassostrea virginica] S4_6h 
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-28.16031439 complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea 
virginica] 
RI_6h 
-2.942969529 complement C1q-like protein 2 [Crassostrea virginica] S4_6h 
-2.720935883 complement C1q-like protein 2 [Crassostrea virginica] RE22_6h 
-4.990716982 complement C1q-like protein 4 [Crassostrea virginica] RE22_6h 
5.323119114 fucolectin-like [Crassostrea virginica] S4_6h 
5.500587362 fucolectin-like [Crassostrea virginica] RI_6h 
6.563854383 fucolectin-like [Crassostrea virginica] RE22_6h 
-21.98669883 hepatic lectin-like [Crassostrea virginica] S4_6h 
Scavenger receptors  
-24.64487832 scavenger receptor class B member 1 isoform B [Alligator mississippiensis] RI_6h 
-25.10222908 scavenger receptor class B member 1 isoform B [Alligator mississippiensis] RE22_6h 
-5.982694265 scavenger receptor class F member 2-like [Crassostrea virginica] S4_6h 
PGRP   
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-5.798327381 peptidoglycan-recognition protein SC2-like [Crassostrea virginica] S4_6h 
LRRs   
-5.147401101 leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein 
[Crassostrea virginica] 
S4_24h 
-6.212337034 leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein 
[Crassostrea virginica] 
RI_24h 
-21.92443052 leucine-rich repeat and fibronectin type-III domain-containing protein 5-like isoform X1 
[Crassostrea virginica] 
RI_24h 
9.844842922 leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea 
virginica] 
RI_6h 
20.97197566 leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea 
virginica] 
RI_6h 
20.96078701 leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea 
virginica] 
RE22_6h 
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-23.84553133 leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica] S4_6h 
-23.84658918 leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica] S4_24h 
-23.04060289 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] S4_24h 
-15.08871621 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] S4_24h 
-8.156979152 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] S4_24h 
20.08727174 leucine-rich repeat-containing protein 28-like isoform X3 [Crassostrea virginica] S4_24h 
6.821818096 leucine-rich repeat-containing protein 34-like isoform X2 [Crassostrea virginica] S4_6h 
-23.06503275 leucine-rich repeat-containing protein 45-like [Crassostrea virginica] S4_24h 
-23.72912188 leucine-rich repeat-containing protein 45-like [Crassostrea virginica] RI_24h 
22.71972652 leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] S4_6h 
20.7202629 leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] RI_6h 
22.88621537 leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica] RI_24h 
-24.40103127 leucine-rich repeat-containing protein 70-like [Crassostrea virginica] S4_24h 
-25.58565569 leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea virginica] S4_24h 
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-11.00397714 leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica] S4_6h 
-11.92749456 leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica] S4_6h 
-22.72669381 leucine-rich repeat-containing protein 74B-like [Crassostrea virginica] S4_24h 
-23.52071418 leucine-rich repeat-containing protein 74B-like [Crassostrea virginica] RI_24h 
5.554434603 leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica] S4_6h 
7.401747777 leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica] S4_24h 
-23.01756736 leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] RI_6h 
-5.5609716 leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] RI_6h 
-5.297693704 leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica] RE22_6h 
Fibronectin type III domain  
-4.785308683 fibronectin type III domain-containing protein 1-like [Crassostrea virginica] S4_24h 
-23.90865588 fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] RI_24h 
-22.69764157 fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] RI_24h 
-24.13260348 fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica] RE22_6h 
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C1q proteins   
-28.16031439 complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea 
virginica] 
RI_6h 
-2.942969529 complement C1q-like protein 2 [Crassostrea virginica] S4_6h 
-2.720935883 complement C1q-like protein 2 [Crassostrea virginica] RE22_6h 
-4.990716982 complement C1q-like protein 4 [Crassostrea virginica] RE22_6h 
-27.07147054 alpha-1-macroglobulin-like [Crassostrea virginica] S4_6h 
-27.09597681 alpha-1-macroglobulin-like [Crassostrea virginica] S4_24h 
-4.827641592 alpha-1-macroglobulin-like [Crassostrea virginica] S4_24h 
-16.82943987 Macrophage mannose receptor 1 [Crassostrea gigas] S4_24h 
-23.67745527 macrophage mannose receptor 1-like isoform X1 [Crassostrea virginica] RI_24h 
Metabolic Enzymes with New Role of Carbohydrate Binding  
-3.019898078 Phosphoenolpyruvate carboxykinase  S4_24h 
20.50362782 hexokinase-2-like isoform X2 [Crassostrea virginica] S4_6h 
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-27.8856754 hexokinase-2-like isoform X2 [Crassostrea virginica] RI_6h 
-24.29212676 hexokinase-2-like isoform X2 [Crassostrea virginica] RI_6h 
10.04796022 hexokinase-2-like isoform X2 [Crassostrea virginica] RI_6h 
20.45474609 hexokinase-2-like isoform X2 [Crassostrea virginica] RI_6h 
-27.93663561 hexokinase-2-like isoform X2 [Crassostrea virginica] RI_24h 
-28.20643409 hexokinase-2-like isoform X2 [Crassostrea virginica] RE22_6h 
-24.71581303 hexokinase-2-like isoform X2 [Crassostrea virginica] RE22_6h 
11.04164794 hexokinase-2-like isoform X2 [Crassostrea virginica] RE22_6h 
21.25153221 hexokinase-2-like isoform X2 [Crassostrea virginica] RE22_6h 
 Cholinergic immunomodulation  
2.908686031 glutamate receptor 2-like [Crassostrea virginica] RI_6h 
-23.53192783 glutamate receptor ionotropic S4_24h 
-8.851813981 glutamate receptor ionotropic S4_24h 
-26.48442583 glutamate receptor ionotropic RI_6h 
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-22.22604191 glutamate receptor ionotropic RE22_6h 
20.55673148 glutamate receptor-interacting protein 1-like isoform X4 [Crassostrea virginica] RI_24h 
7.766510402 muscarinic acetylcholine receptor M3-like [Crassostrea virginica] RE22_6h 
-23.96329241 neuronal acetylcholine receptor subunit alpha-2-like [Crassostrea virginica] RE22_6h 
10.39346971 neuronal acetylcholine receptor subunit alpha-5-like isoform X1 [Crassostrea virginica] RE22_6h 
21.77501036 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] S4_24h 
21.26581499 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] RI_24h 
-23.03542166 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] S4_24h 
-4.54262089 neuropeptide SIFamide receptor-like [Crassostrea virginica] S4_6h 
-23.60128855 neuropeptide Y receptor type 2-like [Crassostrea virginica] RE22_6h 
Signaling pathways in Immune response   
-11.1762089 TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica] S4_6h 
-9.894522176 TNF receptor-associated factor 4-like isoform X5 [Crassostrea virginica] RE22_6h 
24.64790366 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] S4_6h 
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-23.39582662 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] S4_24h 
-4.478976796 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] S4_24h 
-21.85010489 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] RI_6h 
25.29177394 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] RI_24h 
24.11940272 LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica] RE22_6h 
-7.662488479 signal transducer and activator of transcription 3-like isoform X6 [Crassostrea virginica] RI_24h 
-26.82508167 LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] RE22_6h 
-20.08059767 LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] S4_24h 
-20.7042899 LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica] RI_24h 
-21.98909234 epidermal growth factor receptor-like [Crassostrea virginica] S4_24h 
-21.85708608 epidermal growth factor receptor-like isoform X2 [Crassostrea virginica] S4_6h 
-22.21636099 epidermal growth factor receptor-like isoform X2 [Crassostrea virginica] RI_24h 
3.582236878 epidermal growth factor receptor-like isoform X2 [Crassostrea virginica] S4_6h 
-26.61502073 epidermal growth factor receptor-like isoform X4 [Crassostrea virginica] S4_24h 
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4.440719006 epidermal growth factor receptor-like isoform X4 [Crassostrea virginica] S4_24h 
4.780146091 PREDICTED: tyrosine-protein phosphatase non-receptor type 11 isoform X3 
[Crassostrea gigas] 
S4_6h 
-24.59389772 tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea 
virginica] 
S4_6h 
-21.79438105 tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea 
virginica] 
S4_6h 
-21.90808833 tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea 
virginica] 
S4_24h 
-23.41598784 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
S4_6h 
20.99622685 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
S4_6h 
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20.32249114 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
S4_24h 
21.72359644 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
RI_6h 
22.3115501 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
RI_24h 
20.18049393 tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea 
virginica] 
RE22_6h 
19.62125156 tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea 
virginica] 
S4_6h 
21.66755905 tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea 
virginica] 
S4_24h 
23.55240592 tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea 
virginica] 
RI_6h 
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22.38124103 tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea 
virginica] 
RI_24h 
23.05607193 tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea 
virginica] 
RE22_6h 
-10.65160003 tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea 
virginica] 
S4_6h 
-10.6365949 tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea 
virginica] 
S4_24h 
-8.931960108 tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea 
virginica] 
RE22_6h 
-24.13233234 tyrosine-protein phosphatase non-receptor type 9-like isoform X2 [Crassostrea 
virginica] 
RI_24h 
-23.73611409 NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica] S4_6h 
-9.500032383 NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica] RI_6h 
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-9.657932705 NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica] RE22_6h 
-24.81953437 NF-kappa-B-activating protein-like [Crassostrea virginica] S4_6h 
-24.69597209 NF-kappa-B-activating protein-like [Crassostrea virginica] S4_24h 
-24.42843374 NF-kappa-B-activating protein-like [Crassostrea virginica] S4_24h 
-23.65126954 NF-kappa-B-activating protein-like [Crassostrea virginica] S4_24h 
-24.77085054 NF-kappa-B-activating protein-like [Crassostrea virginica] RI_6h 
-25.40980564 NF-kappa-B-activating protein-like [Crassostrea virginica] RI_24h 
-24.86565855 NF-kappa-B-activating protein-like [Crassostrea virginica] RI_24h 
-25.18633897 NF-kappa-B-activating protein-like [Crassostrea virginica] RE22_6h 
-21.62114724 smad nuclear interacting protein 1-like [Crassostrea virginica] S4_6h 
-22.01002997 smad nuclear interacting protein 1-like [Crassostrea virginica] RI_6h 
22.23806571 TNFAIP3-interacting protein 1-like [Crassostrea virginica] RI_6h 
23.32946941 TNFAIP3-interacting protein 1-like [Crassostrea virginica] RE22_6h 
3.669180885 PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas] S4_6h 
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5.125890801 PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas] S4_24h 
-24.48845992 ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] RI_6h 
-24.52498266 ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] RI_24h 
22.90392037 ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] S4_24h 
21.99071309 ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] RI_24h 
21.29621653 adapter protein CIKS-like [Crassostrea virginica] S4_6h 
21.89981234 adapter protein CIKS-like [Crassostrea virginica] S4_24h 
19.10179883 adapter protein CIKS-like [Crassostrea virginica] RI_6h 
21.9145228 adapter protein CIKS-like [Crassostrea virginica] RI_24h 
21.96174137 adapter protein CIKS-like [Crassostrea virginica] RE22_6h 
-21.68449844 adapter protein CIKS-like isoform X4 [Crassostrea virginica] RI_24h 
-5.87337841 PREDICTED: dual specificity mitogen-activated protein kinase kinase 1-like isoform 
X1 [Crassostrea gigas] 
RI_24h 
-25.72060852 MAP kinase-activated protein kinase 2-like isoform X2 [Crassostrea virginica] RI_24h 
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-2.470755161 mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea 
virginica] 
S4_24h 
-24.25502986 mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea 
virginica] 
RI_24h 
-7.716909755 Mitogen-activated protein kinase kinase kinase 7 [Crassostrea gigas] RI_6h 
-21.70047837 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h 
-2.753446313 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h 
22.14143778 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h 
-21.62740093 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_24h 
21.84933712 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RI_6h 
-3.340398882 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RI_24h 
-22.1261532 mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RE22_6h 
20.30696981 dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea 
virginica] 
S4_6h 
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21.95392224 dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea 
virginica] 
S4_24h 
21.12567936 dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea 
virginica] 
RI_6h 
-18.51291804 dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea 
virginica] 
RI_24h 
22.55409809 dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea 
virginica] 
RE22_6h 
-10.42721287 LOW QUALITY PROTEIN: mitogen-activated protein kinase 14A-like [Crassostrea 
virginica] 
RI_6h 
-22.51874945 LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3-
like [Crassostrea virginica] 
S4_24h 
-23.17120745 LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3-
like [Crassostrea virginica] 
RI_24h 
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7.880002894 transforming growth factor-beta, partial [Crassostrea ariakensis] RI_24h 
6.414756431 transforming growth factor-beta, partial [Crassostrea ariakensis] S4_24h 
-24.5406632 LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like 
[Crassostrea virginica] 
S4_24h 
-23.28637433 LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like 
[Crassostrea virginica] 
S4_24h 
8.201025972 extracellular signal-regulated kinase 2-like isoform X4 [Crassostrea virginica] RI_24h 
-22.50186319 stimulator of interferon genes protein-like [Crassostrea virginica] S4_6h 
20.17836595 stimulator of interferon genes protein-like [Crassostrea virginica] S4_6h 
-16.95226096 stimulator of interferon genes protein-like [Crassostrea virginica] S4_24h 
-7.478972473 stimulator of interferon genes protein-like [Crassostrea virginica] RI_6h 
17.42282629 stimulator of interferon genes protein-like [Crassostrea virginica] RI_6h 
20.17813132 stimulator of interferon genes protein-like [Crassostrea virginica] RI_24h 
20.42313211 stimulator of interferon genes protein-like [Crassostrea virginica] RE22_6h 
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-6.713339842 death domain-containing protein 1-like [Crassostrea virginica] S4_6h 
-6.937781661 death domain-containing protein 1-like [Crassostrea virginica] S4_24h 
-4.130539001 death domain-containing protein 1-like [Crassostrea virginica] RI_6h 
-6.57016357 death domain-containing protein 1-like [Crassostrea virginica] RE22_6h 
21.29117555 death domain-containing protein CRADD-like [Crassostrea virginica] S4_6h 
19.33282647 death domain-containing protein CRADD-like [Crassostrea virginica] RI_6h 
21.07018009 death domain-containing protein CRADD-like [Crassostrea virginica] RE22_6h 
19.40341779 integrin alpha-4-like isoform X1 [Crassostrea virginica] S4_24h 
20.6821385 integrin alpha-4-like isoform X1 [Crassostrea virginica] RI_24h 
-2.282127264 integrin beta-3-like [Crassostrea virginica] S4_24h 
11.0047672 ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis] S4_6h 
21.44939539 ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis] S4_24h 
11.5782336 ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis] RI_6h 
21.74942278 ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis] RI_24h 
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11.12138173 ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis] RE22_6h 
-24.21434106 ubiquitin carboxyl-terminal hydrolase 20-like isoform X2 [Crassostrea virginica] S4_24h 
22.53788386 ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] S4_6h 
19.53896908 ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] S4_24h 
21.61706409 ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] RI_6h 
21.55529349 ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] RI_24h 
22.99322029 ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica] RE22_6h 
 Effectors  
-7.636639706 serine protease 44-like [Crassostrea virginica] S4_24h 
21.50670849 serine protease inhibitor Cvsi-2-like [Crassostrea virginica] S4_6h 
12.83482328 serine protease inhibitor Cvsi-2-like [Crassostrea virginica] S4_24h 
21.11968406 serine protease inhibitor Cvsi-2-like [Crassostrea virginica] RI_6h 
20.26304644 serine protease inhibitor Cvsi-2-like [Crassostrea virginica] RI_24h 
28.4447526 serine protease inhibitor dipetalogastin-like [Crassostrea virginica] S4_6h 
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22.31014239 serine protease inhibitor dipetalogastin-like [Crassostrea virginica] RI_24h 
15.3518296 serine protease inhibitor dipetalogastin-like [Crassostrea virginica] S4_24h 
-22.79409461 kunitz-type protease inhibitor 1-like [Crassostrea virginica] S4_6h 
20.0825116 LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] S4_6h 
20.26000192 LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] S4_24h 
21.99420619 LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] RI_6h 
19.1215388 LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica] RI_24h 
-23.58012026 Signaling mucin HKR1 [Mizuhopecten yessoensis] S4_6h 
-23.80421719 Signaling mucin HKR1 [Mizuhopecten yessoensis] S4_24h 
-9.356963695 Signaling mucin HKR1 [Mizuhopecten yessoensis] S4_24h 
-24.38357841 Signaling mucin HKR1 [Mizuhopecten yessoensis] RI_6h 
-21.90572271 Signaling mucin HKR1 [Mizuhopecten yessoensis] RI_6h 
-16.19910691 Signaling mucin HKR1 [Mizuhopecten yessoensis] RI_24h 
-24.51441136 Signaling mucin HKR1 [Mizuhopecten yessoensis] RE22_6h 
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-2.369460824 integumentary mucin C.1-like [Crassostrea virginica] S4_24h 
3.541415795 integumentary mucin C.1-like [Crassostrea virginica] RI_24h 
21.31111159 integumentary mucin C.1-like isoform X1 [Crassostrea virginica] S4_24h 
-15.40397187 integumentary mucin C.1-like isoform X1 [Crassostrea virginica] RI_24h 
-23.4017782 integumentary mucin C.1-like isoform X3 [Crassostrea virginica] S4_24h 
-24.11558579 integumentary mucin C.1-like isoform X3 [Crassostrea virginica] RI_6h 
15.84736053 LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica] S4_6h 
19.8605114 LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica] S4_24h 
21.24020302 LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica] RI_6h 
20.3172585 LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica] RI_24h 
20.50006596 LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica] RE22_6h 
-25.58549501 mucin-17-like isoform X2 [Crassostrea virginica] S4_6h 
-22.60499384 mucin-17-like isoform X2 [Crassostrea virginica] S4_24h 
-23.3302576 mucin-17-like isoform X2 [Crassostrea virginica] RI_24h 
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-12.40357314 mucin-2-like [Crassostrea virginica] RE22_6h 
3.74775207 mucin-3B-like isoform X4 [Crassostrea virginica] S4_6h 
4.020665081 mucin-3B-like isoform X4 [Crassostrea virginica] S4_6h 
-22.20357216 mucin-3B-like isoform X4 [Crassostrea virginica] S4_24h 
3.986726111 mucin-3B-like isoform X4 [Crassostrea virginica] RI_6h 
4.460044136 mucin-3B-like isoform X4 [Crassostrea virginica] RI_24h 
-10.73484035 mucin-3B-like isoform X4 [Crassostrea virginica] S4_24h 
-23.44462362 mucin-4-like isoform X7 [Crassostrea virginica] S4_24h 
-6.728200181 mucin-4-like isoform X8 [Crassostrea virginica] RI_6h 
19.8087086 mucin-5AC-like [Crassostrea virginica] S4_24h 
24.20835013 mucin-5AC-like [Crassostrea virginica] RI_24h 
-23.63449535 mucin-5AC-like isoform X2 [Crassostrea virginica] S4_24h 
-25.71724187 mucin-5AC-like isoform X5 [Crassostrea virginica] S4_24h 
-25.5565658 mucin-5AC-like isoform X5 [Crassostrea virginica] S4_24h 
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-25.02710707 mucin-5AC-like isoform X5 [Crassostrea virginica] S4_24h 
-24.9869002 mucin-5AC-like isoform X5 [Crassostrea virginica] S4_24h 
-24.55559512 mucin-5AC-like isoform X5 [Crassostrea virginica] S4_24h 
20.15216503 macrophage-expressed gene 1 protein-like [Crassostrea virginica] S4_6h 
-23.12210565 macrophage-expressed gene 1 protein-like [Crassostrea virginica] S4_24h 
21.2588995 macrophage-expressed gene 1 protein-like [Crassostrea virginica] S4_24h 
21.13829677 macrophage-expressed gene 1 protein-like [Crassostrea virginica] RI_6h 
19.19639966 macrophage-expressed gene 1 protein-like [Crassostrea virginica] RI_24h 
-25.14528973 antistasin-like [Crassostrea virginica] RI_6h 
-25.22546326 antistasin-like [Crassostrea virginica] RI_24h 
-8.191296146 cystatin-A-like [Crassostrea virginica] RI_24h 
 Apoptosis  
-6.21042132 caspase-1-like [Crassostrea virginica] S4_24h 
20.95052586 caspase-1-like [Crassostrea virginica] S4_6h 
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20.96735265 caspase-1-like [Crassostrea virginica] S4_24h 
21.36960577 caspase-1-like [Crassostrea virginica] RI_6h 
21.94629746 caspase-1-like [Crassostrea virginica] RI_24h 
20.13240973 caspase-1-like [Crassostrea virginica] RE22_6h 
8.059692737 caspase-3-like isoform X2 [Crassostrea virginica] S4_6h 
-22.07884074 caspase-3-like isoform X2 [Crassostrea virginica] S4_24h 
19.83057052 caspase-3-like isoform X2 [Crassostrea virginica] S4_24h 
-8.724115052 caspase-3-like isoform X2 [Crassostrea virginica] RI_24h 
18.89735984 caspase-3-like isoform X2 [Crassostrea virginica] RI_24h 
5.865260258 caspase-6-like [Crassostrea virginica] RI_6h 
6.332228555 caspase-6-like [Crassostrea virginica] RE22_6h 
-11.6773146 caspase-6-like isoform X2 [Crassostrea virginica] S4_24h 
-8.871803044 caspase-6-like isoform X2 [Crassostrea virginica] S4_24h 
3.340083172 caspase-6-like isoform X2 [Crassostrea virginica] S4_24h 
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-12.17173082 caspase-6-like isoform X2 [Crassostrea virginica] RI_24h 
-8.404424419 caspase-6-like isoform X2 [Crassostrea virginica] RI_24h 
3.27853441 caspase-6-like isoform X2 [Crassostrea virginica] RI_24h 
18.19169296 caspase-7-like [Crassostrea virginica] S4_6h 
19.24463486 caspase-7-like [Crassostrea virginica] RI_6h 
19.8989936 caspase-7-like [Crassostrea virginica] RE22_6h 
-7.554426297 caspase-7-like isoform X1 [Crassostrea virginica] S4_6h 
-6.02479199 caspase-7-like isoform X1 [Crassostrea virginica] S4_24h 
-6.826149987 caspase-7-like isoform X1 [Crassostrea virginica] RI_24h 
-6.880726858 caspase-7-like isoform X1 [Crassostrea virginica] RE22_6h 
-21.01107236 caspase-7-like isoform X3 [Crassostrea virginica] RI_24h 
-21.23808674 caspase-7-like isoform X3 [Crassostrea virginica] RE22_6h 
-25.94532375 baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica] S4_24h 
-26.32635634 baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica] RE22_6h 
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-24.35012269 baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica] S4_24h 
19.47455056 baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] S4_6h 
19.10971772 baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] RI_6h 
21.20706554 baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica] RE22_6h 
-11.87771995 baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica] S4_6h 
-6.7526098 baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica] S4_6h 
-23.00355415 baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica] RI_24h 
-23.45580618 baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica] RI_24h 
18.88003432 putative inhibitor of apoptosis [Crassostrea virginica]  RE22_6h 
20.38877928 putative inhibitor of apoptosis [Crassostrea virginica]  RI_6h 
20.544862 putative inhibitor of apoptosis [Crassostrea virginica]  S4_6h 
20.82027693 putative inhibitor of apoptosis [Crassostrea virginica]  RI_24h 
21.23594337 putative inhibitor of apoptosis [Crassostrea virginica] S4_24h 
-21.79877969 bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica] S4_6h 
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-21.84056799 bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica] S4_24h 
-4.862913449 apoptogenic protein 1 RI_6h 
-22.71920742 cathepsin L-like isoform X2 [Crassostrea virginica] S4_24h 
-25.24123094 cathepsin L-like isoform X2 [Crassostrea virginica] RI_6h 
-22.92152325 cathepsin O-like [Crassostrea virginica] S4_6h 
-24.09391392 programmed cell death 6-interacting protein-like isoform X3 [Crassostrea virginica] S4_24h 
-7.976483879 programmed cell death protein 6-like isoform X2 [Crassostrea virginica] S4_6h 
23.29208898 XK-related protein 6-like [Crassostrea virginica] RI_6h 
24.85645254 XK-related protein 6, partial [Stegodyphus mimosarum] RE22_6h 
8.288290515 XK-related protein 6, partial [Stegodyphus mimosarum] RI_6h 
20.4704348 XK-related protein 6, partial [Stegodyphus mimosarum] S4_6h 
24.25694523 XK-related protein 6, partial [Stegodyphus mimosarum] RI_24h 
23.1394026 XK-related protein 6, partial [Stegodyphus mimosarum] S4_24h 
19.26657006 XK-related protein 8-like isoform X2 [Crassostrea virginica] RE22_6h 
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20.93957528 XK-related protein 8-like isoform X2 [Crassostrea virginica] RI_6h 
19.66346021 XK-related protein 8-like isoform X2 [Crassostrea virginica] S4_6h 
4.704739877 cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica] S4_6h 
7.038385691 cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica] S4_24h 
 Autophagy  
19.68063935 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] S4_6h 
22.23975139 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] S4_6h 
19.00211451 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] S4_24h 
20.33463466 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] S4_24h 
20.2328524 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RI_6h 
22.04434718 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RI_6h 
17.69258697 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RI_24h 
19.97079557 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RI_24h 
17.464467 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RE22_6h 
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20.11113826 autophagy-related protein 9A-like isoform X1 [Crassostrea virginica] RE22_6h 
-22.38835903 transcription factor SPT20 homolog isoform X1 [Crassostrea virginica] S4_6h 
-22.81940536 transcription factor SPT20 homolog isoform X1 [Crassostrea virginica] RI_6h 
-23.79270551 vacuole membrane protein 1-like [Crassostrea virginica] S4_6h 
-24.49304386 vacuole membrane protein 1-like [Crassostrea virginica] RI_6h 
-22.8200889 PREDICTED: protein kinase C delta type [Crassostrea gigas] S4_24h 
-23.97489076 PREDICTED: protein kinase C delta type [Crassostrea gigas] RI_24h 
20.26349909 DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] S4_6h 
20.91174474 DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] S4_24h 
20.84051785 DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica] RE22_6h 
-6.547974505 run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like 
isoform X3 [Crassostrea virginica] 
S4_24h 
20.7845565 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like 
isoform X1 [Crassostrea virginica] 
S4_6h 
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21.39532399 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like 
isoform X1 [Crassostrea virginica] 
S4_24h 
22.58624048 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like 
isoform X1 [Crassostrea virginica] 
RI_6h 
21.22674556 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like 
isoform X1 [Crassostrea virginica] 
RI_24h 
22.60384771 phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like 
isoform X1 [Crassostrea virginica] 
RE22_6h 
 Phagosome  
-11.04839433 Actin, cytoplasmic [Crassostrea gigas] S4_6h 
-22.15040686 actin-3-like isoform X1 [Crassostrea virginica] S4_6h 
-23.28807439 actin-3-like isoform X1 [Crassostrea virginica] RI_6h 
-2.009714808 actin-like [Crassostrea virginica] S4_24h 
-25.67615427 cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica] S4_6h 
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-24.78846969 cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica] S4_24h 
-18.35355926 cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea 
virginica] 
S4_6h 
-23.99337051 cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea 
virginica] 
S4_24h 
20.46400243 cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] S4_6h 
19.94858466 cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] S4_24h 
19.68213706 cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] RI_6h 
20.2666716 cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] RI_24h 
19.56136995 cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica] RE22_6h 
22.04398056 cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica] S4_6h 
-6.510608147 cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica] RI_6h 
22.65257645 cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica] RI_6h 
22.2320337 cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica] RI_24h 
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21.24015816 cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica] RE22_6h 
Lysosome   
-26.35735397 lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica] S4_6h 
-27.83132813 lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica] RI_24h 
-5.595601397 lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica] RI_6h 
Endocytosis & Peroxisome  
7.204505845 AP-2 complex subunit mu-1 [Crassostrea gigas] RI_24h 
8.234098827 probable peroxisomal membrane protein PEX13 [Crassostrea virginica] S4_6h 
7.151949067 probable peroxisomal membrane protein PEX13 [Crassostrea virginica] S4_24h 
-24.32891036 peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] RI_24h 
-23.1387346 peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] S4_24h 
-23.64616222 peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica] RI_24h 
-6.184641444 peroxisomal acyl-coenzyme A oxidase 1-like isoform X2 [Crassostrea virginica] S4_24h 
Antioxidant enzymes  
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-3.86662093 glutathione peroxidase 7-like [Crassostrea virginica] S4_24h 
-21.14341297 glutathione S-transferase C-terminal domain-containing protein-like isoform X1 
[Crassostrea virginica] 
S4_24h 
4.340577781 glutathione S-transferase kappa 1-like [Crassostrea virginica] RI_6h 
-21.74743898 maleylacetoacetate isomerase-like [Crassostrea virginica] S4_6h 
-22.28036183 maleylacetoacetate isomerase-like [Crassostrea virginica] RI_24h 
-22.57607848 maleylacetoacetate isomerase-like [Crassostrea virginica] RE22_6h 
-9.092994732 Superoxide dismutase [Cu-Zn] [Crassostrea gigas] S4_24h 
24.656834 thioredoxin domain-containing protein 15-like [Crassostrea virginica] S4_6h 
22.08653805 thioredoxin domain-containing protein 15-like [Crassostrea virginica] RE22_6h 
-22.17861058 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_6h 
-5.275085802 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_6h 
-24.08250505 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_24h 
-22.68468309 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_24h 
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-15.3248519 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_24h 
9.959973369 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_24h 
19.68049721 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] S4_24h 
-22.94170493 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_6h 
-24.96201578 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
-24.87983434 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
-22.95218203 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
7.365024046 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
18.02755971 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
23.85507502 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RI_24h 
-23.27838106 thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica] RE22_6h 
-2.096359322 thioredoxin domain-containing protein 5-like [Crassostrea virginica] S4_24h 
-25.88062202 thioredoxin-like [Crassostrea virginica] S4_24h 
-10.64240601 thioredoxin-like [Crassostrea virginica] RI_6h 
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-26.51486203 thioredoxin-like [Crassostrea virginica] RI_24h 
-3.729163339 thioredoxin-like protein 1 [Crassostrea virginica] RI_24h 
3.293281563 thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica] RI_6h 
3.156411653 thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica] RI_24h 
-24.70491532 thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica] RI_24h 
-24.9360089 thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica] RE22_6h 
Acute phase proteins  
-9.723127722 Heat shock 70 kDa protein 12A [Crassostrea gigas] S4_24h 
5.535364462 heat shock 70 kDa protein 12A-like [Crassostrea virginica] S4_24h 
5.686282343 heat shock 70 kDa protein 12A-like [Crassostrea virginica] RI_24h 
-22.26223254 heat shock 70 kDa protein 12A-like [Crassostrea virginica] RE22_6h 
-23.79702313 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] S4_6h 
6.658680636 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] S4_6h 
5.254504823 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] RI_6h 
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5.250678277 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] RE22_6h 
-4.162351016 heat shock 70 kDa protein 12B-like [Crassostrea virginica] RE22_6h 
-23.06134796 heat shock 70 kDa protein 12B-like [Crassostrea virginica] S4_24h 
19.64075977 heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] S4_6h 
19.49655284 heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] RI_6h 
18.54456763 heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica] RE22_6h 
-22.43374437 heat shock factor protein-like [Crassostrea virginica] RI_24h 
-18.35638131 heat shock protein 30C-like [Crassostrea virginica] S4_24h 
3.254119893 heat shock protein HSP 90-beta-like [Crassostrea virginica] S4_6h 
Cytoskeletal organization  
-24.67660059 PREDICTED: dynamin-1 isoform X2 [Crassostrea gigas] S4_6h 
-11.01417755 dynamin-1-like isoform X6 [Crassostrea virginica] S4_6h 
23.58398582 dynamin-1-like isoform X6 [Crassostrea virginica] S4_6h 
-21.25056055 dynamin-1-like isoform X6 [Crassostrea virginica] S4_24h 
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-23.67694566 dynamin-1-like isoform X6 [Crassostrea virginica] RI_6h 
23.2104963 dynamin-1-like isoform X6 [Crassostrea virginica] RI_6h 
-13.1405264 dynamin-1-like isoform X6 [Crassostrea virginica] RI_24h 
18.62495089 dynamin-1-like isoform X6 [Crassostrea virginica] RE22_6h 
9.249110026 PREDICTED: septin-7 isoform X3 [Crassostrea gigas] S4_6h 
9.161299284 PREDICTED: septin-7 isoform X3 [Crassostrea gigas] RI_6h 
-21.6896377 septin-11-like isoform X2 [Crassostrea virginica] RE22_6h 
-22.00129053 septin-2-like isoform X1 [Crassostrea virginica] S4_6h 
7.044855946 septin-2-like isoform X1 [Crassostrea virginica] S4_6h 
-21.88584245 septin-2-like isoform X1 [Crassostrea virginica] S4_24h 
-22.73608544 septin-2-like isoform X1 [Crassostrea virginica] RI_24h 
-23.27740458 septin-2-like isoform X1 [Crassostrea virginica] S4_24h 
-10.38732509 septin-2-like isoform X8 [Crassostrea virginica] RI_6h 
-7.952386425 septin-2-like isoform X8 [Crassostrea virginica] RI_6h 
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Others   
-23.59339061 multidrug resistance protein 1-like isoform X1 [Crassostrea virginica] S4_6h 
-14.96548899 multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] S4_24h 
21.14757041 multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] RI_6h 
22.22331368 multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] RI_24h 
21.3339868 multidrug resistance protein 1-like isoform X6 [Crassostrea virginica] RE22_6h 
-25.28253245 multidrug resistance-associated protein 4-like [Crassostrea virginica] S4_6h 
-11.35931265 multidrug resistance-associated protein 4-like [Crassostrea virginica] S4_24h 
-2.996574031 multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] S4_24h 
-22.29106079 multidrug resistance-associated protein 7-like [Crassostrea virginica] S4_24h 
-2.512272237 laccase-3-like [Crassostrea virginica] RI_24h 
-4.990554678 laccase-like [Crassostrea virginica] RI_6h 
-23.49586873 Hemicentin-1, partial [Crassostrea gigas] S4_6h 
-21.69620493 Hemicentin-1 S4_6h 
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-8.779619013 Hemicentin-1 S4_6h 
-26.12075367 Hemicentin-1 S4_24h 
-22.82446184 Hemicentin-1 RE22_6h 
4.970041769 hemicentin-1-like [Crassostrea virginica] S4_6h 
-23.57120259 hemicentin-1-like [Crassostrea virginica] S4_6h 
7.211995212 hemicentin-1-like [Crassostrea virginica] S4_6h 
-24.43651737 hemicentin-1-like [Crassostrea virginica] RE22_6h 
-22.74745907 hemicentin-1-like isoform X2 [Crassostrea virginica] S4_24h 
-22.04213544 hemicentin-1-like isoform X2 [Crassostrea virginica] S4_24h 
-23.91446285 hemicentin-1-like isoform X2 [Crassostrea virginica] RE22_6h 
-6.483050928 hemicentin-1-like isoform X2 [Crassostrea virginica] RI_6h 
-20.92100668 hemicentin-1-like isoform X21 [Crassostrea virginica] S4_6h 
-21.90630905 hemicentin-1-like isoform X21 [Crassostrea virginica] RI_6h 
-21.71429592 hemicentin-1-like isoform X21 [Crassostrea virginica] RI_24h 
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-22.25262628 hemicentin-1-like isoform X21 [Crassostrea virginica] RE22_6h 
-21.95606244 hemicentin-1-like isoform X21 [Crassostrea virginica] RE22_6h 
-25.24784795 hemicentin-1-like isoform X3 [Crassostrea virginica] S4_24h 
15.22210309 hemicentin-1-like isoform X34 [Crassostrea virginica] S4_6h 
19.54287658 hemicentin-1-like isoform X34 [Crassostrea virginica] S4_24h 
19.38940516 hemicentin-1-like isoform X34 [Crassostrea virginica] RI_6h 
19.36636019 hemicentin-1-like isoform X34 [Crassostrea virginica] RI_24h 
19.77553284 hemicentin-1-like isoform X34 [Crassostrea virginica] RE22_6h 
-21.26298714 hemicentin-1-like isoform X40 [Crassostrea virginica] S4_6h 
-22.32330998 hemicentin-1-like isoform X40 [Crassostrea virginica] S4_24h 
7.289148836 hemicentin-1-like isoform X5 [Crassostrea virginica] S4_6h 
17.82784086 hemicentin-1-like isoform X5 [Crassostrea virginica] S4_24h 
20.84952352 hemicentin-1-like isoform X5 [Crassostrea virginica] RI_24h 
-24.07441428 hemicentin-1-like isoform X6 [Crassostrea virginica] S4_6h 
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-22.70945451 hemicentin-1-like isoform X9 [Crassostrea virginica] S4_24h 
-25.40188462 hemicentin-1-like isoform X9 [Crassostrea virginica] RI_6h 
-29.99115794 hemicentin-1-like isoform X9 [Crassostrea virginica] RI_24h 
9.38130971 hemicentin-2-like isoform X2 [Crassostrea virginica] S4_6h 
20.95642279 hemicentin-2-like isoform X2 [Crassostrea virginica] S4_24h 
9.373853638 hemicentin-2-like isoform X2 [Crassostrea virginica] RI_6h 
20.55310454 hemicentin-2-like isoform X2 [Crassostrea virginica] RI_24h 
9.777286784 hemicentin-2-like isoform X2 [Crassostrea virginica] RE22_6h 
-8.922154094 histamine H2 receptor-like [Crassostrea virginica] S4_24h 
-22.19114574 histamine H2 receptor-like [Crassostrea virginica] S4_24h 
-22.75801453 histamine H2 receptor-like [Crassostrea virginica] RI_24h 
-22.90867354 histamine H2 receptor-like [Crassostrea virginica] RE22_6h 
-5.471576144 oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica] S4_6h 
-9.718337318 oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica] RI_6h 
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-6.452016421 oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica] RE22_6h 
-2.071397009 cytochrome b [Crassostrea virginica] RI_6h 
20.23697806 cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] S4_24h 
22.07024714 cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] RI_6h 
17.91802039 cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] RI_24h 
21.0441541 cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] RE22_6h 
-30 cytochrome c oxidase subunit I [Crassostrea virginica] S4_6h 
-12.21152488 cytochrome c oxidase subunit I [Crassostrea virginica] S4_6h 
13.83136184 cytochrome c oxidase subunit I [Crassostrea virginica] S4_6h 
-12.7345641 cytochrome c oxidase subunit I [Crassostrea virginica] S4_24h 
23.04305396 cytochrome c oxidase subunit I [Crassostrea virginica] S4_24h 
27.42296011 cytochrome c oxidase subunit I [Crassostrea virginica] S4_24h 
29.20729823 cytochrome c oxidase subunit I [Crassostrea virginica] S4_24h 
-24.69050988 cytochrome c oxidase subunit I [Crassostrea virginica] RI_6h 
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-24.66864706 cytochrome c oxidase subunit I [Crassostrea virginica] RI_6h 
29.16889206 cytochrome c oxidase subunit I [Crassostrea virginica] RI_6h 
-30 cytochrome c oxidase subunit I [Crassostrea virginica] RI_24h 
-13.01827661 cytochrome c oxidase subunit I [Crassostrea virginica] RI_24h 
20.69401443 cytochrome c oxidase subunit I [Crassostrea virginica] RI_24h 
30 cytochrome c oxidase subunit I [Crassostrea virginica] RI_24h 
-30 cytochrome c oxidase subunit I [Crassostrea virginica] RE22_6h 
-11.365341 cytochrome c oxidase subunit I [Crassostrea virginica] RE22_6h 
-10.31599264 cytochrome c oxidase subunit I [Crassostrea virginica] RE22_6h 
30 cytochrome c oxidase subunit I [Crassostrea virginica] RE22_6h 
-12.33130181 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_24h 
-26.50197006 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_6h 
-17.04367675 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_24h 
11.0050444 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_6h 
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15.84125515 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_6h 
26.82143733 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_6h 
28.26611263 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_6h 
10.86124348 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_24h 
11.67321719 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_24h 
30 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_24h 
30 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] S4_24h 
12.78997263 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_6h 
30 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_6h 
30 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_6h 
14.9301273 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_24h 
25.83550682 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_24h 
27.94606978 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RI_24h 
15.68484216 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RE22_6h 
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29.89148054 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] RE22_6h 
7.51088163 cytochrome P450 27C1-like [Crassostrea virginica] S4_6h 
8.171393189 cytochrome P450 27C1-like [Crassostrea virginica] S4_24h 
-24.81197395 cytochrome P450 27C1-like [Crassostrea virginica] RI_6h 
9.022848188 cytochrome P450 27C1-like [Crassostrea virginica] RI_6h 
7.477144414 cytochrome P450 27C1-like [Crassostrea virginica] RI_24h 
6.794994273 cytochrome P450 27C1-like [Crassostrea virginica] RE22_6h 
21.27504686 cytochrome P450 2C28-like isoform X2 [Crassostrea virginica] S4_6h 
18.70986303 cytochrome P450 2C28-like isoform X2 [Crassostrea virginica] S4_24h 
-22.33591302 cytochrome P450 2C28-like isoform X2 [Crassostrea virginica] RI_6h 
20.28813849 cytochrome P450 2C28-like isoform X2 [Crassostrea virginica] RI_24h 
20.46500703 cytochrome P450 2C28-like isoform X2 [Crassostrea virginica] RE22_6h 
6.238313253 Cytochrome P450 2D14 [Crassostrea gigas] RI_6h 
-21.35382089 cytochrome P450 2F5-like [Crassostrea virginica] S4_6h 
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-21.63670878 cytochrome P450 2F5-like [Crassostrea virginica] S4_24h 
-22.27759983 cytochrome P450 2F5-like [Crassostrea virginica] RI_24h 
-22.65584492 cytochrome P450 2F5-like [Crassostrea virginica] RE22_6h 
-21.3071929 cytochrome P450 2J5-like isoform X2 [Crassostrea virginica] S4_24h 
-22.51502577 cytochrome P450 3A6-like [Crassostrea virginica] S4_24h 
-9.01112453 cytochrome P450 4A25-like [Crassostrea virginica] S4_6h 
-10.01277913 cytochrome P450 4V2-like isoform X1 [Crassostrea virginica] S4_6h 
-20.02751343 cytochrome P450 4V2-like isoform X1 [Crassostrea virginica] RI_24h 
-8.791304071 dual specificity protein phosphatase 1-A-like [Crassostrea virginica] RI_24h 
4.381729845 dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica] RI_24h 
-23.83873688 dual specificity protein phosphatase 18-like [Crassostrea virginica] RI_24h 
-24.07000154 dual specificity protein phosphatase 18-like [Crassostrea virginica] RE22_6h 
9.288349328 dual specificity protein phosphatase 19-like [Crassostrea virginica] S4_24h 
8.034347824 dual specificity protein phosphatase 19-like [Crassostrea virginica] RI_24h 
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-24.95777889 dual specificity protein phosphatase 7-like [Crassostrea virginica] RI_6h 
8.541240553 dual specificity protein phosphatase 7-like [Crassostrea virginica] RI_24h 
-25.38312764 dual specificity protein phosphatase 7-like [Crassostrea virginica] RE22_6h 
-8.245775085 protein phosphatase 1 regulatory subunit 12A-like isoform X4 [Crassostrea virginica] S4_24h 
-24.53980697 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] S4_6h 
10.20776883 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] S4_6h 
9.225134929 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] S4_24h 
9.587762441 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] RI_6h 
8.067829643 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] RI_24h 
8.666364977 protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica] RE22_6h 
8.659545152 protein phosphatase 1 regulatory subunit 36-like isoform X1 [Crassostrea virginica] RI_6h 
-7.364558291 protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica] S4_6h 
-7.980896037 protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica] RE22_6h 
7.015542075 protein phosphatase 1 regulatory subunit 42-like isoform X1 [Crassostrea virginica] RI_24h 
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-24.30599943 protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea virginica] S4_24h 
20.18059945 Tripartite motif-containing protein 2 [Crassostrea gigas] S4_6h 
23.03367057 Tripartite motif-containing protein 2 [Crassostrea gigas] S4_6h 
-7.262763056 Tripartite motif-containing protein 2 [Crassostrea gigas] S4_24h 
21.37325729 Tripartite motif-containing protein 2 [Crassostrea gigas] S4_24h 
-22.62992934 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_6h 
-11.07407202 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_6h 
20.48455649 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_6h 
20.56883143 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_6h 
-22.63181448 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_24h 
21.63871709 Tripartite motif-containing protein 2 [Crassostrea gigas] RI_24h 
19.01092158 Tripartite motif-containing protein 2 [Crassostrea gigas] RE22_6h 
21.96955011 Tripartite motif-containing protein 2 [Crassostrea gigas] RE22_6h 
-9.107874381 Tripartite motif-containing protein 2 [Crassostrea gigas] S4_24h 
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-24.94189095 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_6h 
-21.21518109 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_6h 
-24.99785172 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-22.97055523 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-22.56316651 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-21.63143212 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-21.555795 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-21.48502657 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
2.440722296 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
-23.52232576 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_24h 
-22.27754888 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_24h 
-6.664288475 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_24h 
-23.67795281 tripartite motif-containing protein 2-like [Crassostrea virginica] RE22_6h 
-22.94845541 tripartite motif-containing protein 2-like [Crassostrea virginica] RE22_6h 
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20.60131168 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_6h 
20.75582702 tripartite motif-containing protein 2-like [Crassostrea virginica] S4_24h 
20.51645227 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_6h 
-23.97927626 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_24h 
20.6240354 tripartite motif-containing protein 2-like [Crassostrea virginica] RI_24h 
20.61455877 tripartite motif-containing protein 2-like [Crassostrea virginica] RE22_6h 
-21.16657646 tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] S4_6h 
9.572758843 tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] S4_6h 
-21.69698695 tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] RI_6h 
7.793596061 tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica] RI_6h 
22.30459712 tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica] S4_6h 
21.31432232 tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica] RE22_6h 
-24.62951513 tripartite motif-containing protein 3-like [Crassostrea virginica] S4_24h 
-25.52121202 tripartite motif-containing protein 3-like [Crassostrea virginica] RI_24h 
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-25.70706555 tripartite motif-containing protein 3-like [Crassostrea virginica] RE22_6h 
-6.057275712 tripartite motif-containing protein 3-like [Crassostrea virginica] RE22_6h 
-24.1355023 tripartite motif-containing protein 45-like [Crassostrea virginica] RE22_6h 
-21.78539178 tripartite motif-containing protein 5-like isoform X2 [Crassostrea virginica] RI_24h 
Biomineralization  
-21.98439629 perlucin-like [Crassostrea virginica] S4_6h 
-23.38363804 perlucin-like [Crassostrea virginica] S4_24h 
-21.96732063 perlucin-like [Crassostrea virginica] S4_24h 
-8.094282488 perlucin-like [Crassostrea virginica] S4_24h 
-23.03677587 perlucin-like isoform X1 [Crassostrea virginica] S4_24h 
-22.45971194 perlucin-like isoform X1 [Crassostrea virginica] RE22_6h 
18.507209 perlucin-like isoform X2 [Crassostrea virginica] S4_24h 
15.20165795 perlucin-like isoform X2 [Crassostrea virginica] RI_24h 
-23.43817576 perlucin-like protein [Crassostrea virginica] S4_24h 
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-6.765931252 perlucin-like protein [Crassostrea virginica] RI_24h 
21.94929471 perlucin-like protein isoform X1 [Crassostrea virginica] S4_6h 
21.68188164 perlucin-like protein isoform X1 [Crassostrea virginica] RE22_6h 
25.09518802 Chitin synthase 3 [Crassostrea gigas] RE22_6h 
24.46274385 Chitin synthase 3 [Crassostrea gigas] RI_6h 
21.58959401 Chitin synthase 3 [Crassostrea gigas] S4_6h 
-7.045235918 Chitin synthase C [Crassostrea gigas] S4_24h 
 
 
Table 3: Differentially expressed genes with log fold change for probiotic treatment when compared to control in hatchery 
transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). HT-RI: larvae treated daily with 
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days 
 
Log2FoldChange Hit_def Treatment 
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Recognition 
TLRs   
-6.333302299 toll-like receptor 1 [Crassostrea virginica] HT_RI 
-5.117571098 toll-like receptor 6 [Crassostrea virginica] HT_RI 
10.50152784 toll-like receptor 6 [Crassostrea virginica] HT_RI 
-7.016997176 toll-like receptor 4 isoform X1 [Crassostrea virginica] HT_RI 
5.181661209 toll-like receptor 4 isoform X1 [Crassostrea virginica] HT_RI 
-13.50652647 toll-like receptor 4 isoform X1 [Crassostrea virginica] HT_RI 
-28.195436 toll-like receptor 4 isoform X1 [Crassostrea virginica] HT_RI 
-10.52830632 toll-like receptor 13 [Crassostrea virginica] HT_RI 
Lectin   
-7.548517655 C-type lectin domain family 4 member E-like [Crassostrea virginica] HT_RI 
-9.313083618 C-type lectin domain family 3 member A-like [Crassostrea virginica] HT_RI 
Scavenger receptors  
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-8.035179262 scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica] HT_RI 
-8.089778373 scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica] HT_RI 
-3.505324316 scavenger receptor cysteine-rich type 1 protein M130-like isoform X1 
[Crassostrea virginica] 
HT_RI 
-5.113872743 scavenger receptor cysteine-rich type 1 protein M130-like isoform X1 
[Crassostrea virginica] 
HT_RI 
LRFN   
-7.614151619 leucine-rich repeat and fibronectin type III domain-containing protein 1-like 
protein [Crassostrea virginica] 
HT_RI 
-10.54947853 leucine-rich repeat and fibronectin type-III domain-containing protein 5-like 
[Crassostrea virginica] 
HT_RI 
LRRs   
7.538001578 leucine-rich repeat and IQ domain-containing protein 1-like [Crassostrea 
virginica] 
HT_RI 
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7.603603801 leucine-rich repeat neuronal protein 3-like [Crassostrea virginica] HT_RI 
-7.290369986 leucine-rich repeat neuronal protein 3-like [Crassostrea virginica] HT_RI 
-3.910728944 leucine-rich repeat transmembrane protein FLRT3-like [Crassostrea virginica] HT_RI 
8.884936086 leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea 
virginica] 
HT_RI 
-5.222764772 leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea 
virginica] 
HT_RI 
6.417892215 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] HT_RI 
-5.851688629 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] HT_RI 
-6.888253251 leucine-rich repeat-containing protein 24-like [Crassostrea virginica] HT_RI 
-10.67681921 leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea 
virginica] 
HT_RI 
11.13843633 leucine-rich repeat-containing protein 71-like isoform X22 [Crassostrea 
virginica] 
HT_RI 
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-12.72995479 leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea 
virginica] 
HT_RI 
-9.675716266 leucine-rich repeat-containing protein 74B-like isoform X3 [Crassostrea 
virginica] 
HT_RI 
Fibronectin domain containing  
3.471877714 fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea 
virginica] 
HT_RI 
-7.597144145 fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea 
virginica] 
HT_RI 
C1q proteins   
7.068747239 complement C1q tumor necrosis factor-related protein 2-like [Crassostrea 
virginica] 
HT_RI 
-8.687727906 complement C1q tumor necrosis factor-related protein 4-like isoform X3 
[Crassostrea virginica] 
HT_RI 
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Others   
-5.683456288 Macrophage mannose receptor 1 [Crassostrea gigas] HT_RI 
-9.358422983 macrophage mannose receptor 1-like [Crassostrea virginica] HT_RI 
7.683007501 macrophage migration inhibitory factor-like [Crassostrea virginica] HT_RI 
Cholinergic immunomodulation  
-6.155933795 muscarinic acetylcholine receptor M1-like [Crassostrea virginica] HT_RI 
-10.64631968 muscarinic acetylcholine receptor M1-like [Crassostrea virginica] HT_RI 
-10.62270936 glutamate receptor ionotropic HT_RI 
-10.76881678 glutamate receptor ionotropic HT_RI 
-9.746999757 neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea 
virginica] 
HT_RI 
-10.55585177 neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea 
virginica] 
HT_RI 
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-10.41167226 neuronal acetylcholine receptor subunit alpha-10-like isoform X3 [Crassostrea 
virginica] 
HT_RI 
2.6604451 neuronal acetylcholine receptor subunit alpha-6-like [Crassostrea virginica] HT_RI 
11.8076763 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] HT_RI 
-7.276192743 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] HT_RI 
-12.41663085 neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica] HT_RI 
10.57507598 neuropeptide FF receptor 2-like [Crassostrea virginica] HT_RI 
19.88309004 neuropeptide Y receptor type 1-like [Crassostrea virginica] HT_RI 
Signaling pathways   
-11.49570393 TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica] HT_RI 
8.268728895 tumor necrosis factor receptor superfamily member 1B-like isoform X1 
[Crassostrea virginica] 
HT_RI 
4.135043574 NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea 
virginica] 
HT_RI 
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3.572468448 NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea 
virginica] 
HT_RI 
-6.180435424 nuclear factor NF-kappa-B p105 subunit-like isoform X2 [Crassostrea virginica] HT_RI 
6.794484856 C-Jun-amino-terminal kinase-interacting protein 4-like [Crassostrea virginica] HT_RI 
11.83894875 stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica] HT_RI 
11.81769312 stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica] HT_RI 
5.027413466 stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica] HT_RI 
-7.126718787 mitogen-activated protein kinase 11-like [Crassostrea virginica] HT_RI 
-9.730631672 mitogen-activated protein kinase 11-like [Crassostrea virginica] HT_RI 
-13.9275785 mitogen-activated protein kinase 11-like [Crassostrea virginica] HT_RI 
-10.23892565 mitogen-activated protein kinase 7-like isoform X2 [Crassostrea virginica] HT_RI 
-11.91394746 interferon regulatory factor 2-binding protein-like [Crassostrea virginica] HT_RI 
-10.43886642 integrin alpha-2-like isoform X10 [Crassostrea virginica] HT_RI 
11.26277301 integrin alpha-2-like isoform X5 [Crassostrea virginica] HT_RI 
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12.22522579 integrin beta-like protein C isoform X1 [Crassostrea virginica] HT_RI 
9.093480693 nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica] HT_RI 
3.339268822 nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica] HT_RI 
Effectors 
5.805191913 serine protease inhibitor Cvsi-2-like [Crassostrea virginica] HT_RI 
-2.31732885 kunitz-type serine protease inhibitor conotoxin Cal9.1b-like [Crassostrea 
virginica] 
HT_RI 
-11.91394746 interferon regulatory factor 2-binding protein-like [Crassostrea virginica] HT_RI 
10.23389419 interferon-induced protein 44-like isoform X2 [Crassostrea virginica] HT_RI 
4.93870882 interferon-induced protein 44-like isoform X2 [Crassostrea virginica] HT_RI 
10.86738137 Signaling mucin HKR1 [Mizuhopecten yessoensis] HT_RI 
-9.926277007 Signaling mucin HKR1 [Mizuhopecten yessoensis] HT_RI 
-11.19554614 Signaling mucin HKR1 [Mizuhopecten yessoensis] HT_RI 
-7.627259354 integumentary mucin C.1-like isoform X3 [Crassostrea virginica] HT_RI 
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5.366202536 mucin-17-like isoform X2 [Crassostrea virginica] HT_RI 
-5.772730703 mucin-17-like isoform X2 [Crassostrea virginica] HT_RI 
-13.12905042 mucin-2-like [Crassostrea virginica] HT_RI 
-5.905452651 mucin-5AC-like [Crassostrea virginica] HT_RI 
-8.77598416 mucin-5AC-like isoform X5 [Crassostrea virginica] HT_RI 
Apoptosis 
-7.924485961 caspase-1-like [Crassostrea virginica] HT_RI 
-9.46806142 caspase-1-like [Crassostrea virginica] HT_RI 
10.97406116 caspase-14-like isoform X2 [Crassostrea virginica] HT_RI 
-3.233698531 caspase-7-like [Crassostrea virginica] HT_RI 
-10.00654536 caspase-7-like [Crassostrea virginica] HT_RI 
-3.686137851 caspase recruitment domain-containing protein 14-like isoform X5 [Crassostrea 
virginica] 
HT_RI 
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6.279723333 baculoviral IAP repeat-containing protein 2-like isoform X1 [Crassostrea 
virginica] 
HT_RI 
10.35840243 baculoviral IAP repeat-containing protein 2-like isoform X2 [Crassostrea 
virginica] 
HT_RI 
-9.552992158 baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica] HT_RI 
-10.01313701 baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica] HT_RI 
-7.12622932 baculoviral IAP repeat-containing protein 7-like isoform X3 [Crassostrea 
virginica] 
HT_RI 
11.86479373 Apoptosis inhibitor IAP [Crassostrea gigas] HT_RI 
5.960093895 LOW QUALITY PROTEIN: apoptosis-inducing factor 3-like [Crassostrea 
virginica] 
HT_RI 
2.788401176 protein kinase C iota type-like isoform X4 [Crassostrea virginica] HT_RI 
20.80442465 multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] HT_RI 
-6.43860015 multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] HT_RI 
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-7.224748576 multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica] HT_RI 
10.58406136 multiple epidermal growth factor-like domains protein 10 isoform X2 
[Crassostrea virginica] 
HT_RI 
7.215833061 multiple epidermal growth factor-like domains protein 10 isoform X2 
[Crassostrea virginica] 
HT_RI 
5.064940886 multiple epidermal growth factor-like domains protein 10 isoform X2 
[Crassostrea virginica] 
HT_RI 
2.789935488 multiple epidermal growth factor-like domains protein 10 isoform X2 
[Crassostrea virginica] 
HT_RI 
8.594189834 multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica] HT_RI 
-10.50534165 multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica] HT_RI 
10.20740385 multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea 
virginica] 
HT_RI 
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10.20312945 multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea 
virginica] 
HT_RI 
7.471679862 multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea 
virginica] 
HT_RI 
8.053324948 programmed cell death protein 2-like isoform X1 [Crassostrea virginica] HT_RI 
11.33719413 cell death abnormality protein 1-like [Crassostrea virginica] HT_RI 
11.40372414 GTPase IMAP family member 7-like isoform X1 [Crassostrea virginica] HT_RI 
-10.0861395 DNA damage-regulated autophagy modulator protein 2-like [Crassostrea 
virginica] 
HT_RI 
Cytoskeletal reorganization  
9.029226712 LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica] HT_RI 
5.82670463 LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica] HT_RI 
4.705387778 LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica] HT_RI 
Others 
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-9.657810466 lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica] HT_RI 
14.2444413 lysosomal alpha-glucosidase-like isoform X1 [Crassostrea virginica] HT_RI 
-10.73769432 lysosomal-trafficking regulator-like isoform X4 [Crassostrea virginica] HT_RI 
10.97945875 glutathione S-transferase C-terminal domain-containing protein-like isoform X1 
[Crassostrea virginica] 
HT_RI 
-6.354844406 glutathione-independent glyoxalase HSP31-like [Crassostrea virginica] HT_RI 
4.264547363 maleylacetoacetate isomerase-like [Crassostrea virginica] HT_RI 
11.70064297 Heat shock 70 kDa protein 12A [Crassostrea gigas] HT_RI 
-6.944842925 Heat shock 70 kDa protein 12A [Crassostrea gigas] HT_RI 
-6.695090302 heat shock 70 kDa protein 12A-like [Crassostrea virginica] HT_RI 
-10.35513436 heat shock 70 kDa protein 12A-like [Crassostrea virginica] HT_RI 
-10.53471861 heat shock 70 kDa protein 12A-like [Crassostrea virginica] HT_RI 
-10.66480031 heat shock 70 kDa protein 12A-like [Crassostrea virginica] HT_RI 
10.32935057 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] HT_RI 
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5.822952857 heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica] HT_RI 
3.278219628 actin HT_RI 
11.26723475 actin-3-like isoform X1 [Crassostrea virginica] HT_RI 
-3.288605929 tripartite motif-containing protein 2-like [Crassostrea virginica] HT_RI 
-28.23091398 tripartite motif-containing protein 2-like [Crassostrea virginica] HT_RI 
11.97821512 tripartite motif-containing protein 2-like isoform X1 [Crassostrea virginica] HT_RI 
6.138377301 tripartite motif-containing protein 3-like [Crassostrea virginica] HT_RI 
4.616161652 tripartite motif-containing protein 3-like [Crassostrea virginica] HT_RI 
-5.355761746 tripartite motif-containing protein 3-like [Crassostrea virginica] HT_RI 
20.95857011 tripartite motif-containing protein 3-like isoform X1 [Crassostrea virginica] HT_RI 
-6.051600924 tripartite motif-containing protein 55-like [Crassostrea virginica] HT_RI 
-12.53777229 protein phosphatase 1 regulatory subunit 11-like [Crassostrea virginica] HT_RI 
7.873357051 protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea 
virginica] 
HT_RI 
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7.282656314 protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea 
virginica] 
HT_RI 
-12.67858882 protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea 
virginica] 
HT_RI 
14.50001928 protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica] HT_RI 
-3.004388061 protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica] HT_RI 
-6.650729756 protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea 
virginica] 
HT_RI 
6.602761261 multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] HT_RI 
-10.91470969 multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] HT_RI 
-13.24809012 multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica] HT_RI 
9.2023305 cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica] HT_RI 
16.35993502 cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica] HT_RI 
-12.35764438 cytochrome P450 27C1-like [Crassostrea virginica] HT_RI 
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-10.85697882 cytochrome P450 2C42-like [Crassostrea virginica] HT_RI 
2.675102652 Cytochrome P450 3A11 [Crassostrea gigas] HT_RI 
-4.440107252 cytochrome P450 3A29-like [Crassostrea virginica] HT_RI 
-7.518489118 cytochrome P450 4V2-like isoform X1 [Crassostrea virginica] HT_RI 
-12.02720282 Ig-like and fibronectin type-III domain-containing protein 2 [Crassostrea 
virginica] 
HT_RI 
7.683007501 macrophage migration inhibitory factor-like [Crassostrea virginica] HT_RI 
2.309585304 histone H2B-like [Crassostrea virginica] HT_RI 
-9.231433964 perlucin-like isoform X2 [Crassostrea virginica] HT_RI 
9.231041006 perlucin-like protein [Crassostrea virginica] HT_RI 
9.062890569 perlucin-like protein [Crassostrea virginica] HT_RI 
-4.500074021 perlucin-like protein [Crassostrea virginica] HT_RI 
-6.333143999 Chitin synthase C [Crassostrea gigas] HT_RI 
